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Abstract 
Chronic hepatitis C is a viral infection affecting 230,000 people in Australia 
that can lead to liver cirrhosis or liver cancer. Most Australians living with 
the hepatitis C virus (HCV) are current or former injecting drug users (IDUs). 
Despite the widespread availability of HCV treatment in Australia, and some 
studies estimating high levels of intention to uptake treatment, uptake remains 
low among IDUs. Several factors are responsible for IDUs’ low rate of HCV 
treatment uptake; they include lack of treatment efficacy (low probability of 
viral clearance), debilitating treatment side effects, lengthy treatment duration 
and the stigma associated with HCV and IDU. To date, only a few studies 
have examined the intention of IDUs to undertake treatment and the factors 
that influence uptake. Consequently, this study was designed to explore the 
factors that influence intention to undertake HCV treatment, using data 
collected from HCV infected IDUs in the Perth metropolitan area. 
 
A mixed-methods design consisting of semi-structured interviews, focus 
groups and a cross-sectional survey was selected for this study. In the 
qualitative phase, which ran from September 2012 until March 2013, IDUs 
were recruited through the Western Australian Substance Users’ Association 
(WASUA) and HepatitisWA. Twenty-one HCV infected IDUs who had 
experienced treatment (the treatment group) and 25 who had not (the non-
treatment group) were interviewed individually about the factors influenc ing 
their intention to undertake HCV treatment, their experiences of HCV stigma 
and their beliefs about HCV treatment. Five focus group discussions (with 
five IDUs in each group) were conducted over June–August 2013 to gain 
further insight into the perceptions of HCV-infected IDUs with no treatment 
experience about triple HCV therapy (pegylated interferon and ribavirin in 
combination with either boceprevir or telaprevir) and to confirm the themes 
that emerged from the one-on-one interviews. In the cross-sectional survey 
(December 2013 to November 2014), 336 HCV-infected IDUs with no 
treatment experience were recruited from WASUA, HepatitisWA and the 
WA AIDS Council (WAAC). Participants completed a purpose-designed 
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questionnaire about their socio-demographic characteristics, drug-use 
history, health-care-seeking characteristics, aspects of treatment, stigma, 
support and their intention to undertake treatment. 
 
Analysis of the qualitative data has revealed the factors influencing HCV-
infected IDUs’ intention to undertake HCV treatment; treatment side effects; 
treatment effectiveness; treatment duration; concern about stigma; and lack 
of support. In addition to these factors, protecting family, increasing quality 
of life, and maintaining careers were reported by the treatment group, and 
unstable housing was reported by the non-treatment group, as important 
factors that influenced their treatment intention to undertake HCV treatment. 
Both groups reported that peers’ experiences of treatment, both positive and 
negative, were an important influence on their intention to undertake HCV 
treatment.  
 
The qualitative study was valuable in guiding development of the quantitat ive 
survey instrument. The survey confirmed most of the findings that emerged 
from the qualitative study. Analysis of survey data revealed significant 
associations between intention to undertake HCV treatment and the following 
factors: support; treatment side effects; treatment efficacy; stigma; not 
drinking alcohol in the past year; non-homeless status; and non-Aborigina l 
ethnicity. The study also found a high overall level of expressed intention to 
undertake HCV treatment, with 63% of participants responding positively. 
 
This study was conducted when HCV treatment consisted of the standard 
combination of pegylated interferon and ribavirin, and triple therapy. 
However, new interferon-free HCV treatments – direct-acting antivira ls 
(DAAs), which feature minimal side effects, shorter treatment duration and 
higher efficacy than the old treatments – were listed on Australia’s 
Pharmaceutical Benefits Scheme (PBS) in March 2016. However, some other 
factors such as unstable housing, forgetfulness, lack of priority for treatment, 
lack of control in life, pre-existing psychiatric illness and stigma, could 
significantly influence intention of HCV- infected IDUs to undertake new 
HCV treatment.  
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Hence, the study results have ongoing utility for policymakers and service 
providers seeking to increase the uptake of HCV treatment among IDUs. 
Clinics offering HCV treatment in community settings, training on DAAs for 
relevant health care practitioners, training for health care practitioners about 
reducing stigma and discrimination relating to injecting drug use, and 
facilitation of family and other support for patients will bolster HCV 
treatment uptake and reduce the burden of HCV-associated disease in 
Australia. In addition, future research about intention to undertake treatment 
with DAAs using a cohort method with a large sample size is recommended 
to enrich and confirm the results of this study. This will enable a more 
accurate estimate of the rate of intention and factors that predict intention to 
undertake treatment. 
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Chapter 1: Introduction  
This chapter includes the background to the study, the research questions, 
study aim and objectives and the perceived significance of the study.  
1.1 Background of the study  
The hepatitis C virus (HCV) is a significant public concern, affecting 170 
million people worldwide (WHO 2015). In Australia, an estimated 230,000 
individuals are currently infected (Sievert et al. 2014). The majority of cases 
of HCV in high income countries were acquired through injecting drug use 
(Grebely et al. 2008). HCV has six genotypes (1–6), but the most common 
genotypes in Australia are 1, 2 and 3. HCV is often asymptomatic and over 
decades can lead to cirrhosis and to hepatocellular carcinoma (HCC) (Sievert 
et al. 2014). In Australia, it is expected that the annual number of HCV-related 
HCC cases will increase by 245% between 2013 and 2030 (from 590 to more 
than 2000) and annual HCV liver-related deaths will increase by 230% (from 
530 to more than 1700) (Sievert et al. 2014).  
Until April 2013 HCV treatment for HCV genotypes 1,2 and 3 was based on 
a combination of pegylated interferon and ribavirin, known as standard 
combination treatment (Manns et al. 2001, Manns, Wedemeyer, and 
Cornberg 2006). It was subsidised by the Federal Government through the 
Pharmaceutical Benefits Scheme (PBS) (DOHAC 2000). This combination 
of drugs produced a sustained virological response (SVR) in almost 50% of 
people with genotype 1 and 70–80% of people with genotypes 2 and 3 (Manns 
et al. 2001, Manns, Wedemeyer, and Cornberg 2006). Standard combination 
treatment involved adverse side effects, such as physical, psychiatr ic, 
cognitive and dermatological side effects, and had to be given for a total of 
48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3 (Manns et al. 
2001, Manns, Wedemeyer, and Cornberg 2006). In April 2013, the first 
direct-acting antivirals (DAAs) were listed on the PBS, including boceprevir 
and telaprevir, and were added to the standard combination therapy for HCV 
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genotype 1, called triple therapy (He´zode 2012 ). The study described in this 
thesis was conducted when standard combination treatment and triple therapy 
were the only options available for HCV-infected injecting drug users (IDUs).  
 
New DAAs have revolutionised the treatment of HCV. They are interferon-
free for most genotypes and require daily tablets, rather than weekly 
injections in combination with tablets (Poonsapaya et al. 2015). The 
treatments are also much shorter in duration New HCV treatments 
(Poonsapaya et al. 2015) were listed on the PBS in March 2016 
(HepatitisAustralia 2016). Figure 2.1 summarises information on the new 
HCV treatment regimens; with more detailed information provided in 
Chapter 2. Despite the widespread availability of publicly funded HCV 
treatment in Australia, uptake among people with chronic HCV has been low 
with less than 2% of affected people receiving antiviral therapies per annum 
(Guy and McGregor 2015).  
 
Moreover, the reported intention among IDUs to take up HCV treatment is 
low and actual uptake in this population remains very low (Sievert et al. 2014) 
Low uptake of treatment among HCV-infected IDUs has significant 
implications for the numbers of people progressing to cirrhosis and HCC in 
future years (Sievert et al. 2014). However, the introduction of the new HCV 
treatments (more detailed information is given in Chapter 2) could 
significantly increase the rate of HCV treatment uptake among HCV-infected 
IDUs. 
 
Few researchers to date have examined the prevalence of reported intention 
to undertake treatment among IDUs and there has been no research conducted 
on this topic in metropolitan Perth, Western Australia. In recent Australian 
studies, the prevalence of reported intention of HCV-infected IDUs to 
undertake treatment ranged from 53% (Treloar et al. 2012 , Alavi et al. 2013 
) to 67% (Alavi et al. 2015). Several Australian studies have explored factors 
influencing IDUs’ intention to undertake HCV treatment, identifying 
characteristics of treatment, social, personal and demographic factors as 
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strongly associated (Treloar et al. 2012 , Alavi et al. 2015, Alavi et al. 2014, 
McNally, Sievert, and Pitts 2006, Doab, Treloar, and Dore 2005). Experience 
or fear of encountering treatment side effects, lack of treatment efficacy 
(Fusfeld et al. 2013, Treloar, Newland, et al. 2010, Zeremski et al. 2014), 
lengthy treatment duration (Fusfeld et al. 2013, Berg et al. 2006) peers’ 
experiences of treatment (Treloar et al. 2014, Swan et al. 2010) and lack of 
support (Evon et al. 2011, Wilson et al. 2010) have been associated with 
treatment refusal and discontinuation of treatment among HCV-infected 
IDUs. Stigma associated with HCV and IDUs (Harris 2009, Tinda, Cook, and 
Foster 2010), housing status (Harris, Rhodes, and Martin 2013, Treloar, 
Newland, et al. 2010), ethnicity, older age (35-45 years) (Alavi et al. 2015) 
and employment status (Grebely et al. 2008) have also been reported as 
influencing the intention of HCV-infected IDUs not to undertake treatment.  
 
However, in Australia little attention has been given simultaneously to the 
factors influencing treatment intention and the predictors of intention to take 
up treatment. A few studies have been conducted in the Eastern States 
(Treloar et al. 2012 , Alavi et al. 2015, Doab, Treloar, and Dore 2005), but no 
study in the Perth metropolitan area has attempted either to examine or to 
provide a systemic review of factors that influence intentions of HCV-
infected IDUs to take up treatment. This study was designed to fill this gap 
by collecting evidence for development of appropriate interventions for 
increasing intention to take up treatment and actual treatment uptake through 
discovering the associations between predictive factors and intention to take 
up HCV treatment among IDUs in the Perth metropolitan area. 
1.2 Research aim and questions 
The overarching aim of this study was to gain better understanding of what 
factors can influence the intentions of HCV-infected IDUs’ uptake of HCV 
treatment.  
1. What factors influence the intentions of HCV-infected IDUs in relation to 
the uptake of HCV treatment? 
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2. What is the prevalence rate of intention to undertake HCV treatment among 
HCV- infected IDUs in Perth metropolitan area? 
3. What is the association between socio-demographic, drug use and health-
care-seeking characteristics and intention to undertake HCV treatment?  
 
4. What is the association between treatment side effects, treatment 
effectiveness, treatment duration, support, stigma and intention to undertake 
HCV treatment? 
  
1.3 Objectives of the study  
With respect to HCV-infected IDUs in the Perth metropolitan area: 
1. Identify the determinants of treatment intention and the uptake of HCV 
treatment.  
 
2. Measure the prevalence rate of intention to undertake HCV treatment.  
 
3. Determine the socio-demographic characteristics, drug history 
characteristics and health-care-seeking characteristics associated with 
intention to undertake HCV treatment. 
 
4. Determine the characteristics of treatment, support and stigma associated 
with intention to undertake HCV treatment. 
 
5. Recommend strategies for increasing uptake of HCV treatment. 
1.4 Significance  
This study was designed to identify and explore the factors that influence the 
intention of HCV-infected IDUs to take up of HCV treatment. A recent study 
has suggested that the number of people living with chronic HCV in Australia 
is expected to increase to 255, 500 by 2025 and then decline to 251,970 by 
2030 (Sievert et al. 2014). Despite improvements in HCV treatment, many 
HCV-infected individuals remain untreated or have been treated 
unsuccessfully (Razavi et al. 2014 ). The number of cases of decompensated 
cirrhosis and HCC are predicted to increase from 1430 to 4170 and from 590 
to 2040 respectively over the period 2013–2030 (Sievert et al. 2014). This 
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will result in an increase in the number of deaths from HCV-related liver 
disease to 630 by 2030 compared with 250 in 2013, if the rate of treatment 
uptake does not increase (Razavi et al. 2014 ).  
Although, some researchers have studied Australian IDUs’ intention to take 
up treatment these studies have been conducted in the Eastern States and have 
not included Perth (Treloar et al. 2012 , Alavi et al. 2015, Doab, Treloar, and 
Dore 2005). Given the sample size of  85  (Treloar et al. 2012 ) and 100 (Doab, 
Treloar, and Dore 2005) and assessing study population by health care 
providers (Doab, Treloar, and Dore 2005, Alavi et al. 2015) could represent 
a study group who were more engaged in health services which could lead to 
higher estimation of HCV treatment intention. Therefore, the results of these 
studies were not generalisable to the populations of current IDUs in Perth. 
There is no data relating to the treatment intentions of IDUs for the Perth 
metropolitan area in either clinical or non-clinical setting.  Perth is also the 
most remote city where access to health services is more limited. It is 
plausible that HCV-infected individuals in Perth have novel perspectives that 
are yet to be explored on why their intention to undertake treatment is low 
and why they struggle to complete the treatment regimen. Moreover, few 
studies of HCV treatment have used a mixed-methods approach, despite the 
obvious value of such a design for this sensitive and little-known topic. This 
study used exploratory sequential mixed methods, commencing with semi-
structured interviews, then focus group discussions and finally a cross-
sectional survey, to capture the perspectives of IDUs who had experienced 
HCV treatment and IDUs who had not experienced treatment. Conducting 
mixed-methods research in a complementary way strengthened the study, and 
added validity and reliability to the findings. 
Focus groups enabled rich descriptions of IDUs’ perceptions of triple therapy 
( standard treatment in combination with either boceprevir or telaprevir ), 
providing detailed understanding from a user perspective. Despite the proven 
benefits of the triple treatment regime over the previous pegylated interfe ron 
and ribavirin treatment, including reduced treatment duration and improved 
SVR rate, there is no empirical evidence (Evon et al. 2013, Treloar et al. 2012 
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) showing how IDUs view triple treatment and whether or not they intend to 
undertake this treatment. Arguably this is because the treatment is novel and 
studies have almost invariably focused on evaluation of the safety and 
efficacy of triple therapy within a clinical trial framework (Hézode 2012, 
Pearlman 2012), with little attention to identifying how the triple regime is 
valued and perceived by IDUs, and what processes must be in place to enable 
IDUs to access treatment. 
 
This study, by adding new information on IDUs’ perspectives to the extant 
literature on factors influencing treatment intention, develops a more 
complete and comprehensive picture of the topic. The mixed-methods design 
of this study produced rich and varied data that is useful for developing 
relevant interventions that enable increased intention to undertake treatment. 
It is expected that the research presented in this thesis offers an improved 
understanding of the factors which influence intention of HCV-infected IDUs 
to undertake HCV treatment and adds valuable knowledge to the scholarly 
literature. The findings of this study will enable policymakers to develop 
HCV treatment strategies to increase rates of uptake, and represent a 
foundation for further research in the field. 
1.5 Outline of the thesis  
This thesis contains seven chapters. The current chapter (1) provides a brief 
background to HCV treatment and the likely factors related to low uptake of 
HCV treatment among IDUs. It also presents the research questions, 
objectives and outlines the significance of the study. 
Chapter 2 contains a review of relevant literature, covering both the past 
situation and the recent changes in HCV treatment in Australia. Literature on 
the factors influencing HCV treatment intention among HCV-infected IDUs 
is examined in detail.  
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Chapter 3 describes the methods used in the study, including the research 
design, interview questions, sample size, recruitment of subjects, data 
collection, and analysis. Ethical considerations are also outlined.  
Chapters 4 and 5 describe the findings of the qualitative and quantitat ive  
analyses.  
Chapter 6 contains a detailed discussion of the findings presented in Chapters 
4 and 5 with reference to the existing literature.  
Chapter 7 presents the conclusion of the thesis, the limitations of the study, 
and recommendations for future research.  
Information sheets, the consent form, interview questions, questionnaires and 
other relevant documents are provided as Appendices 1 to 14.  
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Chapter 2: Review of the Literature  
This literature review provides a brief background to HCV, its clinica l 
manifestations, disease progression, risk factors, prevalence and burden, 
followed by an overview of the history of HCV treatment. This chapter 
reviews the existing literature relevant to intention to undertake HCV 
treatment in Australia and few developed countries. This is because they are 
similar to Australia in terms of low rates of HCV treatment uptake among 
HCV-infected IDUs and the majority of HCV infections being associated 
with injecting drug use. Finally, the chapter presents the factors influenc ing 
intention of HCV-infected IDUs to undertake HCV treatment.  
2.1 Hepatitis C  
The hepatitis C virus, originally referred to as non-A,-non-B hepatitis, first 
came to the attention of clinicians in February 1963 when 50% of cases of 
post-transfusion hepatitis were found to be neither hepatitis B nor hepatitis A 
(Hampers, Prager, and Senior 1964). Accumulating evidence in the 1960s and 
1970s revealed other features of non-A, non-B hepatitis, such as chronicity 
and progression towards cirrhosis (Alter et al. 1978). In 1989, non-A, non-B 
hepatitis–associated ribonucleic acid (RNA) was isolated using advanced 
molecular approaches and the new virus came to be known as hepatitis C 
(Choo et al. 1990). The genetic organisation of this enveloped, positive-strand 
RNA virus is considered similar to those of pestiviruses and flaviviruses 
(Choo et al. 1990, Barreiro et al. 2012).  
2.1.1 Viral genotypes  
HCV has six genotypes, each containing subtypes which are categorised 
based on viral nucleotide sequence heterogeneity (Kuiken and Simmonds 
2009). The genotypes and subtypes differ by approximately 31–33% and 20–
25% respectively at the nucleotide level (Kuiken and Simmonds 2009). HCV 
genotypes are important as they are strong predictors of the outcomes of HCV 
treatment: genotypes 2 and 3 were the most susceptible to the standard 
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combination of pegylated interferon and ribavirin treatment, while genotypes 
1 and 4 were the least susceptible (Imhof and Simmonds 2011). However, 
with the advent of the new DAAs, genotypes 1, 2 and 3 are now the most 
susceptible to treatment (Sarrazin 2016). Genotype also plays a role in disease 
outcomes, particularly for those infected with genotype 1b and genotype 3, 
who are at higher risk for HCC and steatosis respectively (Rubbia-Brandt et 
al. 2000).  
2.1.2 Clinical manifestations of hepatitis C infection 
There are two phases in HCV infection: acute and chronic. The acute phase 
refers to the first six months following HCV infection (Busch and Shafer 
2005). During this period, antibodies are developed and liver enzymes such 
as serum alanine aminotransferase are raised (Busch and Shafer 2005). 
Within this period, an estimated 20% of infected individuals clear the virus 
spontaneously (Zeuzem et al. 2011), which is referred to as a ‘resolved 
infection’; the remaining 80% develop chronic HCV infection. During the 
acute phase, there can be significant elevation of liver enzymes in the first 2-
8 weeks following exposure, reflecting acute hepatocellular damage (Chen 
and Morgan 2006). Nevertheless, symptoms of an acute HCV infection are 
often very general and may go unrecognised, with 70–80% of HCV-infected 
individuals not diagnosed during this period (Chen and Morgan 2006). An 
estimated 75-85% of acute infected cases who do not clear the virus within 
six months and develop chronic HCV infection (Chen and Morgan 2006).  
Chronic HCV infection is characterised by HCV RNA persisting in the blood 
for at least six months after the acute phase and can progress to cirrhosis, 
HCC and liver failure over two to three decades (Cacouba et al. 2014). This 
stage of chronic HCV infection is frequently asymptomatic and can last as 
long as 40 years (Lee et al. 2012). 
 Chronic HCV infection can also lead to numerous extrahepatic 
manifestations, and 40–74% of HCV infected patients , develop at least one 
extrahepatic manifestations over the course of their disease (Cacouba et al. 
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2014). The most common extrahepatic manifestation associated with HCV is 
mixed cryglobulinemia (an abnormal blood protein), which is a systemic 
vasculitis. Mixed cryglobulinemia is often asymptomatic, but may present 
symptoms such as fatigue, muscle pain, rash, joint pain, kidney disease, 
numbness and tingling (Lee et al. 2012). Other conditions possibly associated 
with HCV, but which are less likely to occur include porphyria cutanea tarda, 
lichen planus (skin problems), non-Hodgkins lymphoma, autoimmune 
thyroiditis, Sjogrens syndrome (dryness of the mouth and eyes) and 
seronegative arthritis. Extrahepatic manifestations associated with HCV vary 
in severity, but HCV treatment often leads to resolution of these symptoms 
(Cacouba et al. 2014).  
2.1.3 Disease progression  
Liver disease has four stages, which are classified based on the variation in 
the degree of fibrosis (scarring) and inflammation. As the disease progress, 
liver function which may ultimately be inhibited (Goodman 2007). At stages 
0, 1 and 2, the degree of fibrosis has little effect on liver function (Goodman 
2007, Pinzani, Rossellia, and Zuckermanna 2011). Within this period, 
inflammation responds to HCV treatment and often resolves infection, 
preventing progression to the more serious stages of liver disease (Pinzani, 
Rossellia, and Zuckermanna 2011). 
By stages 3 or 4 of fibrosis, liver function is affected due to obstruction of 
blood flow though the liver (Davis et al. 2010). In the final stage, called 
cirrhosis, the liver architecture is disrupted by irreversible scarring and it is 
not possible to return liver function to normal even after successful 
virological treatment (Davis et al. 2010). In spite of this, HCV treatment for 
people with advanced fibrosis and cirrhosis is important to limit progression 
to decompensated cirrhosis (see below), HCC and liver failure (Morgan et al. 
2013). The progression from acquisition of HCV to cirrhosis may take at least 
10 to 20 years (Hoofnagle 1997). 
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There are two types of cirrhosis: compensated and decompensated cirrhosis. 
Compensated cirrhosis is marked by severe scarring of the liver, which 
nonetheless remain capable of performing many vital bodily functions 
(Pinzani, Rossellia, and Zuckermanna 2011). Decompensated cirrhosis is 
defined as extensive scarring of the liver to the extent that it is incapable of 
functioning properly, leading to complications (Zipprich et al. 2012). 
Symptoms of decompensated cirrhosis include tiredness, loss of appetite, 
vomiting, jaundice, weight loss, abdominal pain and bleeding (Zipprich et al. 
2012). Not all people with cirrhosis experience symptoms until the 
occurrence of severe complications such as oedema (accumulation of fluid in 
the extremities, particularly the feet and legs), enlargement of the spleen and 
portal hypertension (Pinzani, Rossellia, and Zuckermanna 2011). Individua ls 
who experience such complications are likely to progress to the final stage of 
liver disease, where the liver is no longer capable of performing its functions. 
Liver transplantation is the only treatment for this final stage. 
People with chronic HCV initially develop chronic inflammation, leading to 
cirrhosis in some (20–40%), and of these 4–6% develop HCC within 10–40 
years of infection (Castelloa et al. 2010). It is estimated that 350,000 to 
500,000 people die globally per annum from HCV-related complications, 
mainly cirrhosis and HCC (WHO 2015). Progression to HCC occurs more 
quickly among chronically infected individuals who have alcoholic liver 
disease (Mueller, Millonig, and Seitz 2009).  
2.1.4 Risk Factors for HCV  
HCV is a blood-borne virus; the most efficient means of transmission is 
through percutaneous exposure to contaminated blood (Lavanchy 2009). 
Well-documented means of transmission (with widely varying degrees of 
efficiency) include: sharing of contaminated needles or equipment for drug 
use; reuse of needles in health care; contaminated blood transfusions or blood 
products (in countries where the blood supply is not screened); vertical 
transmission from mother to child; sharing of personal items such as razors 
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and toothbrushes; and tattooing and body piercing. These transmission routes 
and their importance for the HCV epidemic are described below.  
2.1.4.1 Injecting drug use  
Injecting drug use is considered to be the predominant mode of HCV 
transmission in most countries (Backmund et al. 2005, Alter 1997, Xia et al. 
2008). Major factors which influence HCV transmission in IDUs include the 
fact that parenteral transmission of hepatitis C is highly effective, the size of 
the vulnerable population, and the prevalence of risk behaviours (Maher et al. 
2006). HCV risk is highly correlated with the sharing of needles, syringes and 
other injecting equipment, as well as the duration of injecting; the longer an 
individual has been injecting, the more likely they are to have been exposed 
to hepatitis C (Hagan et al. 2006b, Brewer et al. 2006, Shannon et al. 2008).  
Although the sharing of needles is the highest risk factor for IDUs, sharing or 
reusing other equipment such as swabs, cottons, spoons, water vials, 
tourniquets and fingers are also implicated the spread of HCV (Crofts, Aitken, 
and Kaldor 1999). For example, Koester et al. indicated that if a contaminated 
needle is used in a cooker (a container for mixing drugs using heat), the 
cooker becomes contaminated and even two or three days later a pathway for 
HCV transmission could be created (Koester, Booth, and Zhang 1996).  
Injecting drug use is the primary route of HCV transmission in Australia 
(Grebely et al. 2008, Treloar et al. 2014, Dore et al. 2003), but it is not in itself 
a risk factor for HCV if sterile equipment and aseptic techniques are used. 
Harm-reduction strategies such as needle and syringe programs (NSP) have 
been highly effective in reducing transmission of HCV, preventing an 
estimated 97,000 new HCV infections in Australia over the decade 2000–
2009 (Middleton et al. 2013 ). Transmission can occur when people who have 
HCV are unaware they are infected and pass it on unknowingly through the 
sharing of injecting equipment (Pugh 2008). Transmission risk of HCV is 
high (2.5–5.0%) when unsafe injecting practices are employed (Grebely and 
Dore 2011). Unsafe injecting practices account for nearly 80% of all current 
HCV infections and more than 90% of all new infections (Razalia et al. 2007). 
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Australian NSP surveys have found that the prevalence of reported re-use of 
syringes, including reuse of one’s own syringe, reduced from 31% to 21% 
over the period 1997–2014, but remained stable from 2010 to 2014 (Iversen 
and Maher 2015). There was also a reduction in the proportion of participants 
reporting receptive sharing of drug-preparation equipment from 45% to 30% 
between 1999 and 2014. In all survey years, spoons and water were the most 
commonly shared drug-preparation items (Iversen and Maher 2015).  
2.1.4.2Blood transfusion and its products  
Prior to the development of a laboratory detection method for HCV, blood 
transfusion was a major mode of transmission (Donahue et al. 1992). People 
with thalassaemia or haemophilia were at high risk of acquiring HCV due to 
receiving multiple transfusions (Brettler et al. 1990). A study in a large US 
haemophilic population indicated that almost 89% had active HCV infect ion 
(Troisi et al. 1993 ). A British study estimated the frequency of infectious 
donations entering the blood supply at one in 520,000 over 1993–1998, 
decreasing to one in 30 million between 1999 and 2001, when all donations 
started being tested for HCV RNA (Soldan et al. 2003). Universal screening 
of blood donations for HCV was introduced in 1990 in Australia (Donahue et 
al. 1992), resulting in a significant decrease in the number of cases of 
transfusion-acquired HCV (Humphery et al. 2004). The number of cases of 
HCV acquired through blood transfusion reduced significantly in Australia 
from 13 in 1995 to zero in 2000 (Humphery et al. 2004). There were no 
transfusion-acquired HCV infections between 2005 and 2014 in Australia 
(Ismay et al. 2015).  
Although screening of the blood supply for HCV has almost eliminated this 
mode of transmission in developed countries (Busch et al. 2005), the risk of 
HCV infection through blood transfusion remains an important risk factor in 
some developing countries due to lack of resources for screening blood 
donors and use of commercial donors (Liu et al. 2010, Hladik et al. 2006, 
Luby et al. 2000). For example in Africa, the recent risk of HCV infection via 
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blood transfusion was estimated to be one in 100,000 transfusions 
(Rerambiah et al. 2014).  
2.1.4.3 Mother-to-child transmission  
The risk of HCV transmission from pregnant mother to infant is around 4% 
(McMenamin et al. 2008, Dienstag 1997). This risk is increased when the 
mother is co-infected with HIV or hepatitis B (Ferrero et al. 2003, Thomas et 
al. 1998). The vertical transmission rate has been estimated at 5.4% in human 
immunodeficiency virus (HIV) co-infected women, compared to 2.0% in 
HIV-negative women (Ferrero et al. 2003). The risk of vertically transmitted 
HCV infection was 3.2 times higher in HIV-infected infants than non-HIV-
infected infants (Thomas et al. 1998). Eight studies that were part of a single 
meta-analysis conducted among HIV-positive and HIV-negative women 
reported crude rates of mother-to-infant transmission of 22.1% and 4.3% 
respectively (Maccabruni et al. 1995, Granovsky et al. 1998, Zuccotti et al. 
1995, Tovo et al. 1997, Zanetti et al. 1998, Paccagnini et al. 1995, Mazza et 
al. 1998, Gussetti et al. 1998). There is no evidence of HCV transmission via 
delivery or breastfeeding (Ferrero et al. 2003, McMenamin et al. 2008), but 
some studies have suggested the risk of transmission from mother to baby 
could increase with an increasing viral load at the time of delivery 
(Schwimmer and Balistreri 2000, McMenamin et al. 2008, Tosone et al. 2014, 
Ferrero et al. 2003). Pregnancy has been shown to affect HCV viral loads, 
with a reduction in the first and second trimesters and an increase in the third 
trimester, which could increase the risk of transmission at birth (Wejstål, 
Widell, and Norkrans 2001, Paternoster et al. 2001, Tosone et al. 2014).  
2.1.4.4 Sexual contact  
The risk of transmission of HCV through sexual activity is not clear. Some 
studies have identified HCV RNA in the saliva and semen of HCV-infected 
individuals, suggesting that sexual contact is a potential route of HCV 
exposure (Liou et al. 1992, Briat et al. 2005). Several researchers who 
examined the association between sexual contact and HCV transmiss ion 
among high-risk groups such as men who have sex with men (MSM), HIV-
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positive people and serodiscordant monogamous couples have suggested that 
the risk of HCV transmission is positively associated with the number of 
sexual partners as well as when the sexual partner is co-infected with 
HIV/HCV (Leruez-Ville et al. 2000, Nyamathi et al. 2002, Workowski and 
Berman 2010).  
 
Sexual HCV transmission has been supported in a study which reported that 
15% of non-IDU women having unprotected sex with an HCV-infected 
injecting partner became HCV positive (Goldberg et al. 2001). However, a 
10-year prospective study of 895 monogamous spouses of chronically 
infected partners showed a rate that was very low or even nil (Vandelli et al. 
2004). Sexual HCV transmission varies by the type of sexual relationship . 
Incidence of HCV was reported to be 0–0.6% per year among long-term 
monogamous heterosexual relationships, while among heterosexua l 
relationships with multiple partners or a history of sexual transmitted diseases 
it was 0.4–1.8% per year (Terrault 2002). Overall, sexual transmission of 
HCV is thought to be uncommon, but less so in high-risk populations 
(Terrault et al. 2013). 
2.1.4.5 Sharing of personal items 
Other documented means of transmission include sharing personal care items 
like toothbrushes, razors, nail clippers and other items that may come into 
contact with blood from HCV-infected individuals (Janjua et al. 2010, Lock 
et al. 2006). These routes of HCV transmission are not regarded as efficient 
and there is insufficient data to indicate their contribution to the transmiss ion 
of HCV (Janjua et al. 2010, Lock et al. 2006). However, researchers who 
tested the toothbrushes of HCV-infected individuals have found that 40% had 
detectable HCV RNA (Lock et al. 2006). In addition, a cross-sectional study 
conducted in a psychiatric institution indicated that razor-sharing was a 
plausible route of HCV transmission, after adjusting for age, duration of 
hospitalisation and history of surgery (Sawayama et al. 2000).  
16 
 
2.1.4.6 Tattooing and body piercing  
Although tattooing and body piercing involve potential percutaneous 
exposure, the risk of HCV transmission via these activities is very low 
provided that adequate infection control measures are in place (Jafarib et al. 
2007). However, non-professional tattooing and multiple tattoos have been 
associated with increased probability of HCV transmission (Haley and 
Fischer 2003, Nishioka et al. 2002). The relative contribution of body piercing 
as an independent risk factor for HCV is poorly defined, particularly in 
developed countries (Kim 2002, Shepard, Finelli, and Alter 2005). 
2.1.5 Prevalence of HCV 
HCV is a disease of global importance that requires multiple interventions for 
its prevention and control (Lavanchy 2011). The prevalence of HCV infect ion 
is approximately 2.2–3.0% worldwide, which equates to 185 million people 
infected with chronic HCV (WHO 2014). In developed countries, the highes t 
prevalence of HCV is among IDUs (Aceijas and Rhodes 2007). There are an 
estimated 10 million active IDUs worldwide (Nelson et al. 2011) and 8 
million have chronic HCV (Hagan et al. 2008).  
In Australia, the estimated prevalence of HCV is published in an annual 
surveillance report (Iversen and Maher 2015). This surveillance activity has 
been conducted every year since 1997 (Iversen and Maher 2015). However, 
notification rates of HCV in Australia do not necessarily reflect the number 
of recently infected individuals because the infection is often asymptomatic 
and people are unlikely to present for testing until sometime following 
exposure (Middleton et al. 2013 ). It has been estimated that 40,000–50,000 
Australians remain unaware that they are infected with chronic HCV 
(Middleton et al. 2013 ).  
The most recent estimate of the number of Australians who are anti-HCV 
antibody-positive is 308,110, a national prevalence of 1.3% (Sievert et al. 
2014). Of these, an estimated 80,000 individuals have cleared HCV naturally 
(Sievert et al. 2014). It has been reported that 230,470 Australians had chronic 
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HCV at the end of 2014 (Guy and McGregor 2015), giving a prevalence of 
HCV viraemia of 1.05% (Sievert et al. 2014). New South Wales had the 
highest number of reported chronic HCV infections (81,940), followed by 
Victoria (55,760), Queensland (47,950) and Western Australia (20,510) (Guy 
and McGregor 2015).  
According to recent Australian NSP surveys, the prevalence of HCV among 
IDUs was highest at 60% from 1995 to 2008, declining to 53–54% the over 
period 2010–2014 (Iversen and Maher 2015). The rate of new diagnoses of 
HCV in Australia has declined from 61 to 46 per 100,000 between 2005–2014 
(Guy and McGregor 2015). This decline has occurred in most age groups but 
is most noticeable among people aged 25–29 and 20–24 years (49% and 44% 
respectively) (Guy and McGregor 2015). However, these two age groups still 
had the highest rates of newly acquired HCV infections. Rates of HCV 
diagnosis in 2014 were almost five times higher in the Indigenous population 
than in the non-Indigenous population (Guy and McGregor 2015). Overall, it 
is predicted that the number of people with chronic HCV in Australia will 
reach 255,500 by 2025, then decline to 251,970 by 2030 (Sievert et al. 2014).  
HCV prevalence is estimated at 3.5% in Central and East Asia and in North 
Africa and the Middle East, and 1.5–3.5% in South and Southeast Asia, sub-
Saharan Africa and Latin America (Lavanchy 2011). The Asia-Pacific region 
and North America have an estimated prevalence of less than 1.5% (Lavanchy 
2011). The prevalence of HCV in Northern Europe ranges from 0.1% to 1%, 
in Central Europe from 0.2% to 1.2% and in Southern Europe from 2.5% and 
3.5% (Esteban, Sauleda, and Quer 2008).  
 
In Sub-Saharan Africa an estimated 28 million people are infected (Lavanchy 
2011), giving an HCV seroprevalence of 3%, ranging from 2.1% in Southeast 
Africa to 2.8% in West Africa to 7% in Central Africa (Hanafiah et al. 2013). 
The primary mode of HCV transmission in Africa has not been documented  
(Layden et al. 2014). Unsterile needles, unsafe transfusions of blood products 
and co-infection with HIV are plausible reasons, but lack of both primary data 
and population-based studies in Sub-Saharan Africa prevent determination of 
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the routes of HCV transmission (Layden et al. 2014). In Southern, East, West, 
and Central Africa the estimated prevalence of HCV is 1.8% in blood donors, 
2.5% in pregnant women, 3.5% in individuals with comorbid HIV, 5.4% in 
individuals from the general population, 8% in those with a chronic illness 
(diabetes and liver disease ) and 10.2% in those at high risk of infect ion 
(prisoners, IDUs, sex workers, hemodialysis patients, hospital workers and 
adults and children with sickle cell anaemia) (Mora et al. 2016).  
 
Egypt has the highest national prevalence of HCV. Frequent reuse of syringes 
during a schistosomiasis suppression program in the 1960s and 1970s spread 
HCV widely (Frank et al. 2000) and it is also associated with unsafe injection 
practices, lack of infection control in tertiary hospitals and use of unscreened 
blood for transfusions (Miller and Abu-Raddadb 2010). Older age groups 
have higher prevalence of HCV than younger groups (Umar et al. 2013 ): 
prevalence of chronic infection was 22.1% among people aged 55–59 years 
and less than 1% among people aged below 20 years in 2009 (Umar et al. 
2013 ). Also, social determinants of health, including education level, 
socioeconomic status, and place of residence can impact on HCV prevalence 
(El-Zanaty and Way 2009). For instance, HCV prevalence is higher in rural 
(5.1%) and illiterate people (14.5%) than in urban areas (3.1%) and among 
those who have completed secondary education or higher (4.1%) (El-Zanaty 
and Way 2009). Exposure to HCV information (therapeutic and preventive ) 
through the media (Chemaitelly, Abu-Raddad, and Miller 2013) and engaging 
in health education programs (Mohamoud et al. 2013) might also explain the 
disparity in HCV prevalence among urban versus rural residents and more 
educated versus less educated people.  
2.1.6 Burden of HCV disease  
The burden of HCV disease affects many countries, but differs widely 
between them (Mathurin 2013) depending on HCV prevalence, mean 
duration of infection, age, alcohol intake, and uptake and success of HCV 
treatment (Mathurin 2013). HCV is the most common cause of chronic liver 
disease, particularly in Australia, the USA, and Europe (Hanafiah et al. 2013). 
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As noted earlier, an estimated 2.8% of the world’s population suffer from 
HCV and a significant proportion of these people will develop liver 
complications. It is estimated that 350,000 to 500,000 people die per annum 
from HCV-related complications, mainly liver cirrhosis and HCC (WHO 
2015). The WHO has estimated that 27% of cirrhosis and 25% of HCC can 
be attributed to HCV worldwide (WHO 2015). 
Globally, the burden of HCV disease associated with HCC and cirrhosis is 
15–20 times higher among cases with chronic HCV infection compared to 
HCV RNA–negative but HCV antibody positive individual (El-Serag 2012). 
HCC is the fifth most common carcinoma and the third most common cause 
of cancer deaths globally (Parkin et al. 2005). HCC develops after 20 years 
of HCV infection and its risk increases among patients with cirrhosis or 
advanced fibrosis (Hanafiah et al. 2013).  
 
Epidemiological capacity varies greatly, so the HCV disease burden is not 
well understood in many countries (Averhoff, Glass, and Holtzman 2012 ). 
In some countries the burden of HCV disease is derived from serologica l 
surveys, but this method is too expensive for others, where the burden is 
estimated from other sources, such as surveys of blood donors, high-risk 
populations and pregnant women, and so is not generalisable to a wider 
population (Averhoff, Glass, and Holtzman 2012 ). A recent global 
assessment of HCV estimated that 195,700 people died from HCV-related 
HCC in 2010 (Razavi et al. 2014 ). Egypt has the highest burden of HCV 
disease, including an estimated 770,000 people with HCV-related cirrhosis 
and 16,000 with HCV-related HCC, and 33,000 HCV-related deaths from 
liver failure in 2013 (Razavi et al. 2014 ). Brazil has the next highest level of 
HCV related-HCC with 8,400, followed by Turkey with 2,200 infected 
people (Dore, Ward, and Thursz 2014). Denmark with 80 HCC cases and the 
Czech Republic with 70 have the lowest burden of HCV disease as measured 
by the incidence of HCV-related HCC, due to a very low HCV prevalence 
and young age distribution respectively (Dore, Ward, and Thursz 2014).  
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In Australia, HCV represents a major burden on the health system (Sievert et 
al. 2014). There was a high incidence of HCV infection among IDUs in the 
1980s and 1990s, and it is expected that, as the population ages, cases of HCC 
and HCV-related cirrhosis will increase considerably over the next two 
decades, inflating health costs (Sievert et al. 2014). The most recent data 
shows that there were 1430 cases of decompensated cirrhosis in Australia in 
2013 (Razavi et al. 2014 ) and 590 cases of HCV-related HCC in the same 
year. It is projected that these numbers will almost triple by 2030 (Razavi et 
al. 2014 ).  
 
HCV is the most common indication for liver transplantation in adults in 
Australia, which reflects the increasing burden of end-stage liver disease 
(HCC and liver failure) due to HCV (Sievert et al. 2014). Gidding and her 
colleagues collected data from all transplant units in Australia on all patients 
listed for liver transplantation over 1997–2006, finding that 30% had HCV-
related cirrhosis and 50% of recipients had HCC related to HCV (Gidding et 
al. 2009). The number of liver transplants attributable to HCV infect ion 
increased from 63 (33% of all liver transplants) to 81 (36%) between 2012 
and 2014 (Guy and McGregor 2015). In Australia, annual liver-related deaths 
increased from 250 to 630 over 2003–2013 (McDonald et al. 2014) and are 
forecast to increase to more than 1700 by 2030 (Sievert et al. 2014).  
2.1.7 History of HCV treatment  
The aim of HCV treatment is to eradicate the virus from the body, thus 
avoiding progression to liver damage and extrahepatic disease. Major 
advances in the treatment of HCV have occurred over the past two decades 
(Figure 2.1). Interferon treatment for non-A, non-B hepatitis was first 
introduced in 1986; administered for 24 weeks, it achieved normalisation of 
liver enzymes among 6–10% of those who were treated (Davis et al. 1989, 
Bisceglie et al. 1989). With the addition of ribavirin (which increases the 
antiviral action of interferon, as well as reducing the risk of relapse after 
completion) to interferon in the 1990s, SVR rates improved to 30% for 
genotype 1 (48 weeks’ treatment) and 62% for genotypes 2 and 3 (24 weeks) 
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(Poynard et al. 1998, McHutchison et al. 1998). The combination of 
interferon and ribavirin was adopted as the standard treatment in 1998, with 
ribavirin administered orally twice a day and interferon injected three times 
per week (McHutchison et al. 1998).  
Pegylated interferon was introduced in 2001 and again the SVR increased 
considerably, reaching up to 80% for genotypes 2 or 3 (24 weeks’ treatment) 
and 50% for genotype 1 (48 week) (Manns et al. 2001, Manns, Wedemeyer, 
and Cornberg 2006). Pegylated interferon was administered as a single 
injection once a week, along with ribavirin tablets taken twice daily. 
However, HCV treatment with either interferon or pegylated interferon had 
significant side effects such as flu-like symptoms (fever, fatigue, headache 
and muscle pain), lack of appetite, nausea and vomiting, injection site 
reactions and psychiatric side effects (depression, anxiety irritability and in 
some cases suicidal ideation and insomnia), compounded by ribavirin side 
effects including anaemia and skin rashes (Manns et al. 2001, Manns, 
Wedemeyer, and Cornberg 2006).  
 
Until 2011, pegylated interferon and ribavirin combination therapy with a 
duration of 24–48 weeks (depending on genotype) was considered the gold 
standard of HCV treatment. However, in 2011 a third drug, the first DAA (a 
combination of boceprevir and telaprevir), was added to the standard 
combination therapy for treatment of genotype 1 (Bacon et al. 2011, Poordad 
et al. 2011). These drugs were approved for use in Australia in 2012 and were 
listed on the PBS from April 2013 (HepatitisAustralia 2016) These first-
generation DAAs had additional side effects such as severe skin reactions 
(Lawitz 2011) and more marked anaemia (Poordad et al. 2011, Bacon et al. 
2011), but this triple therapy achieved SVR rates of 66–69% among 
treatment-naïve individuals with genotype 1 over 22–48 weeks. In treatment-
experienced cases, SVR rates reached 83% for those who had previous ly 
relapsed and 59% among partial responders (Ghany et al. 2011). Generally, 
SVR rates for patients with HCV genotype 1 infection reached 70%, 
significantly higher than the 50% achieved with pegylated interferon and 
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ribavirin (Poordad et al. 2011). Among those with cirrhosis, SVR rates were 
around 50% (Poordad et al. 2011, Bacon et al. 2011, Zeuzem et al. 2011).  
  
In 2013, a second-generation HCV-specific protease inhibitor known as 
simeprevir was released and approved for treatment of HCV genotypes 1 and 
4 (Manns et al. 2013). However, in Australia this preparation was not listed 
on the PBS until late 2014 (Thompson and Holmes 2015). Unlike telaprevir 
and boceprevir, this protease inhibitor did not cause additional side effects 
(Manns et al. 2013, Jacobson et al. 2013 ). SVR rates for simeprevir in 
combination with pegylated interferon and ribavirin among naïve patients 
with genotype 1 and 4 were around 80% after only 24 weeks (Manns et al. 
2013, Jacobson et al. 2013 ). However, prior to commencing treatment with 
simeprevir, HCV-infected individuals with genotype 1a should be screened 
for a genetic mutation known as Q80K polymorphism, which reduces the 
efficacy of simeprevir-containing triple treatment (Izquierdo et al. 2014). The 
frequency of Q80K varies by country and it is more common where HCV 
genotype 1a is predominant, such as in Europe and North America (Sarrazina 
et al. 2015 ). An SVR rate of 85% has been recorded in cases without the 
Q80K variant, compared to 50% in those with it (Jacobson et al. 2014). 
However, simeprevir is not recommended for patients who have previous ly 
been treated with pegylated interferon and ribavirin, with or without 
boceprevir/telaprevir (Izquierdo et al. 2014). 
 
The greatest development in HCV treatment to date occurred with the release 
of sofosbuvir in 2013. Sofosbuvir is a polymerase inhibitor and has pan-
genotypic activity (Lam et al. 2012). The addition of sofosbuvir to pegylated 
interferon and ribavirin resulted in SVR rates of 90% for patients with HCV 
genotype 1; 97% for genotypes 4, 5 and 6 among both naïve and treatment-
experienced patients within 12 weeks; 93% for patients with genotype 2 with 
cirrhosis; 85% for patients with genotype 3 with or without cirrhosis; and 
100% for patients with genotype 2 without cirrhosis (Lawitz et al. 2015). For 
genotypes 2 and 3, sofosbuvir and ribavirin without pegylated interfe ron 
achieved 93% and 85% SVR over 12 weeks and 24 weeks among naïve and 
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treatment-experienced cases respectively (Lawitz et al. 2015). Due to the 
success of these new anti-HCV drugs, sales and distribution of telaprevir was 
discontinued in 2014 and Merck announced that it planned to stop selling 
boceprevir by the end of 2015 (Jie and Douglas 2014).  
 
In 2014, new DAAs consisting of Harvoni, Viekira Pak (3D therapy) and 
daclatasvir were approved for treatment of HCV genotype 1. Harvoni is a pill 
with a combination of sofosbuvir and ledipasvir, and requires treatment for 8 
weeks for people with no treatment experience and no cirrhosis, 12 weeks for 
people with no treatment experience and cirrhosis, and 24 weeks for people 
with treatment experience and cirrhosis (Jensen and Holle 2016). Viekira Pak 
contains four antiviral drugs – paritaprevir, ombitasvir, ritonavir and 
dasabuvir – and is used for both treatment-naïve and treatment-experienced 
patients. Treatment duration and addition of ribavirin depend on whether 
cases are cirrhotic or non-cirrhotic and on genotype 1 subtype (Carrion, 
Gutierrez, and Martin 2014, Guido 2014, Kati et al. 2015). This medicine is 
given over a period of 12 weeks for genotype 1b with or without cirrhosis and 
1a without cirrhosis, and 24 weeks for 1a with cirrhosis (Ferenci et al. 2014, 
Poordad et al. 2014). Reported SVR rates with Harvoni and Viekira Pak are 
90–100% among naïve and previously treated cases (Lam et al. 2015, Ferenci 
et al. 2014, Esteban et al. 2014).  
 
Daclatasvir is given in combination with sofosbuvir, and achieves SVR rates 
of 95% among naïve and treatment-experienced patients with genotype 1. 
They are given for 12 weeks for people with both no treatment experience 
and no cirrhosis and 24 weeks for others (Sulkowski et al. 2014 ). The 
advantages of these DAA treatments over their predecessors are shorter 
duration of treatment, fewer side effects, and higher success rates in clearing 
the virus. Harvoni, sofosbuvir/daclatasvir, sofosbuvir/ribavirin and 
sofosbuvir/pegylated interferon and ribavirin were listed on listed on the PBS 
in March 2016, followed by Viekira Pak in May 2016 (DOH 2016). These 
new medications (interferon-free) are available for treatment of genotypes 1, 
2 and 3, the most common genotypes in Australia, and involve single oral 
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doses (HepatitisAustralia 2016). However, genotypes 4, 5 and 6 still require 
treatment with pegylated interferon and ribavirin in conjunction with one of 
these new medications (HepatitisAustralia 2016).  
 
The recommended treatment regimens for these new DAAs range from 8 to 
24 weeks and depend on HCV genotype, treatment history and the presence 
of cirrhosis, as indicated in Figure 2.1. In Australia, the actual cost of new 
DAAs is estimated around $100,000, however, Australian government has 
approved new dispensing cost. HCV treatment on the PBS and are available 
for the cost of a pharmacy. Treatment costs to general patients and 
concessional patients are $38.30 and $6.20 only for the pharmacy co-payment 
paid for a monthly prescription, respectively (HepatitisAustralia 2016). In 
addition, these new DAAs can be prescribed by general practitioners (GPs, 
who must consult a specialist) (HepatitisAustralia 2016). However, these new 
DAAs antiviral drugs require strict adherence in order to achieve successful 
outcomes of HCV treatment (Colpitts and Baumert 2016). Other DAAs are 
in the pipeline. Velpatasvir is currently under evaluation in various 
combinations in clinical trials (Gane et al. 2015). Other DAAs will 
undoubtedly become available in the near future.  
Figure 2.1 Recommended treatment regimens for the new DAAs 
Source: Hepatitis Australia (2016) 
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2.2 Intention to take up treatment  
Treatment intention refers to the intention to undertake treatment for active 
HCV. Intention to undergo HCV treatment is the result of an individua l’s 
evaluation of their ability to cope with treatment and consideration of 
alternative treatment options. Intention to undertake HCV treatment is viewed 
in some studies as willingness or readiness to undertake treatment (Stein, 
Maksad, and Clarke 2001, Fischer et al. 2005). Despite the variation in 
measurement methods of treatment willingness, most studies have reported 
high levels of intention to undertake treatment. A cross sectional study in the 
USA has found that nearly 81.5% of treatment-naïve HCV-infected IDUs 
aged 18-35 years intend to undertake treatment, particularly those who had a 
high perceived risk of developing liver disease and higher willingness to stop 
injecting drugs (Strathdee et al. 2005).  
 
An opioid use cohort study in a community setting in Sothern Canada 
reported that 80% of IDUs indicated willingness to participate in HCV 
treatment (Fischer et al. 2005). However, in the pre-DAA era, most IDUs 
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emphasised the low efficacy of HCV treatment, indicating willingness to 
undertake treatment, but only if it could guarantee they would clear the virus 
(Fischer et al. 2005). A similar level of to receive HCV treatment (77%) was 
reported by IDUs in two inner-city community health clinics in Vancouver 
and British Columbia (Grebely et al. 2008).  
 
An early Australian exploratory study of IDUs’ intentions and barriers with 
respect to HCV treatment in a primary health facility and methadone clinic in 
inner Sydney, reported that 70–80% of IDUs intended to be treated for HCV 
infection (Doab, Treloar, and Dore 2005). The most recent Australian cohort 
studies, which were conducted in opioid substitution treatment clinics and 
community health centres in New South Wales, indicated that 67% of 
participants were intending to receive treatment (Alavi et al. 2015). A cross-
sectional survey among clients of opioid substitution therapy clinics and the 
medically supervised injecting centre in Sydney reported that 53% of 
participants expressed willingness to undertake HCV treatment (Treloar et al. 
2012 ). The findings of high levels of treatment willingness in these studies 
could be due to recruiting of participants from community settings, where 
better opportunities for delivering HCV care to IDUs are provided, and/or due 
to the self-reporting of treatment willingness. 
 
Despite reporting high levels of intention to undertake treatment in the above 
studies and widespread availability, actual treatment uptake remains low 
among HCV-infected IDUs (Volk 2010, Grebely et al. 2009, Guy and 
McGregor 2015, Sievert et al. 2014). However, little recent data exists on the 
proportion of IDUs who have ever received treatment. A Canadian study 
reported that among 2118 HCV-infected IDUs, only 1.1% initiated treatment 
between 2003–2004; the rate of new HCV seroconversions in this cohort was 
25 times the rate of HCV treatment uptake (Grebely et al. 2009). One study 
collected launch and sales data from 21 European countries and estimated that 
3.5% of HCV-infected of individuals had been treated, ranging from 16% in 
France to 1% in Poland, by the end of 2005 (Lettmeier et al. 2008). Similar ly 
in the USA 663,000 of an estimated 3.2 million HCV-infected people 
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received HCV treatment over 2002–2007 (Volk et al. 2009). A large 
retrospective study in the USA reported the treatment rate was low in 
Veterans Affairs at 13% (251 of 1929 patients), which was similar to the 14% 
rate in HCV specialist clinics (3537 of 24,853 patients) over the period 2004–
2009 (Kramer et al. 2011).  
 
A recent Australian cross-sectional study which examined trends in HCV 
treatment uptake among HCV-infected IDUs who attended NSPs from 1999 
to 2011, reported that the proportion of participants who were on HCV 
treatment increased from 1.1% to 2.1% over this period. Likewise, the 
proportion of participants who had a lifetime history of HCV treatment 
increased from 3.4% to 8.6% between 1999 and 2011 (Iversen et al. 2014 ). 
Despite increases in the uptake of HCV treatment among IDUs in Australia 
over the period 1999–2011, rates of treatment among IDUs in Australia range 
from 1–2% per year (Guy and McGregor 2015, Sievert et al. 2014). Likewise, 
the rate of treatment uptake was less than 1% per year in the USA (Volk 2010) 
and Canada (Grebely et al. 2009). These low rates of treatment uptake 
reported by researchers may be accurate, but there are various factors 
associated with these low rates. The following section goes into deeper 
explanation of these factors.  
2.3 Factors influencing intention to undertake treatment  
2.3.1 Treatment characteristics  
HCV treatment in the pre-DAA era was associated with a wide range of 
physical and psychiatric side effects (Zickmund et al. 2006, Manns, 
Wedemeyer, and Cornberg 2006, Keating and Curran 2003) and on average 
individuals could expect to experience at least eight side effects during the 
course of treatment (Zucker and Miller 2001). An early study among those 
who experienced treatment showed that 10–50% of patients on HCV 
treatment discontinued it due to fatigue (Bernstein et al. 2002), while recent 
studies show that 10–14% of patients withdraw from treatment due to 
depression, anxiety, fatigue and/or headache (Ghany et al. 2009).  
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As noted earlier, physical and psychiatric side effects of HCV treatment, 
include flu-like symptoms (fatigue, headaches, muscle pain), depression, 
suicidal ideation, mood disorders, anxiety, nausea, hair loss, skin rash, 
anaemia, anorexia, lack of concentration and insomnia (Hopwood and Treloar 
2005, Russo and Frie 2003, Grebely et al. 2016, Grebely, Matthews, et al. 
2011a, McGowan and Fried 2012). These side effects debilitate patients and 
weaken their capacity to function normally (Sgorbini, O'Brien, and Jackson 
2009, Hopwood and Treloar 2005). Some patients undergoing treatment are 
unwilling to continue due to these side effects (Grebely et al. 2016, Grebely, 
Matthews, et al. 2011a, McGowan and Fried 2012). Pegylated interfe ron 
exacerbates pre-existing psychiatric problems such as depression, anxiety and 
mood disorders, which are common among HCV-infected IDUs (Alavi et al. 
2012, Sylvestre et al. 2004, Schaefer and Mauss 2008). It is reported that 
IDUs have higher prevalence of psychiatric disorders (22–49%) than the 
general population(17%) (Kessler et al. 2005).  
 
However, maintaining optimism before treatment (Treloar and Hopwood 
2008) and applying adaptive approaches such as learning from past 
experiences of drug dependence, living with chronic disease and coping with 
depression (Hopwood and Treloar 2008) enable some IDUs to manage 
treatment side effects. Numerous studies show that fear or concern about 
treatment side effects is one of the main reasons IDUs refuse to undertake 
HCV treatment when it is offered (Grebely et al. 2009, McNally, Sievert, and 
Pitts 2006, Fischer et al. 2005, Grebely et al. 2008, Doab, Treloar, and Dore 
2005, Treloar et al. 2014, Cooper and Mills 2006, Hopwood, Treloar, and 
Redsull 2006, Alavi et al. 2013 ).  
 
As discussed earlier, the standard pre-DAA HCV treatment, based on 
pegylated interferon and ribavirin, had relatively low efficacy in HCV-
infected people, particularly those with genotype 1 (Grebely et al. 2009, 
Manns, Wedemeyer, and Cornberg 2006, Mehta et al. 2008), and the overall 
efficacy of HCV treatment among IDUs was low (Doab, Treloar, and Dore 
2005, Stoove, Gifford, and Dore 2005, Fleming et al. 2003). A study 
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conducted in the USA among IDUs reported that of 418 participants who had 
heard of HCV treatment, 30 participants (7.2%) refused treatment, 76 (18.8%) 
were not interested and 20 (4.7%) deferred their treatment. Of the 292 
remaining participants, who indicated interest in treatment, only 55 agreed to 
commence treatment and of these only 5 participants cleared their HCV 
(Mehta et al. 2008). This study reported that low treatment effectiveness in 
achieving SVR was one of the main reasons that discouraged participants 
from undertaking HCV treatment (Mehta et al. 2008).  
 
An Australian study that evaluated IDUs’ attitude towards HCV treatment at 
different levels of efficacy reported that willingness to consider treatment 
increased with treatment efficacy, ranging from 36% to 93% for 20% and 
70% efficacy respectively (Doab, Treloar, and Dore 2005). In other studies, 
HCV patients stated that they would prioritise HCV treatment if they had a 
guarantee of clearing the virus (Fischer et al. 2005). Therefore, perceptions 
of and concerns about treatment effectiveness were significant barriers to 
HCV treatment uptake (McNally, Sievert, and Pitts 2006, Treloar, Newland, 
et al. 2010, Khokhar and Lewis 2007, Parkes et al. 2006).  
 
In addition to treatment side effects and efficacy, treatment duration is a 
concern for those considering HCV treatment (Falck-Ytter et al. 2002, 
Khokhar and Lewis 2007, Parkes et al. 2006). Lengthy treatment duration has 
led to low intention to undertake treatment and high dropout rates (Berg et al. 
2006, Fusfeld et al. 2013). Adherence is crucial, as IDUs who take more than 
80% of antiviral therapy for more than 80% of the required treatment duration 
are significantly more likely to eradicate the virus than those who do not 
(McNally, Sievert, and Pitts 2006). Nevertheless, treatment of 24 to 48 weeks 
duration with significant side effects can seriously interrupt the work and 
family life of IDUs (Hopwood and Treloar 2005, Hopwood, Treloar, and 
Bryant 2006). An abbreviated treatment duration of 12–24 weeks is 
reportedly more appealing to IDUs (Kamal et al. 2006, Rosa et al. 2006, 
Jaeckel et al. 2001, Wiegand et al. 2006). In particular, shorter treatment 
would be an advantage for IDUs who have comorbid psychiatric illness and 
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may lead to an increase in the number of patients interested in undertaking 
treatment (Grebely et al. 2010). For example, one study indicated that 
adherence to HCV treatment among patients with genotypes 1 and 2 was high 
for the first three and six months then after three and six months period after 
which individuals became reluctant to continue the treatment course (Kamal 
et al. 2006). Doubts about being able to complete treatment duration were 
reported in a study by Fusfeld et al. and participants in this study indicated 
that they would have been more willing to tolerate treatment side effects if 
treatment duration was shorter (Fusfeld et al. 2013).  
 
Each of the described studies demonstrates that factors such as lack of 
treatment efficacy, lengthy treatment duration and fear of treatment side 
effects can create a challenging treatment experience for IDUs. When this 
population is considered for such treatment, it is clear that there are also other 
significant factors that can make seeking treatment difficult for IDUs. The 
next section reviews the literature on social and personal factors in relation to 
the uptake of HCV treatment.  
2.3.2 Social and personal factors  
2.3.2.1 Stigma  
Researchers have suggested that the stigma associated with HCV and IDU 
can strongly influence IDUs’ intention to undertake HCV treatment. Stigma 
occurs within general society, the health care system and family/persona l 
relationships (Grebely et al. 2009, Harris and Rhodes 2013, Swan et al. 2010, 
Treloar, Rance, and Backmund 2013 ). The experience of stigma often leads 
to self-isolation, which decreases the intention to seek HCV treatment 
(Grebely et al. 2009). Harris, who conducted qualitative interviews with 40 
HCV-positive IDUs in New Zealand and Australia, noted that due to 
internalising the social stigma of HCV, some participants considered their 
HCV a lower priority than other health issues; they viewed HCV not only as 
a health issue, but also as a moral issue (Harris 2009).  
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The main cause of stigmatisation is society’s association of HCV with IDU 
(Nguyen et al. 2007), even for those who have contracted HCV through blood 
transfusion (Sgorbini, O'Brien, and Jackson 2009, Feiring, Taska, and Lewis 
1996). This assumption also exists in health care settings, where IDUs can be 
treated differently from others with chronic disease (Sgorbini, O'Brien, and 
Jackson 2009). A lack of knowledge and awareness of HCV within health 
care settings  as well as lack of interaction between health care providers and 
patients, in particular GPs, some of whom are not interested in providing care 
to IDUs can lead to stigmatisation (Hopwood and Southgate 2003, Zickmund 
et al. 2003, Sgorbini, O'Brien, and Jackson 2009). 
 
When disclosing their HCV status and/or drug use status, HCV-positive 
individuals often experience stigma from friends and family in the form of 
shame (Corrigan, Watson, and Miller 2006, Zickmund et al. 2003). Fear of 
being left alone, negative reactions, deterioration of relationships and being 
pushed aside or abandoned by their family prevents many from disclosing 
their status (Tinda, Cook, and Foster 2010). This can render people unable to 
cope with HCV treatment and its side effects (Zickmund et al. 2003). 
Therefore, stigmatisation of HCV and its association with IDU can reduce 
willingness to undertake HCV treatment (Grebely et al. 2009). Moreover, this 
stigma can limit the network of families and friends who could provide 
support during HCV treatment (Phillips and Barnes 2016 ). HCV-infected 
individuals have reported that their friends physically moved away from 
them, refused to approach them and reduced or stopped communication with 
them (Moore, Hawley, and Bradley 2009). 
Social support is a key factor in undertaking HCV treatment (Bangsberg 2008 
, Phillips and Barnes 2016 , Sylvestre and Zweben 2007, Grebely, Bryant, et 
al. 2011, McNally, Temple-Smith, and Pitts 2004), through the integration of 
partners or other important family members into HCV treatment (Sgorbini, 
O'Brien, and Jackson 2009). A supportive environment can assist individua ls 
to cope with the emotional and physical side effects of HCV treatment 
(Fraenkel et al. 2006) and improve treatment outcomes in general (Sgorbini, 
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O'Brien, and Jackson 2009). HCV patients who attended support groups 
benefited from talking with peers, who enabled them to validate the quality 
and severity of their symptoms (Fraenkel et al. 2006) maintain motivation in 
the face of adverse effects and share coping strategies (Rifai et al. 2006). It 
has been reported that individuals who have social support, live with family 
and/or friends (Alavi et al. 2013 , Alavi et al. 2015, Grebely, Bryant, et al. 
2011) and/or have peer support (Treloar et al. 2014, Grebely et al. 2007, 
Crawford and Bath 2013, Norman et al. 2008) are more likely to be assessed 
for HCV treatment and are best equipped to undertake it.  
The research outlined above demonstrates that significant stigmatisation and 
lack of social support exist in various forms and from several sources, and 
foster feelings of isolation within HCV-infected IDUs, thereby decreasing 
their intention to engage with health care settings, especially in seeking HCV 
treatment. A significant factor in eliminating stigma, highlight the importance 
of social support and so increasing the uptake of treatment is the identificat ion 
of the sources and experience of both stigma and lack of support for IDUs. 
2.3.2.2 Housing status  
Unstable housing has been identified as one of the main factors that deter 
IDUs from undertaking HCV treatment (Mehta et al. 2008, Harris and Rhodes 
2013, Cooper 2008). IDUs are more likely to experience unstable housing 
than members of the non-IDU population and this fundamental disadvantage 
reduces their ability to undergo HCV treatment (Harris and Rhodes 2013). A 
strong association exists between unstable housing and low HCV treatment 
uptake (Strathdee et al. 2005, Charlebois et al. 2012, Grebely, Bryant, et al. 
2011).  
A US study found that homeless IDUs reported drug treatment was 
ineffective in promoting abstinence because of their lack of stable 
accommodation after treatment (Freund and Hawkinsb 2004). Homeless 
IDUs are more likely to suffer from physical and mental health problems 
(Fischer et al. 2006, Gundlapalli et al. 2015 ), be involved in illegal activit ie s 
for the purpose of income generation (Fischer et al. 2006), share needles 
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(Jarlais, Braine, and Friedmann 2007), and consume alcohol in a risky manner 
than those who are stably housed (Gundlapalli et al. 2015 , Charlebois et al. 
2012, Cooper and Mills 2006, Stein et al. 2002). Lack of a permanent address 
and telephone number make it difficult to make and keep doctors’ 
appointments, register with health care services, safely store medications, 
cope with treatment side effects and meet basic needs during treatment 
(Harris and Rhodes 2013). 
A study assessing the factors affecting care-provider decisions to initiate 
HCV treatment for HIV/HCV co-infected homeless and marginally housed 
people found that the most common reasons for not offering HCV treatment 
were likelihood of poor medication adherence, depression, being a current 
IDU, and lack of patient interest in treatment (Thompsona et al. 2005). 
However, many clinicians were unwilling to recommend pegylated interfe ron 
and ribavirin for homeless HCV-positive people due to the drugs’ side effects 
(Gundlapalli et al. 2015 ). An Australian study of the uptake of HCV 
treatment among clients of an opiate substitution program reported that a 
homelessness and unstable housing  as barriers to engage with HCV treatment 
(Treloar, Newland, et al. 2010). Hence, homeless HCV sufferers are less 
likely to be treated than stably housed patients (Gundlapalli et al. 2015). 
Likewise, Charlebois et al. (2012) reported housing status was significantly 
associated with commencement of treatment: 87.5% of those who underwent 
treatment had stable housing compared to 62.8% of those who did not. This 
is confirmed by previous studies showing that provision of housing and 
housing improvement result in better health behaviours and outcomes 
(Fitzpatrick-Lewis et al. 2011, Thomson et al. 2009). Beyond, the 
characteristics of treatment, stigma, lack of social support and homelessness 
status, there is another significant factor that influence whether IDUs to 
accept or refuse HCV treatment. This factor, peer experience, which is 
discussed in the following sub section.  
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2.3.2.3 Peer experience 
Circulation of positive information among peers can encourage HCV-
infected IDUs to undergo treatment, but the reverse is also true. For example, 
a study showed that peer-delivered information about adverse effects, 
including depression, mood swings, weight loss, hair loss and experiences 
similar to heroin withdrawal, aroused fear among HCV-positive IDUs and 
made them reluctant to engage with HCV treatment (Swan et al. 2010). 
However, the same study showed that observing peers and family members 
who completed HCV treatment (even with unpleasant side effects) and 
obtained successful outcomes motivated IDUs to undergo treatment (Swan et 
al. 2010). Similarly, other research shows that many HCV-positive people are 
discouraged from undertaking treatment due to hearing negative comments 
about HCV medications (Munoz-Plaza et al. 2008, Treloar and Holt 2008).  
Participants in one study reported that their attitudes about undertaking HCV 
treatment were based on either seeing peers going through treatment or 
hearing positive stories about treatment (Bova, Ogawa, and Sullivan-Bolya i 
2010). An Australian study found that HCV-positive IDUs who engaged with 
HCV treatment were motivated by seeing friends become well and hearing 
positive stories of treatment (Treloar et al. 2014). A national study reported 
that participants obtained benefits from hearing about peers’ experiences in 
support groups or through knowing peers who completed treatment, in 
particular for coping with treatment side effects (Hopwood, Treloar, and 
Redsull 2006). Previous studies have highlighted that oral messages spread 
among HCV-positive IDUs can be effective in promoting HCV treatment 
(Swan et al. 2010, Carriera, Laplanteb, and Bruneau 2005, Munoz-Plaza et al. 
2008, Treloar, Byrona, et al. 2010). Along with peer experience, there are 
several personal factors that have also been shown to motivate treatment 
uptake. The following sub section describes some personal motivating factors 
associated with HCV treatment intention.  
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2.3.2.4 Encouraging factors 
The literature on IDUs’ experience of motivating factors for uptake of HCV 
treatment is sparse. However, there are findings from a few studies that 
highlight some facilitating factors, but not specifically among HCV-infected 
IDUs. For example, a US qualitative study conducted among HCV/HIV co-
infected individuals where 95% of participants had a history of substance 
abuse reported four facilitators for HCV treatment uptake: experience in 
disease management; strong patient–provider relationships; gaining sober 
time; having a ‘just get it done’ attitude; and facing treatment head-on (Bova, 
Ogawa, and Sullivan-Bolyai 2010). Taking responsibility for children, 
obtaining information from health care professionals, the influence of trusted 
health professionals and reading material were shown to increase IDUs’ 
interest in taking up HCV treatment in Dublin, Ireland (Swan et al. 2010). In 
particular, information from health care professionals can change perceptions 
of treatments and side effects, and relieve fears (Swan et al. 2010). The 
availability of HCV care and readiness to stop using drugs have also been 
associated with heightened uptake of HCV treatment among IDUs (Strathdee 
et al. 2005). A recent US study identified five motivating factors for initiat ion 
and completion of HCV treatment: possible future health problems due to 
HCV; patients’ willpower; the stage of liver disease; availability of emotiona l 
support; and doctors’ advice (Fusfeld et al. 2013).  
Becoming symptomatic, having physical health problems, a diagnosis of liver 
damage (Swan et al. 2010, Strathdee et al. 2005, Grebely et al. 2008) and the 
desire to promote one’s own health (Lally et al. 2008) and improve life overall 
(Swan et al. 2010) were identified as motivators by HCV-infected IDUs for 
receiving HCV treatment. Australian studies conducted in an opioid 
substitution therapy setting reported the desire to live longer and carry on with 
family responsibilities (Treloar et al. 2014) and encouragement from a trusted 
health professional (Treloar et al. 2014, Treloar, Newland, et al. 2010, 
Grebely, Bryant, et al. 2011) motivated IDUs to undergo HCV treatment. 
Another qualitative study of Australian prisoners who took up treatment in 
prison found the most common motivating factors were: protection of family, 
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partners, children and grandchildren; health and wellbeing; career; drug use 
cessation; and life-changing events (Yap et al. 2014). Swan et al. (2010) 
found that individuals who undertook HCV treatment or were interested in 
undertaking it in the future were usually motivated by emotional bonds with 
partners and children and responsibilities for family, and a desire to move on 
from injecting drugs (Mehta et al. 2008). In addition to the treatment 
facilitators earlier discussed, it is important to understand what other 
characteristics can influence treatment intention. Some of other 
characteristics are discussed briefly in the sub section below.  
2.3.2.5 Additional factors  
Although there is a lack of evidence on the associations between socio-  
demographic and drug-history characteristics, awareness of HCV genotype 
and HCV treatments and intention to take up treatment, several researchers 
have documented the relationship between specific demographics and 
intention to uptake treatment. For HCV genotype, a few have studies found 
that IDUs with non-1 HCV genotypes had higher intention to undertake HCV 
treatment (Alavi et al. 2015, Alavi et al. 2013 ). Other studies from the USA 
also reported that patients were less likely to undergo HCV treatment if they 
had genotype 1 (Kramer et al. 2011, Kanwal et al. 2007).  
IDUs with better knowledge of HCV treatment were more likely to report 
higher intention to have HCV treatment (Treloar et al. 2012 ). In other 
research, injection of illicit drugs and alcohol intake influenced the uptake of 
HCV treatment more than clinical factors (Gidding et al. 2011) and were 
significantly associated with deferral of HCV treatment (Grebely et al. 2009, 
Grebely, Bryant, et al. 2011, Gidding et al. 2011, Kramer et al. 2011, Grebely 
et al. 2008). Similarly, a study by Butt et al. reported that intake of both 
alcohol and illicit drugs were predictive of non-treatment for HCV (Butt et al. 
2007). Heroin use has been independently associated with decreased uptake 
of HCV treatment (Grebely et al. 2008, Kramer et al. 2011) and 
methamphetamine use marginally associated with higher intention to 
undertake HCV treatment (Alavi et al. 2015).  
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A Canadian survey of IDUs revealed that male IDUs showed greater intent ion 
to undertake HCV treatment compared to their female counterparts (Grebely 
et al. 2009). However, a US study reported that males, both IDUs and non-
IDUs, were less likely to undergo HCV treatment(Kramer et al. 2011). In an 
Australian study, there was no significant difference in the intention to 
undertake HCV treatment between genders, with 47% of female IDUs 
expressing intention to take up treatment compared to 53% of male IDUs 
(Alavi et al. 2015).  
The importance of ethnicity on treatment intention is also discussed in the 
literature, indicating a relationship between ethnicity and intention to take up 
treatment. For instance, Indigenous Australians struggle to undertake HCV 
treatment compared to non-Indigenous people (Alavi et al. 2015, Grebely et 
al. 2009, Alavi et al. 2014). US studies have also found African-American 
were less likely to undergo HCV treatment compared to Caucasians (Butt et 
al. 2007, Kramer et al. 2011). Other demographic characteristics reported to 
be associated with HCV treatment intention include older age – 35–45 years 
(Alavi et al. 2015) and ≥ 65 years old (Kramer et al. 2011) – and living with 
a spouse or other relatives/friends (Alavi et al. 2015, Alavi et al. 2013 ). 
2.4 Summary of the literature  
The hepatitis C virus was cloned and named in 1989. Although up to 25% of 
acute cases of HCV infection resolve spontaneously and infection is often 
asymptomatic for many years, the majority of acute infections, 75%, progress 
to chronic infection and can cause severe and even life-threatening 
complications in the long term. Development of liver disease is often 
measured over decades and is characterised by hepatocellular damage, 
inflammation and fibrosis. Worsening hepatic fibrosis may ultimately lead to 
cirrhosis, decompensated liver disease, HCC and end-stage liver disease, 
which requires liver transplantation. HCV is transmitted through blood-to-
blood contact and sharing drug-injecting equipment is the dominant mode of 
transmission. Other forms of transmission (blood transfusions from infected 
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donors, tattooing and body piercing, sexual intercourse and vertical 
transmission during childbirth) are less common and pose smaller risks.  
HCV prevalence in Australia is estimated to decrease by 2030, but if 
treatment uptake remains low, the numbers of HCV-associated cases of 
cirrhosis and HCC will increase, leading to substantial health care costs. 
Despite the widespread availability of HCV treatment in Australia, uptake 
remains low, particularly among IDUs – the population group with the 
greatest future disease burden. The literature shows that several factors 
influence the intention of HCV-positive IDUs to undertake treatment: 
treatment side effects; low treatment efficacy; lengthy treatment duration; 
lack of support; peers’ experiences of treatment; stigma associated with IDU 
and HCV; unstable housing; and the desire to protect family, increase quality 
of life and maintain a career. The next chapter describes the research 
methodology and study design to address the research objectives.  
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Chapter 3: Methods  
This chapter describes the methodology used in this study, this study design 
and site, the procedures used for the data collection, the data cleaning, 
analysis and storage. Methods employed to ensure reliability of the data are 
also presented. Furthermore, this chapter describes the ethical considerations 
related to the study. 
3.1 Mixed-methods research  
A mixed-methods approach enables the researcher to capture the details of a 
situation by providing rich and meaningful data that reflects participants ’ 
views at the individual level (Bryman 2015). This method consists of a two-
phase design in which the qualitative research is conducted first and informs 
the following quantitative research. This design is particularly helpful when 
the variables of interest are unidentified (Creswell and Clark 2007).  
 
The central principle of mixed-methods research is combining quantitat ive 
and qualitative approaches, rather than using each method in isolat ion 
(Creswell and Clark 2007). Creswell (2003) classified mixed-methods 
research into six groups: sequential explanatory; sequential exploratory; 
sequential transformative; concurrent triangulation; concurrent nested; and 
concurrent transformative (Creswell 2003). The sequential explanatory 
category refers to the researcher collecting quantitative data then qualitat ive 
data, while in the sequential exploratory category the qualitative data is 
collected first (Creswell 2003). Combining quantitative and qualitative data 
in a single study allows the researcher to gain better understanding of complex 
phenomena (Creswell and Clark 2007). Johnson and Onwuegbuzie (2004) 
asserted that “researchers should collect multiple data using different 
strategies, approaches, and methods in such a way that the resulting mixture 
or combination is likely to result in complementary strengths and non-
overlapping weakness” (Johnson and Onwuegbuzie 2004,18).  
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Although the two types of data can be combined effectively, there are 
considerable theoretical differences between qualitative and quantitat ive 
research paradigms. Quantitative researchers have a positivist or empiric is t 
ideology, which highlights observable phenomena. Bryman (1984) stated that 
“the paraphernalia of positivism are characterized typically in the 
methodological literature as exhibiting a preoccupation with operational 
definitions, objectivity, replicability, causality, and the like”(Bryman 
1984,77). Through forms of random sampling, quantitative methods enable 
the researcher to generalise from the data collected from the sample to the 
entire population. Quantitative research typically involves a greater number 
of participants than qualitative research. It focuses on describing the concepts 
at hand and the relationships between them. “Quantitative researchers seek 
explanations and predictions that will generate to other persons and places. 
The intent is to establish, confirm, or validate relationships and to develop 
generalizations that contribute to theory” (Leedy and Ormrod 2005, 102). 
In contrast, qualitative researchers “argue for the superiority of 
constructivism, idealism, relativism, humanism, hermeneutics, and, 
sometimes, postmodernism”(Johnson and Onwuegbuzie 2004,14). 
Qualitative research attempts to achieve understanding of the meanings that 
people depict from the conditions and actions in which they are involved 
(Creswell 2009). This is useful method when there is a need to explore a 
phenomenon involving people whose voices have been inaudible and should 
be heard, as well as when a problematic condition needs to be explored in 
more detail (Creswell 2009). Having direct contact with an individua l 
experiencing the phenomenon in their natural surroundings, where they can 
tell their hidden stories, plays a significant role in achieving the detailed 
understanding possible with qualitative research (Creswell 2007).  
Qualitative data collection can be sensitive and informative, and its analysis 
can create patterns or themes which reflect participants’ opinions and the 
researcher’s reflexivity (Creswell 2007). However, qualitative research 
approaches are limited to studying small numbers of individuals in depth, 
which means the results cannot be generalised or used for quantitat ive 
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predictions (Sim and Wright 2000). Furthermore, qualitative research is time-
consuming and more labour-intensive than quantitative research (Sim and 
Wright 2000).  
3.2 Research design  
Given the nature of the phenomena of interest in this study, a sequentia l 
exploratory mixed-methods research study (QUAL → QUAN) was designed 
to develop a better understanding of the context of treatment intentions of 
IDUs in metropolitan Perth, Western Australia. The study involved collect ion 
and analysis of qualitative data in the form of personal interviews and focus 
groups, followed by quantitative data collected using a questionnaire-based 
survey. In this study, the qualitative component was dominant. It was 
conducted first to obtain richly detailed descriptions of participants’ opinions 
regarding the factors that influenced their intentions to undertake treatment. 
The qualitative phase informed the quantitative phase and was designed to 
examine the associations between the HCV treatment intention and socio-
demographic characteristics, drug-history characteristics and health-care-
seeking characteristics, support, treatment factors and stigma among HCV-
infected IDUs.  
There were three benefits to this sequential mixed-methods process (Greene, 
Caracelli, and Graham 1989). Firstly, it allowed the researcher to create a 
novel data collection instrument for assessment of the intentions of IDUs in 
regards to uptake of HCV treatment. Secondly, using this design enabled the 
researcher to quantitatively study specific themes that arose from the 
qualitative data and better determine associations between the dependent and 
independent variables. Third, although the design of this study emphasised 
qualitative aspects, it included a quantitative component to add understand ing 
about predictors of intention to undertake HCV treatment.  
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3.3 Study population  
The target population comprised male and female HCV-infected IDUs aged 
18 years and older living in the Perth metropolitan area. 
3.4 Study Site 
Participants were recruited through organisations that provide NSP services 
to IDUs. The West Australian Substance Users Association (WASUA) and 
WA AIDS Council (WAAC) are Perth’s primary NSP service providers that 
offer needle and syringe exchange program (NESP) and provides outreach 
van services. HepatitisWA is a non-profit community organisation which 
provide free services to the community and is a secondary NSP service 
provider. It provides care and support for individuals affected by viral 
hepatitis and works to increase community awareness of hepatitis. 
3.5 Study duration  
Data collection occurred over 26 months from September 2012 to November 
2014. Semi-structured interviews were conducted between September 2012 
and March 2013, focus groups from June 2013 to August 2013, and 
quantitative data collection from December 2013 until November 2014. 
3.6 Qualitative study  
As noted earlier, the qualitative phase of this study was designed to explore 
factors influencing intentions of HCV-infected IDUs with respect to HCV 
treatment through collection and analysis of rich descriptions of the 
perceptions of IDUs who had and had not experienced treatment. Data was 
collected using semi-structured interviews and focus groups. The focus 
groups were used to follow up the themes identified from the semi-structured 
interviews and to explore HCV-infected IDUs’ perceptions about triple 
treatment. The information obtained in the qualitative phase supported 
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development of the survey questionnaire for the quantitative phase of the 
study. 
3.6.1 Sampling  
The study adopted a non-probability sampling approach using purposive 
sampling and ‘snowball sampling’. In purposive sampling, participants are 
chosen based on their knowledge of phenomena and their characterist ic s 
(Bryman 2015). Participants in this study were purposively selected using 
certain criteria to ensure the sample covered an appropriate group of IDUs 
who had experienced HCV treatment (the treatment group) and who had not 
(the non-treatment group and focus groups). Purposive sampling was utilised 
to recruit the desired number of participants for each group. In snowball 
sampling, potential participants are nominated or suggested by existing 
participants. The snowball technique is the most common form of purposive 
sampling and is useful when participants are not easily accessible (Suri 2011), 
enabling the researcher to approach potential participants who were familia r 
about a given research topic.  
3.6. 2 Data collection  
3.6.2.1 Semi-structured interviews  
The first phase of data collection for this research project involved semi-
structured interviews. A semi-structured interview format provided a uniform 
set of topics to discuss with each participant, as well as the flexibility to probe 
and draw rich descriptive statements from the participants, explore the 
phrasing of questions, and identify new ways of understanding the 
phenomenon under study (Patton 2002). Semi-structured interviews were 
used to explore the factors influencing the intentions of HCV-infected IDUs 
in regards to treatment uptake, experiences of HCV-related stigma and beliefs 
about HCV treatment. The researcher developed an interview guide through 
a series of informal discussions with the primary supervisor and reviews of 
past research in the field. The interview questions began with socio-
demographic and drug-history questions (see Appendix 1) which were 
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adopted from a 1995 study (Loxley, Carruthers, and Bevan 1995), and then 
the questions asked in the interviews with the treatment group (see Appendix 
2) were slightly different from those asked of the non-treatment group (see 
Appendix 3). This was necessary to identify the perceptions of IDUs who had 
experienced treatment regarding the factors that influenced their 
commencement and discontinuation of treatment, as well as the perceptions 
of IDUs who had not experienced treatment regarding the factors that stopped 
them from undergoing treatment. Interviews took approximately 30–45 
minutes and this timing meets the recommended guidelines for this method 
(Gill et al. 2008). 
3.6.2.2 Focus groups  
Focus groups were the second data collection tool. They allowed the 
researcher to capture rich and detailed descriptions of HCV-infected IDUs 
with no treatment experience regarding triple therapy as requiring further 
explanation. The researcher developed the focus group questions (see 
Appendix 4) through consultations with HCV experts (primary supervisor 
and HCV nurse consultant at WASUA). The interview guide consisted of 5 
open-ended questions. Demographic and drug-history questions were simila r 
to those of the semi-structured interviews (see Appendix 1). The initial focus 
group question was an ‘icebreaker’ to get the participants warmed up and 
comfortable with the group, and to build confidence and willingness to 
participate. More sensitive questions were asked later, once trust had been 
established with the participants. Focus group discussions took 60–80 
minutes.  
3.6.3 Recruitment  
The researcher gave verbal presentations about the study to the managers of 
WASUA and HepatitisWA, after which they consented to support the 
research. Participants were recruited from these settings using posters (see 
Appendices 5, 6 and 7) and information sheets (see Appendices 8 and 9) 
which placed where IDUs could see them during routine visits in the selected 
settings. Inclusion and exclusion criteria are documented in Table 3.1. IDUs 
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who self-reported as having received an HCV diagnosis from a health care 
professional (confirmatory tests were not carried out) and were interested 
were asked to contact the researcher directly. Potential participants contacted 
the researcher by telephone to ask further questions and arrange an 
appointment for the interview. Interviews occurred in a suitable room on the 
premises of the organisations involved in recruitment, or at local cafes, on 
dates and times convenient to the participants. All focus group discussions 
took place at WASUA. 
Information and consent forms (see Appendix 10) were presented to 
participants prior to the semi-structured interviews. After the consent form 
had been signed, the researcher asked permission to digitally record the 
interview. Focus groups were held in spacious rooms that offered comfort, 
privacy and good ventilation and lighting. Light refreshments were provided 
at all sessions before the start of the discussion. These discussions were 
facilitated by the researcher. The participants and the researcher sat in a circle 
to create a friendly and non-threatening environment and to allow all 
participants to see and hear each other clearly. Each focus group discussion 
commenced with a welcome followed by a brief description of the intentions 
and procedures for the discussion, including expectations, discussion, 
duration and ethical considerations. Participants were provided with 
identification numbers to protect their identities. 
3.6.4 Sample Size  
The sample size for semi- structured interviews is suggested to be around 20-
25, but a topic with two groups should be doubled up (Trotter 2012) and for 
focus groups should range from 5–10 (Onwuegbuzie et al. 2009). Eventually, 
the researcher interviewed 46 IDUs – 21 with treatment experience (treatment 
group) and 25 without (non-treatment group). Five focus groups were 
conducted, with five participants in each. The researcher expected that these 
numbers would provide rich data. All participants were reimbursed for their 
time and effort with an AU$35 supermarket voucher. Providing 
reimbursement for people who use illicit drugs and who give up their time 
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and their expertise to contribute in research is an acceptable method within 
the research framework (UN 2004). Table 3.1 summarises the inclusion and 
exclusion criteria for the qualitative phase. The main reason for choosing only 
genotype 1 for focus groups was because triple therapy was only used for 
genotype 1.  
Table 3.1 Inclusion and exclusion criteria for the qualitative phase 
 Semi-structured interviews 
 
 
 Treatment-group  Non-treatment-
group 
Focus group 
Inclusion 
criteria 
1. Current IDU who 
is actively injecting  
2. Currently being 
treated or have 
recently been treated 
for chronic HCV 
(within the past 2 
years) 
3. Living in Perth  
4. 18 years or older  
5. Fluent in and 
could read and write 
in English 
1. Current IDU who 
is actively injecting 
2. Received an HCV 
diagnosis more than 
6 months earlier by 
a health care 
professional 
3. Did not take up 
HCV treatment 
4. Living in Perth  
5.18 years or older 
6. Fluent in and 
could read and write 
in English 
 
1. Current IDU who is 
actively injecting 
2. Received an HCV 
diagnosis Genotype 1 more 
than 6 months earlier by 
health care professional  
3. Aware of new treatment 
as triple therapy (pegylated 
interferon and ribavirin in 
combination with either 
boceprevir and telaprevir) 
for chronic HCV  
4. Did not take up HCV 
treatment  
5. Living in Perth 
5. 18 years or older 
7. Fluent in and could read 
and write in English 
 
Exclusion 
criteria 
1. Past IDUs 
2. Did not read or 
speak English  
 
1. Past IDUs 
2. Did not read or 
speak English  
 
1. Past IDUs  
2. Did not read or speak 
English 
 
 
3.6.5 Validity and reliability -qualitative study  
In qualitative research, the validity of interview data depends on how the 
researcher designs the interview questions and collects the data. In this study, 
interviews were digitally recorded then transcribed by the researcher, 
increasing the researcher’s familiarity with the data. NVivo analysis software 
(QSR, Melbourne) was used to prevent coding and transcription errors 
(Gerard et al. 2009 ). In order to maximise the validity of the data collected 
from the study participants, the researcher pilot-tested the semi-structured 
interview schedule with 10 IDUs and the manager at WASUA in September 
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2012. The focus group interview guide was pretested with one group of four 
IDUs in June 2013. They were reimbursed with $30 supermarket vouchers. 
No pilot-test participants had difficulty in understanding the questions and it 
was recommended that there was no need for changing or editing the fina l 
version of the interview guide. 
In terms of the reliability of data collected from interviews, it has been 
suggested that IDUs are less likely to be reliable in their responses than other 
populations because of intoxication “or because of a need to dissemble in 
order to facilitate a stigmatized and illegal lifestyle in a largely hostile 
environment” (Ross et al. 1995, 2). However, many researchers disagree with 
this view. It is indicated that interview data from drug users is reliable and 
their responses show (unexpected) veracity (Dowling-Guyer et al. 1994, 
Napper et al. 2010, Hagan et al. 2006a). Likewise, other scholars have 
suggested that unreliability is principally “associated with poorly worded 
questions and respondent characteristics” (Needle et al. 1995, 242). These 
scholars argued that if drug users are well informed about the purpose of the 
study, the interview questions and the reimbursement for their research time, 
their responses can be reliable. 
3.6.6 Data analysis  
The qualitative data collected from the semi-structured interviews and focus 
groups were managed using ©QSR NVivo 10 software in order to organise 
and prepare the qualitative data for analysis. Sequential thematic analysis of 
interviews and focus groups data took place separately, which allowed the 
researcher to compare emerging codes from both individual interview data 
and focus groups data. This analysis was used to clarify relevant data and 
classified into themes, using several steps which are described below. The 
steps involved in the analysis were similar for both sets of data.  
1. Familiarisation prior to commencing any coding of data. The researcher 
transcribed each interview and focus group in a sequential order to become 
more familiar with the data. Reading and re-reading of transcriptions was 
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performed to identify meaningful ideas and create an initial list relating to 
treatment intention of HCV-positive IDUs about the uptake of HCV 
treatment. 
2. Creating initial codes by coding items through the whole data set and then 
gathering data relevant to each code. Codes refer to “the most basic segment, 
or element, of the raw data or information that can be assessed in a 
meaningful way regarding the phenomenon” (Boyatzis 1998 ,88). Transcripts 
were re-read several times to achieve a general sense of the data. Themes and 
patterns were then identified and documented across questions and 
participants (Braun and Clarke 2006). These first two steps aimed to explore 
the main themes emerging from the interviews and discussions, and to 
commence organising them. 
3. After identifying an extensive list of the various codes from the interviews 
and discussions, the researcher searched for themes by gathering these codes 
into potential themes and collating all relevant data to each potential theme. 
Hence, ideas were categorized into themes and entered into the NVivo 
software. 
4. The researcher checked that the themes applied worked in relation to the 
coded extracts. Also, the researcher regularly referred to the research 
questions (see Chapter 1) in order to ensure that the analysis remained 
focused. In the following qualitative results chapter, these themes are 
illustrated with quotes (stripped of identifying information). Findings were 
organised in relation to the main domain of data collection: the factors 
influencing the intention of HCV-infected IDUs to undertake treatment in 
Perth.  
 
5. The common themes were used to design and develop the survey 
questionnaire in phase two.  
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3.7 Quantitative study  
A cross-sectional survey was conducted to measure the prevalence rate of 
intention of HCV-infected IDUs to undertake HCV treatment in the Perth 
metropolitan area and to examine the associations between intention to 
undertake HCV treatment and socio-demographic characteristics, drug-  
history characteristics and health-care-seeking characteristics, treatment side 
effects, treatment efficacy, treatment duration and stigma. The quantitat ive 
phase was designed to identify the predictors of intention to undertake HCV 
treatment. This phase was guided by the themes arising from the qualitat ive 
interviews. (As mentioned previously, the qualitative interviews provided  
data which helped the researcher to construct an instrument to assess the 
factors influencing the intentions of IDUs towards HCV treatment uptake.) 
Activities in this phase of the research consisted of developing and 
conducting a questionnaire-based survey. 
3.7.1 Sampling  
The study planned to recruit 336 IDUs from the Perth community setting, 
using the formula given below. Existing data on intention to undertake HCV 
treatment was used to determine the sample size. An exploratory Australian 
study found that almost 70% of participants intended to have HCV treatment 
(Doab, Treloar, and Dore 2005), while another found that 67% of HCV-
positive IDUs intended to have HCV treatment (Alavi et al. 2015). This study 
used the higher proportion of 70%, that is, it was assumed that 70% of the 
sample would intend to undertake treatment and 30% would not intend to 
undertake treatment. By an acceptable sampling error of 5% at a 95% level 
of confidence (Vaus 1991) and employing the following formula (Kirkwood 
2000), confirmed by a statistician at Curtin University (Y.Zhao, personal 
communication Jaunary10, 2013), the sample size was calculated as shown 
in Figure 3.1.  
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Figure 3.1 Sample size formula 
n (1-n) = 70(100-70) = 336   
e2  2.5 2 
 
Where: n is the proportion  
e= the required size of standard error  
 Sampling error is two standard errors. 
 
The eligibility criteria for study participants were: 18 or more years of age; 
current IDUs who were actively injecting drugs; self-reported as having 
received an HCV diagnosis by a health care professional more than 6 months 
(confirmatory tests were not carried out) prior to interview; no experience of 
HCV treatment; living in the Perth metropolitan area; able to read and speak 
English; and able to provide informed consent. 
3.7.2 Data collection  
The survey questionnaire was used to collect information from the targeted 
336 participants on demographic characteristics, drug-use history, health-
care- seeking characteristics, aspects of treatment, stigma, support and their 
intention to undertake treatment (see Appendix 11). A questionnaire was 
attached with a brief description of HCV standard combination treatment and 
triple therapy in order to give participants basic knowledge of HCV treatment 
before commencing the survey.  
The socio-demographic and drug-history sections were adopted from a 
national study conducted in Australia in 1995 (Loxley, Carruthers, and Bevan 
1995). Questions about health-care-seeking characteristics were added after 
receiving comments from participants in the pilot study (see Section 3.7.3); 
these questions were also adopted from the previous Australian study 
(McNally, Sievert, and Pitts 2006). Questions about the characteristics of 
treatment were developed by the researcher through consultations with key 
experts in the area of HCV. Questions relating to attitudes around social 
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support were adopted from validated surveys of perceived social support 
conducted in 1988 by Zimet, Dahlem, Zimet and Farley (Zimet et al. 1988). 
Questions about stigma were adopted from validated surveys, including the 
HIV stigma scale developed in the late 1990s (Berger, Ferrans, and Lashley 
2001, Sowell et al. 1997). Questions resulting in an assessment of intent ion 
to undertake HCV treatment were informed by a review of a previous stud y 
(Treloar et al. 2012 ). 
 
The questionnaire consisted of five sections. The first section (socio-
demographics and drug history) contained questions about the participant’s 
age, ethnicity, gender, level of education, employment and marital status, 
accommodation, living status, nationality, sources of income, drugs used in 
the past six months, frequency of injection in the last month, drug preference, 
duration of injection and drinking of alcohol over the last year.  
The second section on health-care-seeking characteristics asked the 
participants the length of time since their HCV diagnosis, knowledge of their 
own HCV genotype, awareness of HCV treatment before commencing the 
survey and whether they had discussed their liver health with a GP.  
The third section on treatment characteristics examined the participants ’ 
perceptions of treatment effectiveness, duration and side effects, and whether 
they had support if they chose to undertake HCV treatment.  
Section four assessed participants’ concern about stigma. In the fifth section, 
participants were asked whether they intended to undertake treatment, on four 
levels: in the next 12 months; in the next1–2 years; in the next 2–5 years; not 
for at least another 5 years. Each questionnaire took approximately 15–20 
minutes to complete.  
Variables  
Socio-demographic characteristics, drug-history characteristics, health-care-  
seeking characteristics and characteristics of treatment, support and stigma 
were the independent variables. Intention to uptake HCV treatment was the 
only dependent variable in this study.  
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3.7.3 Recruitment  
Between December 2013 and November 2014, HCV-infected IDUs were 
recruited from multiple venues in the Perth metropolitan area including: 
WASUA; HepatitisWA; and the WAAC NSEP fixed site; and WAAC NSEP 
mobile van services, which operate in eight locations in the metropolitan area 
(Rockingham, Mirrabooka, Joondalup, Midland, Forrestfield, Armadale, 
Fremantle and Gosnells). NESP outreach workers introduced the researcher 
to NSEP clients in order to give them information about the study. 
Recruitment was undertaken through the distribution of study posters (see 
Appendix 12) and information sheets (see Appendix 13) at the venues 
described above, and potential participants contacted the researcher directly 
by phone for additional information about the study, to determine eligibil it y 
and to arrange a time to complete the questionnaire. The researcher gave each 
potential participant an informed consent form (see Appendix 10); once 
signed, the participant was given a paper questionnaire to complete in a 
private room at the recruitment site or in the WAAC mobile van, or next to 
the mobile van wherever they felt comfortable and safe reading and 
responding to the questions. After completing the questionnaire, each 
participant was asked to wait for five minutes to ensure that all questions had 
been answered. A supermarket voucher valued at AU $20 was given to 
participants who completed the questionnaire. Recruitment continued until 
the target sample size was obtained (in November 2014). 
3.7.4 Validity and reliability quantitative study  
The validity of the questionnaire, defined as “the degree to which the content 
of a test is congruent with testing purposes” (Sireci and Faulkner-Bond 2014 
101), was established in pilot testing. A pilot test is a small case study 
designed to test the validity of a questionnaire (Saunders, Thornhill, and 
Lewis 2009), conducted to improve procedures before commencing a larger 
study. Twenty draft questionnaires were distributed to IDUs at WASUA and 
Hepatitis WA and the manager at WASUA to determine the likelihood of 
participants being unable to understand the questions, and to ensure salience. 
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Prior to this, a brief description of the purpose of the study and information 
about HCV treatment were provided in plain and clear language. The pilot 
test participants were reimbursed with an AU$20 supermarket voucher. The 
pilot study enabled the survey questionnaire to be tested in terms of “length, 
flow, and salience, ease of administration and response and acceptability to 
respondents” (Burns et al. 2008 , 248 ) and to ensure its reliability. 
Participants were asked to provide feedback on the format and clarity of 
questions at the conclusion of the survey. The feedback from these 
participants led to the addition of a health-care-seeking characteristics section 
to the questionnaire. The pilot-study participants made the following 
comments: 
 Giving a brief description about HCV treatment at the beginning of 
the questionnaire was a good idea, but it would be better to find out 
how many IDUs were aware of HCV treatment and know about their 
HCV genotype.  
 The content of the questionnaire is relevant to the issues of current 
HCV treatment, but knowing about how long IDUs have been 
diagnosed with HCV would be helpful. 
 Because of the stigma attached to HCV, it would be good to ask 
whether IDUs have discussed their liver health status with GPs. 
 All questions were clear and easy to understand. The questionna ire 
was not boring or time-consuming. 
The results of the pilot study illustrated that the questionnaire was clear and 
acceptable to the target population, and revealed the time needed for 
completion. 
The reliability of the questionnaire was also assessed for internal consistency. 
Internal consistency correlates the answers to each question in the 
questionnaire with answers to other questions in the same questionna ire 
(Saunders, 2003). The responses to treatment effectiveness, treatment 
duration, treatment side effects, stigma, support and intention were 
statistically tested for internal consistency. Cronbach’s alpha for five domains 
were produced and values ranged from 0.71 to 0.87. Therefore, Cronbach’s 
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alpha surpassed the acceptable limit of 0.6, representing that the items within 
each domain were consistent (see Table 3.2) 
Table 3.2 Instrument reliability 
Variables  Number of items  Cronbach’s alpha 
Treatment effectiveness 2 0.878 
Treatment duration 2 0.926 
Treatment side effects  4 0.975 
Stigma 3 0.990 
Support  2 0.978 
Treatment intention  3 0.716 
 
3.7.5 Coding quantitative data  
Intention to undertake HCV treatment, characteristics of the treatment, stigma 
and support were measured on a 5-point Likert scale: “strongly disagree”; 
“disagree”; “neutral”; “agree”; and “strongly agree”. Analysis of Likert scale 
involves estimating the median score of all items to combine the responses 
from the items, thus generating a new variable (Sullivan and Artino 2013). 
This method was also confirmed by a statistician at Curtin Univers ity 
(Y.Zhao, personal communication November 10, 2015). Answers were 
transformed into dichotomous variables: “disagree” (grouping together the 
first three responses) and “agree” (the last two answers); the response 
“neutral” was included in the first group as it indicated that the subject did 
not necessarily agree (Alavi et al. 2015, Treloar et al. 2012 ). This scoring 
system was also adopted for the following variables characteristics of 
treatment, stigma and support. 
Age in years was converted into a binary variable using the median score as 
the cut off (Tolmie, Muijs, and McAteer 2011, Singh 2007): < 40 years old 
and ≥ 40.  
 
Ethnicity was re-categorised into “Aboriginal” and “non-Aboriginal”, as they 
were the only two responses from participants. 
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The accommodation variable was re-categorised into “non-homeless” (living 
in either own house/flat or parent’s house, rented house/flat, shared house) 
and “homeless”.  
Education was re-categorised into “Year 11 or less” and “Year 12 or 
University/TAFE”; employment was re-categorised into “employed” and 
“unemployed”; sources of income was re-categorised into “government 
benefits” and “employment” (fulltime, part-time, casual). 
Marital status was re-categorised into “single” and “married or lived with 
sexual partner”. Living was re-categorised into “alone” and “sharing with 
others or partners”.  
Drug preference and drugs used in the last six months were re-categorised 
into “heroin” and “methamphetamine”, because all participants selected 
heroin or methamphetamine as their preferred drug and the drug that they had 
injected in the last six months.  
All participants reported injecting drugs for “8–10” years or “more than 11 
years”, therefore the duration of injecting was re-categorised accordingly.  
Participants reported injecting drugs either “once a day” or “more than once 
a day”, so frequency of injection was re-categorised accordingly.  
Time since HCV diagnosis was re-categorised into “5-10 years” and “more 
than 10 years”, as these were the only two responses from participants.  
3.7.6 Data analysis  
The following data analysis was confirmed by a statistician at Curtin 
University (Y.Zhao, personal communication November 10, 2015). Data 
from the questionnaires was coded and entered into SPSS (version 22; IBM, 
Chicago, USA) and cleaned prior to data analysis. Descriptive analysis was 
conducted to describe the background characteristics on all variables 
(predictors and outcomes) in the study and percentage distributions for all 
variables were calculated to describe the full sample of participants. The Chi-
Square test and odds ratio were used to test for the statistical significance of 
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any observed association between the independent variables and the 
dependent variable. In this study, the association between intention to take up 
HCV treatment and a set of demographic, drug history health-care-seek ing 
characteristics, characteristics of treatment, support and stigma were 
investigated.  
Then multivariate analysis was conducted by entering all variables associated 
with intention to undertake HCV treatment at p was equal to or less than 0.1 
in the univariate analysis were entered into a multivariate logistic regression 
model, using odd ratios to examine the strength and direction of the observed 
associations. In the multivariate analysis p<0.05 was considered for the 
retention of variables. Logistic regression models were used to determine the 
predictors of the intention to undertake treatment adjusting for potential 
confounding. The probability level of 95% was applied in all statistical tests. 
The multivariate analysis consisted of two parts in separate models according 
to the type of predictors variables. The first part of the multivariate analysis 
focused on the full sample of IDUs and examined the socio-demographic, 
drug-history and health-care-seeking characteristics associated with intention 
to undertake HCV treatment. A separate logistic regression analysis was 
conducted on the full sample of IDUs and examined the characteristics of 
treatment, stigma and support associated with intention to undertake HCV 
treatment. 
3.8 Ethics  
Ethical approval for the study was granted by the Curtin University and 
Fremantle Hospital Human Research Ethics Committee (Reference Number: 
12/198 and HR 77/2012) (see Appendix 9). As noted previously, to ensure 
that participants were able to give informed consent, the objectives, 
procedures and implications of the study were explained clearly to interested 
potential participants. IDUs were allowed to reach a rational, autonomous 
decision and were not coerced to join the study. An information sheet and 
consent form were offered, and participants were informed that they were free 
to withdraw at any time.  
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All data were de-identified and referred to only by a subject number that could 
not be linked to participants. The interview recordings were transcribed as 
soon as possible after interviews and transcriptions of the data were de-
identified, with participants free to use pseudonyms. The transcripts were 
stored separately from the signed statements of informed consent to ensure 
data could not be linked to individual participants by name.  
No information about individuals was accessible to other study participants 
or health workers. All paper records were kept in a secure filing cabinet in the 
researcher’s office in the Health Sciences Graduate Research Hub, Curtin 
University (Bentley, WA). The Hub has the same level of security as the rest 
of the University, including being accessible only with a valid student 
identification/building access card, password-protected computers, and 
lockable filing cabinets. All electronic data were stored on a computer without 
identifiers and were only accessible to the researcher. This data will be stored 
for a minimum of seven years following publication, after which it can be 
destroyed.  
Risks to which the participants might be exposed (although minimal) were 
considered warranted because of the possible benefits of the study in terms of 
the development of culturally and context specific interventions based on the 
participants’ perspectives. The Australian National Health and Medical 
Research Council’s (2007) ethical guidelines identify particularly vulnerab le 
groups, including persons involved in illicit activities – a category relevant to 
all of the participants in this study. The high prevalence of HCV among IDUs 
is a public health issue, rendering this group’s inclusion in this project of 
genuine importance. However, psychological harm was possible because the 
study involved an examination of individual’s attitudes, beliefs and behaviour 
relating to a sensitive issue, and could have uncovered feelings of guilt due to 
postponing of antiviral therapies and minimising the likelihood of liver 
damage. The researcher was very much aware of the study’s potential for 
psychological harm, so ensured that the questions posed and the manner in 
which they were posed were sensitive in order to limit the possibility of harm.  
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Chapter 4: Qualitative Results 
This chapter presents the findings of the qualitative phase of the research. 
Individual face-to-face semi-structured interviews were conducted with 46 
IDUs who self-disclosed that they were infected with HCV. In order to 
capture rich and detailed descriptions of IDUs’ perceptions regarding triple 
therapy, focus group discussions were also conducted with HCV-infected 
IDUs who had not experienced HCV treatment. This section presents the 
themes drawn from the analysis, illustrated with direct quotations from 
participants. 
4.1 Semi-structured interviews 
Face-to-face interviews were conducted with participants both with and 
without experience of HCV treatment. This section contains the findings of 
analysis of this data. 
4.1.1Sample characteristics of treatment group 
Twenty-one HCV-infected IDUs who had experienced HCV treatment 
participated in the qualitative phase of this study. Table 4 provides an 
overview of the treatment group characteristics. In summary, the numbers of 
male and female participants were almost equal (47.6% male). Participants ’ 
age range was 28–56 years with a median of 47. More than half of the 
participants lived alone. Most participants had completed Year 12 and were 
employed, deriving their main income from paid employment. Most 
participants described themselves as non-Indigenous (see Table 4.1).  
Most of these participants reported heroin as their drug of choice and the drug 
that they had injected most frequently in the last six months; only a few 
nominated methamphetamine. Most participants reported injecting once a day 
and a minority more than once a day (Table 4.1). A large majority reported 
injecting drug-use histories of more than 10 years. None of the participants 
reported drinking alcohol in the past year.  
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Sixteen of participants (71.4%) had genotype 1 and they had not cleared the 
virus during treatment. Two participants with genotype 2 reported eradicating 
the virus through treatment. The remainder, who had genotype 3, had 
relapsed; one male participant who had discontinued treatment a week before 
being interviewed did not know whether he had cleared the virus.  
4.1.2 Sample characteristics of non-treatment group  
The non-treatment group consisted of 25 individuals who were current IDUs 
living with HCV and with no experience of HCV treatment. As illustrated in 
Table 4.1, almost half of these participants were men. Participants ranged in 
age from 30 to 47, with a median age of 38 years. Over half of the participants 
reported stable accommodation; with most living alone; the remainder either 
with their parents or family. Over half of the participants had completed Year 
12. A small proportion of this group identified as Aboriginal; more than two 
thirds were single; a large minority was unemployed and derived income from 
welfare payments.  
Most of the non-treatment group nominated methamphetamine as their 
preferred drug and the most common drug injected in the last six months; the 
remainder preferred heroin (Table 4.1). Most participants reported injecting 
once a day. Most reported injecting for more than 10 years. A majority of 
participants had not consumed alcohol in the past year. 
Table 4.1 Characteristics of treatment and non-treatment groups  
Socio-demographic and drug characteristics  
 
 Treatment Group  
 n=21 
Non-treatment  
n=25 
Gender 
 Male 
 Female 
 
11(52.4) 
10 (47.6) 
 
12 (48) 
13 (52) 
 
Median age (range)  
 
47 (28-56) 
 
38 (30 - 47) 
 
Accommodation  
 Homeless  
 Non-homeless 
 
0 
21 (100) 
 
 
10 (40) 
15 (60) 
Live with 
 Alone 
 
12 (57) 
 
12 (57) 
60 
 
 Partner/family 
  
9 (43) 9 (43)  
Education  
 ≤Year 11 
 Year 12  
 TAFE/Uni 
 
2 (9.5) 
13 (62) 
6 (28.6) 
 
 
6 (24) 
14 (56) 
5 (20) 
 
Ethnicity 
 Aboriginal  
 Non-Aboriginal  
 
1 (4.8) 
20 (95.2) 
 
4 (16) 
21 (84) 
 
Marital status  
 Single 
 Married/lived with sexual partner 
 
 
12 (57) 
9 (43) 
 
 
19 (76) 
6 (24)  
 
Employment status and source of income  
 Non-Employed and Government 
 benefits 
 Employed and job   
 
 
 
6 (28.6) 
15 (71.4) 
 
 
 
 
10 (40) 
15 (60) 
 
Preferred drug and drug used in the last 6 months  
 Methamphetamine 
 Heroin 
 
 
3 (14.3) 
18 (85.7) 
 
 
17 (68) 
8 (32) 
 
Frequency of injection  
 >Once a day  
 Once a day  
 
 
6(28.6) 
15(71.4) 
 
 
10(40) 
15(60) 
 
Drug use duration 
  
  
 
 
8-10 years 3 (14.3) 
>10 years 18 (85.7) 
 
 
8-10 years 5 (20) 
>10 years 20 (80) 
Consumed alcohol in the past year  
 Yes 
 No 
 
0 
21(100) 
 
8 (32) 
17 (68) 
 
4.1.3 Themes from treatment and non-treatment groups  
The themes associated with the factors that influenced treatment intent ion 
emerged through the steps of analysis detailed in Chapter 3. These themes 
describe the factors that contributed to the perceptions of the treatment group 
and the factors that contributed to the perceptions of the non-treatment group 
of HCV treatment. The themes provide a better understanding of the factors 
that influence the intention of HCV-infected IDUs in regards to treatment 
uptake. Several themes emerged from the interview data. These themes were: 
treatment side effects; treatment effectiveness; treatment duration; stigma 
associated with IDU and HCV; and lack of support. In addition to these 
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factors, protecting family, increasing quality of life and maintaining careers 
were concerns also reported by the treatment group, and unstable housing was 
reported by the non-treatment group, as important factors that influenced their 
treatment intention in relation to treatment uptake. Both groups reported that 
peers’ experience of treatment, both positive and negative, was also an 
important influence on their intention in relation to treatment uptake.  
4.1.3.1 Treatment side effects 
Treatment group   
Most (71%) participants in the treatment group had not completed a full 
course of treatment. All participants reported feeling physically and mentally 
ill due to unpleasant side effects of HCV treatment and feeling better when 
they stopped. The most frequently reported side effects were physica l, 
neuropsychiatric and dermatological problems. Physical side effects included 
weight loss, anorexia, dry mouth, nausea and vomiting. One participant 
commented: 
“Interferon killed my appetite, I wasn’t hungry, I had no food inside me, I had 
no appetite to eat. I had to force myself to eat something, but I couldn’t. Plus 
I had constant vomiting; I had to carry a vomit bag all the time, particularly 
on public transport and I thought I was going to die because of the constant 
vomiting” (female, 39 years). 
Some participants experienced physical side effects such as body, bone, joint 
and muscle aches, fever, chills, fatigue and loss of energy (similar to flu 
symptoms) for most of the time while they were on treatment. These were 
particularly felt in the days following the injection of pegylated interferon and 
affected their daily activities, work and family life. One participant 
commented: 
“I had constant aches all over my body. My exercise level dropped off over 
time, I didn’t have energy, I was lethargic due to lack of sleeep, and I had to 
lie on the couch and rest for long periods. I was too tired to do anything, but 
I was so exhausted from doing nothing. I had to push myself hard, but then I 
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became so sick easily. I experienced chest pain, meaning I wasn’t able to walk 
for fifteen minutes. The worst thing is that after stopping treatment , even now 
after six months , I still experience very hot flushes with sweating, which I 
didn’t have before at all and I really don’t know if it is because of after 
treatment or I am going through menopause. In general, I would say coping 
with such a situation was very hard” (female, 39 years). 
Those participants who were employed complained of constant vomiting, 
nausea, headaches and dizziness interfering with their work. Some 
participants took anti-nausea medications, which were not effective. The 
majority described severe, migraine- like headaches. One stated: 
“I had constant headaches every day; I’ve had this issue for quite a while. 
When I first went to the hospital, I thought it was gonna go away, but it didn’t. 
The medication wasn’t making me well. It was really horrible. It affected my 
job; I wasn't well enough to work. I ended up having three weeks off work. 
You know, there was something you needed to change to get better. I couldn’t 
deal with it and then I found it easier to go off the treatment” (female, 37 
years).  
Psychiatric side effects of HCV treatment included depression, mood swings, 
anxiety, insomnia and suicidal thoughts. All participants experienced 
depression, mood swings and anxiety, and complained that their sleep 
patterns were considerably disturbed despite using methods to assist sleep, 
such as reading books, having baths and watching TV. One commented that:  
“Through the period while I was on treatment I felt worthless, I didn’t feel I 
was part of society. All afternoon when I was emotionally down and cried at 
random times, I felt that I couldn’t take it anymore … so I ended up going to 
bed, but I couldn’t sleep at night most of the time. I couldn’t give my full 
attention to my disabled partner, I couldn’t do anything for my disabled 
partner, who is reliant on me, so this made it difficult for me to continue 
treatment” (male, 47 years).  
 Another described her experience as follows. 
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“I didn’t know how bad the depression could be; it was so intense. I felt low 
and I didn’t have hope because I was so grumpy and moody with anxiety. I 
was up most nights. I was also so aggressive. I couldn’t stand anything or 
anyone. Sometimes I lost my control, so I hurt my partner. I made 
uncomfortable situations for my partner at home. I hated myself so … and I 
ended up trying to commit suicide. That’s why I stopped treatment straight 
away” (female, 40 years). 
A few participants experienced cognitive symptoms including forgetfulness 
or difficulty in remembering, and attention and concentration difficultie s. 
These symptoms impacted on daily activities and occupational functioning, 
resulting in work absences and declines in productivity and job performance. 
Two participants provided the following comments: 
 
“The medication wasn’t letting me think straight, stopping me from 
functioning and processing information about my duties and responsibilities. 
I lost my short-term memory and it was very hard for me to track my bills. I 
couldn’t remember what day it was, how much the bill was, as well as the due 
date to pay the bills. In my workplace, I sent the stock to the wrong company, 
then the company called me back and I said to them I am so sorry, ‘I am on 
chemotherapy’, which is why I stopped treatment” (female, 47 years).  
 
“I usually park my car in a certain car park, but I couldn’t remember where 
it was. I usually call my husband during the day while I was working, but one 
day I forgot to take my phone with me and I couldn’t remember the phone 
number, which was very frustrating for me, and I got to the point where I 
couldn’t remembe. It threw me off the treatment” (male, 50 years). 
 
Some participants in the treatment group experienced dermatological side 
effects that persisted post-treatment. A participant who was on treatment for 
eight weeks remarked:  
“I had such a bad skin rash, it was itchy and burning I used lotion and cream, 
they didn’t work. Due to constant itching and burning on my skin, I couldn’t 
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stay longer on treatment. Also, I couldn’t sleep and it was so annoying. Even 
after stopping treatment I still have this issue, even though it has been nearly 
more than one year. I can’t do anything with my hands, I can’t touch any 
chemical products with my hands, and I can’t touch metal, such as on a tap. 
For everything I have to use gloves, even for taking a shower, as whenever I 
touch metal I get an electrical shock” (female, 40 years).  
Another participant described the dermatological side effects: 
“I had such a bad skin rash on my face and legs, it was embarrassing. I tried 
topical cream and lotion and they were not helpful. I couldn’t shave my legs 
at all. I didn’t use any soap or body wash. I took showers with warm water. 
It was so challenging for me not to use soap or body wash. The rash was so 
itchy. I couldn’t go out in public, which meant I had to stay at home. I couldn’t 
wear comfortable clothes; if I did go out, I had to wear something that 
covered my entire body. The worst part was I couldn’t sleep because of skin 
soreness and itchiness. It was a very uncomfortable situation, I couldn’t 
handle it anymore, ending with stopping. I think I was unlucky that I received 
treatment in spring and summer” (female, 39 years). 
Non-treatment group 
Participants in the non-treatment group were concerned about the possible 
side effects of treatment, and this deterred some from enrolling in treatment. 
Concerns about the psychiatric side effects were particularly prominent. One 
participant, who had no history of psychiatric problems, said that the reason 
she did not take up treatment was because of her concerns about depression, 
anxiety, mood swings and panic attacks:  
“I haven't had any history of mental health issues. I just can’t, you know. I 
don't wanna face things like feeling hopeless, feeling low, feeling useless, 
mood swings and suicidal thoughts, as they really scare me. At the moment, 
I’ve got too many other things on my plate, so I can't struggle to cope with 
such side effects too. Particularly, I am scared of the mood swings the most, 
as I am a babysitter. I mean, if I get grumpy with the kids, and can’t 
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understand them and handle them, then I might go off my head and hit them” 
(female, 32 years). 
Some participants had pre-existing depression and described how they had 
been sick for much of their recent lives, dealing with both their drug addiction 
and depression. This precluded some from taking up treatment. One 
participant had the following to say: 
 
 “I have been on anti-depressant medications for four years, and I am not 
happy and bright. Sometimes suicidal thoughts were going through my mind, 
you know, I hated myself. My depression can get worse during treatment with 
interferon. I am not strong enough to cope with such depression” (male, 34 
years).  
 
Some participants in the non-treatment group expressed fear of the physica l 
side effects of HCV treatment; they did not want to risk becoming sick from 
HCV treatment.  
“I have been sick too much in my life because of my multiple sclerosis. I have 
already got pain and aches in my legs. I am tired of being sick, I can’t take it 
no more, I don’t wanna get worse than my current situation. I don’t want to 
get tired and fatigued, as I already am because of my multiple sclerosis. I 
don’t want to lose more energy, I want to be able to do my daily routine. 
That’s why I don’t want to go on HCV treatment, unless something different 
comes up that won’t make me sick” (male, 40 years).  
In particular, employed participants were worried about losing their 
employment due to the physical side effects of HCV treatment. These side 
effects could stop them from working and fulfilling other daily commitments. 
Their jobs were considered a significant part of their life and they were afraid 
of becoming unemployed. These participants believed that find ing 
employment is very difficult, especially for drug users. They did not want to 
lose their jobs because of HCV treatment. One of the employed participants 
who put more importance on her job than undertaking HCV treatment said:  
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“I have been thinking about HCV treatment since I was diagnosed with HCV, 
but having fear of losing my current job, I couldn't convince myself to go for 
it. Because my job is the foundation of my life, and my family life and if I go 
for HCV treatment I will lose my job, definitely. You know, especially in my 
case, as a drug user, getting a job is very difficult. I am so very lucky that I 
have this job and, seriously, I don't want to lose it because of bloody HCV 
treatment” (female, 41 years). 
Other participants mentioned that the physical side effects of HCV treatment 
made them frightened of becoming unemployed, influencing their intent ion 
regarding HCV treatment.  
"I am scared of taking up HCV treatment because of losing my job. I worked 
hard to build to get here where I am, so I don't want to lose it because of 
physical side effects which make me so sick and fatigued"(female, 34 years). 
Many participants believed that their job was essential, giving them direction 
in their life, and feared that physical side effects of HCV treatment would 
interrupt this. One participant who had recently gained stable employment 
said: 
"You know, I am not silly to go onto HCV treatment. I had been waiting for 
this job for ages, so I’m not going to take the risk of losing this job by facing 
physical side effects. I know the side effects of treatment could disrupt my life 
and pull me somewhere, where I have to lose my job” (male, 40 years).  
Some participants who were single parents noted that their work was 
financially vital. They did not want to lose their income due to physical side 
effects:  
“I am a single mum and have two children. I have to work full time to earn 
money. I want to keep my job, which means I don’t want to lose my job 
because of physical side effects” (female, 45 years). 
In addition to physical and psychiatric side effects, most participants 
discussed dermatological side effects such as hair loss and skin rashes/ 
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irritation and itchiness. In particular, female participants believed that these 
factors stopped them from undergoing on HCV treatment. One participant 
said: 
“I’m worried about a bad skin reaction on my face and legs. If the spots stay 
on my face and my body, this will be embarrassing. How can I go to work 
with these rashes? Also, I can’t go to a public place or work. I know a friend 
of mine who had skin problems even one year after completing treatment” 
(female, 30 years). 
4.1.3.2 Treatment duration 
Treatment group  
The second theme was lengthy treatment duration. Many participants in the 
treatment group found having treatment for a long time very tiring and a 
heavy burden. They described devoting six months to one year to HCV 
treatment as very difficult, resulting in stopping treatment early. One 
individual who was on treatment for 11 weeks said: 
“One year is a long commitment. I was so tired and sick of being on the 
treatment. So I reached the point where it was not worth it, then I pulled up 
earlier than was expected. It takes a really long time. I believe no one can 
handle such a long time on HCV treatment” (female, 47 years). 
Most participants in the treatment group considered “burnout” one of the 
negative effects of long-term HCV treatment. One participant explained that 
her treatment was scheduled to last 12 months, but after 6 months she felt she 
was about to burn out of the treatment and discontinued: 
“That’s the thing, being on treatment for such a long period was very hard. 
After six months, I realised I just couldn’t, I reached the point where I was 
emotionally and physically drained over the six months. I felt I was going to 
burn out” (female, 42 years).  
Some participants in the treatment group suggested that the long duration of 
treatment resulted in their failure to complete the full course, even though 
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they understood that the chance of clearing the virus was much higher when 
the full course was completed.  
“You know we can’t deny that people don’t like taking medication over the 
long term. And you know, I’ve learned that if I go off the medication earlier 
than I was supposed to take, I’m not gonna get rid of the virus” (male, 45 
years).  
However, the lengthy treatment duration had a positive impact for one 
participant in the treatment group who described the long duration of HCV 
treatment as acting a reminder of the danger associated with sharing needles.  
“In the past I used to share needles, especially when I was desperate to take 
drugs. And I didn’t care. But now that I went through treatment and cleared 
the virus; there is no way to share stuff” (male, 49 years).  
In summary, excluding the three treatment group participants with genotype 
2, the participants were unanimous that lengthy treatment duration dissuaded 
them from continuing their regimens.  
Non-treatment group 
The importance of treatment duration with respect to course completion was 
clearly acknowledged by most participants in the non-treatment group. One 
participant, who had genotype 1, remarked: 
“I believe being on treatment for one year makes people lose their patience 
and energy, making them so exhausted. I think I’m the type that gets exhausted 
after a couple of weeks being on treatment; seriously, it is too long” (female, 
42 years).  
Participants in the non-treatment group believed that the lengthy duration of 
HCV treatment was not compatible with their busy work schedules which 
appeared to overshadow all other aspects of their lives, including activitie s, 
family relationships, work life and social activity: 
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“I couldn’t go for HCV treatment for one year. I really don’t know how I 
would look after my three children properly. How could I manage my full-
time job? I could have done treatment if it was shorter, like three months, 
because I could have taken three months’ leave from my job and my sister 
could look after my kids” (female, 41 years). 
Participants knew that not completing the course would make HCV treatment 
less effective and decrease the chances of success. Fear of not completing the 
full course of HCV treatment, reported by the majority of participants and 
deterred them from undergoing HCV treatment. 
“It was fear of not finishing the treatment which made me pull out form taking 
treatment. I believe if I don’t finish the whole treatment I wouldn’t clear the 
virus, because I can’t dedicate myself for such a long period. So I just think 
that when you can’t finish the treatment process, it is not worth it to being the 
treatment, because you won’t clear the virus” (male, 39 years). 
4.1.3.3 Treatment effectiveness  
Treatment group 
The treatment group included 18 participants who did not clear the virus 
(genotype 1); two participants with genotype 2 who cleared the virus; and one 
participant with genotype 1 who did not know whether he had cleared the 
virus. This participant was part of a clinical trial of triple therapy (pegylated 
interferon, ribavirin and telaprevir) when interviewed. He had experienced 
HCV treatment three times: monotherapy interferon; combination therapy 
interferon and ribavirin; and combined pegylated interferon and ribavirin. He 
referred to the low efficacy of HCV treatment: 
“Having a guarantee to clear the virus is very important, because it didn’t 
work well for me; I failed three times in HCV treatment. I started my fourth 
round about two months ago and I couldn’t handle it, so I stopped it a week 
ago. I have to suspend my hope; whether it’s going to work or not, I really 
hope it’s my last time going through treatment. Do you think so? I don’t think 
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so. If the nature of the treatment was effective, it would’ve worked for me in 
the previous rounds” (male, 49 years). 
Most participants who had not responded well described how their doctors 
had stopped their HCV treatment at week 12 or 24. Despite having been 
informed by their doctors that their response to the treatment might be poor, 
they were frustrated and unsatisfied about not clearing the virus. Two 
participants explained:  
“Going through HCV treatment was a very hard thing to do, and the most 
awful thing was, after twelve weeks, my doctor told me the treatment didn’t 
work for me, saying it’s better to stop you now, rather than letting you 
continue with treatment until forty-eight weeks. I just wanted to try my chance 
and in this case I would say how unlucky I was” (male, 46 years).  
“I went through treatment , took all my medications plus injections for 
twenty-four weeks, and how annoying it was when I found out that it didn’t 
work and I had to stop the treatment after twenty-four weeks of being on HCV 
treatment. I was so fed up although my doctor had told me I might not get rid 
of it. You know, going through all that and I still have the virus” (male, 49 
years).  
Three participants who had genotype 3 completed the full course of six 
months treatment and successfully cleared the virus, but had virologica l 
relapses after both completing HCV treatment courses and eradicating the 
virus. One participant had a recurrence of HCV after one month and the other 
after two months. They also believed that the treatment effectiveness should 
not last for only short period short period during therapy. Once the treatment 
stopped, the efficacy of treatment stopped as well. One participant who had a 
viral relapse stated:  
“I never wanted to experience treatment with no guarantee of success. My 
test result showed that I didn’t have the virus, but the virus came back just a 
month after I finished the treatment. This was because of the low effectiveness 
of treatment, if it was effective; there was no way the virus would have 
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returned after finishing, I used all the time fresh fits which I always get from 
WASUA, so I didn’t share with anyone because I knew if I shared, the 
treatment wouldn’t work” (female 48 years). 
Non-responder participants commented that the next generation of HCV 
treatment should be offered to individuals with a guaranteed cure. One 
participant who had genotype 3 and relapsed after treatment stated: 
“I wouldn’t go through treatment again until the next one comes with a 
guarantee and a high chance of getting rid of the virus. Hopefully, I’ll get 
better treatment later” (female 38 years).  
Non-treatment group  
Participants in the non-treatment group repeatedly mentioned treatment 
effectiveness as an issue. None of these participants intended to undergo HCV 
treatment. Participants in the non-treatment group who had been diagnosed 
with HCV more than 10 years previously stated that low efficacy of treatment 
was the main factor that dissuaded them from undergoing treatment. 
“I guess failing and not having a positive successful result is another thing 
that also makes me not take HCV treatment. I have got type 1; it is already 
twelve months’ treatment, so if I do twelve months I completely stuff myself, 
plus if I fail to clear the virus, which means going to hell for two years of your 
life” (female, 39 years). 
Many participants believed that the foundation of any treatment is cure and 
commented that the efficacy of HCV treatment was not high enough to 
encourage them to undertake it. They described HCV treatment as gambling, 
where individuals take a risk to become winners or losers. They did not want 
go through a painful process that did not guarantee a cure for the virus. 
“Why should I be bothered to go for such a treatment? It doesn’t give me any 
motivation when there is a lack of efficacy. HCV treatment to me is gambling, 
which means you have a fifty- fifty chance to become a winner or loser. I’m 
not a good gambler. I don’t think it’s worth putting myself in a risky situation 
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when there is no guarantee to clear; as long as there is no guarantee I’m not 
into it” (male 37 years). 
Participants in the non-treatment group described HCV treatment as a battle 
in which HCV is the enemy they wanted to kill. They acknowledged that it is 
in the nature of human beings to want to win a battle; however, the low 
efficacy of HCV treatment meant they were not optimistic about clearing the 
virus – they saw little chance of winning. The “guarantee” idea surfaced 
repeatedly: 
“Going on HCV treatment is like fighting the enemy, in this case the enemy 
is the virus. As human beings, we always want to be winners, not losers. So 
I’m not willing to take treatment as there is a low chance to kill the virus. This 
means I will fail to kill the virus and I can’t fight with the virus, the virus will 
be the winner, not me. Therefore, as long as I can’t be assured that I can 
eradicate it, I won’t go for the treatment”(female, 39 years).  
“In my view, the only thing I care about is getting positive outcome from 
doing everything. Getting a positive outcome from taking HCV treatment 
reinforces our intentions and determination. But I have got type one of HCV, 
which is less likely to get a positive outcome, so why should I take it?” (male, 
34 years).  
Most of the non-treatment group believed that with no guarantee, there was 
little point in having treatment with such a low probability of eradicating the 
virus.  
“I believe that taking fragile people who caused drama in their life, they are 
not going to survive and it’s a cruel things to do at the moment with a 
treatment which has a low success rate and there is no guarantee to be cured, 
so what’s the point? I believe it’s not a wise thing to do” (female, 32 years). 
4.1.3.4 Stigma 
Treatment group 
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All participants in the treatment group described stigma as a very old notion 
derived from individuals’ attitudes, behaviour and actions towards the drug-  
user community, particularly those who were infected with HCV. The 
participants would pretend to be non-drug users, because they did not want to 
be denigrated and suffer emotionally and psychologically. They described 
being very cautious about whom they opened up to about their addictions and 
infections. They did not want to disclose their illicit drug use to HCV care 
providers due to lack of trust in the patient–provider relationship, and they 
feared being judged. They experienced and perceived stigma attached to IDU 
and HCV treatment. The following quotes illustrate the IDUs’ attitudes 
towards stigma: 
“Stigma and discrimination is an old concept which is coming from people’s 
attitude, behaviour and action towards us. I didn’t tell the clinical nurse and 
my specialist that I’m a drug user because I didn’t want them to show negative 
reactions towards me and to treat me differently ,which could affect my self-
esteem and especially losing myself. I am happy that I hide my drug 
addiction” (female, 48 years). 
“Stigma and discrimination complete each other and there is no difference 
between them. When I was on HCV treatment I didn’t mention that I’m a drug 
user. Also, I told my doctor and my nurse in the liver clinic that I got HCV 
through a blood transfusion. As soon as I mention that I’m a drug user, I get 
labelled as a junkie person on the forehead forever. I’ve learned not to 
disclose my status to the point where I am judged. Once I’m a drug user, I 
can’t be trusted. Even before going on treatment I prefer not to discuss about 
my addiction and my HCV to my GPs unless  it’s relevant, for example, if they 
wanted to do a relevant procedure (male, 52 years).” 
These participants reflected on feeling that there is always a difference 
between drug users and non-drug users; they believed they were second-class 
citizens who were not good enough to receive health care services without 
stigmatisation or discrimination. They perceived insensitivity and ignorance 
among health care providers, which led them to hide their IDU status when 
74 
 
they commenced HCV treatment. They felt that being a drug addict is like 
any other disease and, as an individual, they had the right to be treated the 
same as others without discrimination. The following statement is indicat ive 
of how stigma was manifested: 
“Basically, as a person who is [an] injecting drug user over the last twelve 
years, I have seen a big gap between non-drug users and drug users. Let me 
give an example. Once I had to go to the emergency department as I had a 
car accident. I was in such bad pain and I asked for sedation; the nurse told 
me ‘nothing works for you or will reduce your pain because you’re a drug 
user, your body doesn’t respond to our medication’. I’m a person like other 
people, why should I be discriminated against? I have a right to receive health 
care without stigma. I came to a point where I wouldn’t be honest about my 
drug addiction, I always have to lie that I’m not a drug user” (female, 50 
years). 
Unfortunately, drug-user-related stigma exists in the health care setting; some 
health practitioners knowingly or unknowingly stigmatise and discriminate 
against IDUs. All the participants agreed that GPs at health care facilities are 
more likely to practise stigmatisation than professional staff or HCV 
specialists. This was expressed by the majority of participants in the treatment 
group, which influenced their decision to hide their drug-using status when 
undergoing HCV treatment, as they did not want to feel uncomfortable during 
the HCV treatment course, specifically when they wanted to discuss any issue 
related to HCV treatment with their health care providers. One participant 
said:  
“I had some GPs who were so judgemental. They never discussed with me 
anything about HCV treatment. They think that I’m trying to get more drugs 
from them; this assumption had a negative impact on me emotionally. Many 
GPs believe we are junkies. Personally, I prefer not to visit a GP. I changed 
my GP three times to see any difference, but nothing changed at all. My GPs, 
they were all the same , they would criticise me in a negative way, so I learned 
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from past experience not to mention to any health care providers that I’m a 
drug addict” (female, 38 years). 
Two participants in the treatment group reported being treated differently by 
their families on discovery of their drug addiction. Consequently they were 
fearful of telling their family about their HCV treatment. They did not 
disclose their treatment status to family members or in their workplaces due 
to fear of being judged by their families and encountering poor reactions from 
their colleagues. They did not wish to lose their dignity and confidence, which 
would have negatively affected their mental wellbeing. 
“I come from a well-educated family and I live with my parents and sibling. 
Nobody knows about my HCV in my family. I didn't even tell my parents about 
my HCV, because I didn't want to lose my pride and dignity in front of them, 
particularly my sibling. They already label me as dirty or a junkie, and they 
reproach me and discriminate against me, they behave towards me 
differently, and they don’t ask me to join them for lunch or dinner because of 
my drug addiction. So I didn't want to make the situation worse by telling 
them about my HCV status. If they knew, I have no idea how much worse the 
scenario could get, maybe I would have become homeless while I was on 
treatment, which I didn't want. That’s why I didn't tell, there wasn't any point 
to tell them. Can we get rid of stigma attached to drug users or HCV? I don’t 
think so!” (female, 28 years).  
Non-treatment group 
All participants in the non-treatment group perceived HCV stigma as 
disrespectful and dehumanising, through interaction with both drug users’ 
and non-drug users’ community where they might be labelled as 
untrustworthy or irresponsible. They felt high levels of stigma and 
discrimination related to their HCV status, which caused them to exclude 
themselves from their former social networks. Being HCV-positive made it 
harder for them to project and reconfigure their identities; as a result, they 
became isolated from their social networks.  
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“You know, as a drug user and HCV-positive person, I haven't seen anyone 
respect me and take me into account as a human being. People, even drug 
users with no HCV, look at me as useless, reckless and unreliable. I’m shamed 
because of my HCV and I don't have a good reputation in my community and 
other communities, they don’t trust me, they see me as a junkie. Let me give 
you an example. One of my friends who used to put their kids with me for half-
days babysitting, since they found out about my HCV, they never put their 
daughter and son with me. For them I was a different person who needed to 
reshape and reform my personality and my character because of HCV. 
Eventually my friends found out about my HCV, so they distanced themselves 
from me, so I had to put myself away from them with no social activity because 
they didn't want me to be included in their social activities. They used to invite 
me for their birthday or other social events; they just stopped communicating 
with me. So I didn't see any point in keeping in touch or catching up with 
them. I always feel rejected and not accepted by others. We can't ignore the 
fact that as long as a stigma is attached to HCV and inseparable, less people 
including myself will be willing to go on HCV treatment” (female, 40 years). 
Most participants in the non-treatment group who did not disclose their HCV 
status linked their low intention to enter HCV treatment to fear of exclus ion 
from the community, their family, workplace and even the IDU community. 
One participant described his apprehension about HCV treatment as follows : 
I’m too scared to go on HCV treatment, as I did not tell anyone that I’m HCV-
positive, especially my parents, my manager, my colleagues and especially 
my friends. I don’t want to reveal my HCV by going on HCV treatment. It 
would be so embarrassing. I didn't want to be left out them and not feel 
attached to them. I believe it is a very common reason that has stopped people 
going on HCV treatment” (male, 37 years). 
Some of the participants in the non-treatment group did not want to disclose 
their status to their families and those who lived with them because of fear of 
exposing themselves to judgement from those individuals. However, hiding 
their HCV-positive status made the situation harder, as they felt loss or self-
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loathing. Moreover, they feared negative reactions from their families due to 
seeing friends rejected and disavowed by their families when they disclosed 
their HCV status. They associated this issue with refusal to undertake HCV 
treatment. Two participants expressed their opinions about HCV stigma as 
follows: 
“You know it’s very hard for me that I haven't told anyone that I have HCV, 
it’s not me but because of HCV, I have to hide my HCV. I didn't tell my 
partner, but thinking every day that I have hidden my HCV status from my 
partner annoyed me all the time and I hate myself to death” (male, 38 years). 
“I didn't tell my family and my partner because I know them very well, they 
can't cope with this, they would start telling me off, especially my partner, 
who is very cautious not to share any injecting equipment with others. I hate 
myself that I’m not honest with my parents. They would be very negative 
towards me, so I was worried they would reject me and not want me to be a 
part of their family. I couldn't handle this. That’s why I didn't tell them I have 
HCV” (female, 41 years). 
Another dimension of the impact of stigma among non-treatment group 
participants was that their interactions with health care providers did not 
involve with the ethical stance they expected. They felt they were judged and 
discriminated against when they did approach health care services. They 
believed that, as most HCV infections are derived from IDU, health care 
providers linked HCV and the act of injecting, leading to discriminato ry 
behaviour. The following quote demonstrates how some GPs avoid physica l 
contact with HCV-infected people: 
You know better than me that HCV is a blood-to-blood contact and is not 
transmitted by touching or doing physical examination, but all my GPs never 
ever did check my breast lumps. I wasn’t comfortable with them at all, 
because all the time she just wanted to get rid of me quickly, she wouldn’t let 
me to ask her anything and what do I need. We had distance between her and 
me. I never ever got what I wanted. I assume that because I am HCV-positive 
and most of the infected people with HCV are drug users, the doctor jumped 
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to the conclusion that they should be discriminated from others. I believe as 
a doctor and educated person they should see all people as a normal person 
regardless of drug use, HCV or even HIV status. We have a right to receive 
the same and equal health care. I have to tell you, it took me ages to find a 
friendly dentist who doesn’t discriminate” (female, 39 years). 
Participants believed that stigma remains central in the experiences of IDUs 
and HCV, so enduring a whole year of treatment with this stigma would 
expose them to emotional distress. 
“Stigma is attached to HCV for a long time and going on HCV treatment with 
this stigma attached to it for six months or twelve months is very difficult and 
it hurts you emotionally and it could have an impact on your mental health” 
(female, 30 years). 
4.1.3.5 Lack of Support 
Treatment group 
As mentioned above, while participants in the treatment group discontinued 
treatment due to not coping with the side effects, lack of family support was 
also a factor for many. Most participants in the treatment group reported 
receiving low levels of family support while they were on treatment. They 
stated that this lack of support made managing treatment much harder, 
reducing their motivation to continue. It was very difficult for them to tolerate 
the treatment and its side effects without a supportive family. 
You know, I believe having a supportive family is very effective in managing 
HCV treatment, addressing treatment side effects and to stay motivated to 
complete the treatment. I didn't have such support from my partner, he is 
suffering from MS and he is really sick, so at this point I couldn't expect him 
to be supportive and help me while I was dealing and coping with side effects 
on my own. I did try a lot to stay on treatment, but after a couple of months I 
couldn't handle it, then I stopped it. You know, I think if I’d had someone who 
could have supported me, I wouldn't have stopped, so by now I would have 
cleared the virus” (female, 42 years).  
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Participants who discontinued treatment and did not clear the virus reported 
that their partners were not supportive during the treatment and had constant 
arguments, reported that their partners did not understand their situation and 
did not help them, or they had sustained significant emotional hurt from their 
partners which resulted in them feeling isolated, lonely and depressed. When 
family support – sympathy, love and attention – was missing, participants 
were more likely to experience an increased burden, which magnified the side 
effects of treatment, slowed down remission and led them to discontinue 
treatment and consequently not clear the virus. They claimed their familie s 
did not support them when they attended the liver clinic for follow- up 
appointments or when they experienced side effects. Two female participants 
who split from their partners during HCV treatment reported an extreme lack 
of support and that they had absolutely no motivation to remain on treatment:  
“My partner had an awful temper and blamed me for every single fault that 
happened in the house. I had to argue with him for everything from household 
items to looking after the kids. He couldn't understand what I had been 
through; he had no clue whatsoever about my treatment side effects. Day by 
day I was getting down to the point where I was limiting myself to my 
bedroom. I felt so depressed that I couldn't even see my kids and deal with 
them. I felt sorry for myself because I had to manage the treatment on my own 
without my bloody partner, who could see only himself, not others around 
him. He didn't even make me a cup of tea while I was on treatment. He didn't 
give me any motivation to keep going on treatment. I remember one day 
when I was suffering from the side effects, he told me ‘hey babe, just quit the 
treatment, I can't stand you anymore” (female, 40 years).  
“You know, when I was on treatment I was miserable because my partner 
tried to pick on me all the time, because I was so depressed and down. I had 
to argue with him all the time because of his stupid actions and his behaviour. 
He didn't have any physical or emotional relationship with me. He didn’t help 
me, he couldn’t stand me, and he made me choose between him and quitting 
treatment. I chose treatment, and then he left me. I felt so lonely and 
depressed, as my close family lives in NSW, and my depression got worse, 
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which also affected my physical activity as well. I didn't have anyone here 
except my partner. I couldn't believe he did this to me. I was in hell, my 
situation got worse day by day because of the horrible side effects, so I came 
to the conclusion that I had to stop the treatment after seven months and I did 
not end up clearing the virus” (female, 42 years).  
On the other hand, those participants in the treatment group who had 
completed the treatment course and cleared the virus described family support 
that provided a comfortable and peaceful environment for them to cope with 
treatment. They reported that their families were engaged in the treatment 
process, particularly when they administered pegylated interferon injection 
and took ribavirin, and their family members made sure they took their 
medication properly and on time. Family support encouraged these 
participants to complete treatment and clear the virus; the participants felt that 
without this support, they were not capable of completing treatment and 
eradicating the virus. In this regard, one participant stated that: 
“You know, HCV treatment was a time of remarkable change where you need 
someone to be with you during the treatment journey. In my case I was very 
lucky because I had a very supportive family, especially my partner, who 
provided me with the most comfortable situation. He did not let me do 
anything he constantly stood by my side and didn't leave me alone, not even 
for one minute, mainly when I was about to get my injection. He hugged me, 
he kept telling me ‘you are very close to getting rid of the virus, you can do 
it, please don't give up. I’m with you no matter what and we can have a better 
life together’. Then after my injection he put light music on and made me 
herbal tea which made me very calm; without him I wouldn't have got through 
it” (female, 50 years). 
Having family support reduced participants’ stress levels and prevented them 
feeling isolated during treatment. They affirmed that their families created 
pleasant social interactions and provided relief, both emotionally and 
physically. The constant support provided by their families was highly valued 
by participants, who were initially concerned about how treatment side effects 
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would affect them physically and emotionally. They believed that their family 
sacrificed themselves by providing care for the participant. 
“When I just started treatment, I was so worried how I could manage the 
treatment with the nasty side effects, but … my wonderful partner … quit his 
job because of my treatment. While I was on treatment, he kept me busy by 
watching movies, inviting friends for dinner, taking me out sometimes in 
order to not feel lonely and down. He didn't let me think about any negative 
things, we did some meditation together to release the stress and took positive 
energy from the outside. Trust me, without him I couldn't have make it” 
(female, 48 years).  
All participants in the treatment group concluded that family support was the 
strongest determining factor for staying on and completing HCV treatment  
by helping them cope with side effects.  
Non-treatment group 
Most participants in the non-treatment group reported not having family 
support. They felt helpless and had no confidence to undertake HCV 
treatment without a supportive family. Constantly thinking about who would 
look after them during the HCV treatment course discouraged them from 
undertaking treatment; they feared emotional distress and poor mental health. 
They affirmed that lack of support led them to quit HCV treatment due to loss 
of self-esteem, hope and self-efficacy.  
“I have family here, but they are not helpful. I have to manage everything on 
my own if I go on HCV treatment, and keep thinking about who is gonna take 
care if me if I go on HCV treatment. How can I go without having support 
from my family?. When you don’t have support, it means you don’t have 
confidence and any hope to take the treatment, it also stresses me out. Again, 
if I go on treatment on my own, I’ll be in hell mentally and emotionally” 
(female, 43 years).  
They spoke of family support providing kindness, sympathy unconditiona l 
love which could simplify and smooth the treatment journey for them. They 
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believed family support could reinforce their personal strength and make 
them feel attached, connected and accepted. 
“I would say having a supportive family for the HCV treatment is a key item 
which gives you everything, such as love, caring, value, sympathy and 
respect. These items can make the treatment journey easy for you, especially 
when you are trying to adjust yourself with the treatment life. Having family 
around you when you are on treatment gives you more power by hanging out 
with your family all the time, feeling connected to their family, which is the 
best way to overcome the challenges during the treatment journey” (female, 
48 years).  
Some participants believed that lack of a supportive family stopped them 
from undergoing HCV treatment. They believed that living with their family 
would mean receiving better care, and greater comfort and support, and help 
them cope with the side effects. Several non-treatment group participants did 
not live with parents or partners: 
“I live on my own. All my family is not here, they are in the eastern states. 
Living with family gives you luxury to feel relaxed and comfortable. It’s also 
helpful when you face nasty side effects. Living away from my family makes 
me not to think about going on HCV treatment” (male, 37 years).  
Similar feelings were conveyed by other two participants: 
“I don’t live with my family. My family are in Queensland. I don’t have a 
silver spoon and I don’t have privilege. I live on my own. I have to manage 
my life on my own” (female, 34 years). 
“I live alone and I’m getting old and I believe it would be challenging for me 
to go on treatment on my own. My family lives overseas. If I experience 
several side effects, who will look after me?” (male, 42years). 
Participants felt that in the absence of family support, there was no motivat ion 
for them to undertake HCV treatment. They predicted exhaustion, fear and 
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isolation and, as a result, felt that they could not overcome treatment side 
effects and difficult times during the treatment journey.  
“You know, when you don’t have support from your family, you don’t have 
motivation to go on HCV treatment. Going on treatment on your own means 
stress, tiredness, isolation and not being able to cope with treatment side 
effects with no positive results. When you can’t communicate with your 
family, which means there is no help and empathy, it makes you unwilling to 
take HCV treatment. You know the chance of exposing yourself to side effects 
increases when the support decreases, as family support can act as a buffer 
against the challenges and the side effects” (female, 39 years).  
4.1.3.6 Peer experience of treatment 
Treatment group 
Hearing positive and negative treatment experiences from their peers were 
influential in determining participants’ intention to commence HCV 
treatment. Some participants in the treatment group felt that they were at the 
same level as other IDUs who did take up treatment. In other words, feeling 
behind or equal to their peers persuaded them to undertake HCV treatment. 
Hearing positive stories improved their confidence and reinforced their 
strength to manage the HCV treatment course. Participants learned from the 
success stories of their peers, particularly their strategies for coping with 
treatment side effects. Participants in the treatment group reported increased 
self-efficacy through hearing positive experiences and that they had changed 
their negative beliefs, especially when they observed their peers successfully 
undergoing HCV treatment. The following quotes from two participants are 
illustrative: 
“In my opinion hearing or listening to other people who have done treatment 
really helps to figure out your way through HCV treatment. When I saw my 
next-door neighbour, who did complete a treatment course and did clear the 
virus, then I felt that I am behind and I thought ‘why shouldn't I?’ Feeling 
behind pushed me and encouraged me to go for treatment. It gave 
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me confidence to believe in myself, that I can do it. Since I met her I’ve 
changed my mind about treatment. She gave me hints about how to cope 
which helped me a lot while I faced the nasty side effects” (female, 48 years).  
“I am happy that I met one of my friends who did HCV treatment at a friend’s 
birthday. I felt that she is the same as me and both of us are on the same page 
and are equal. If she could do it, I can do it. She was very helpful for me; 
constantly telling me I can handle the treatment, building my confidence by 
providing me with some effective guidance on how to deal with treatment side 
effects and how to adjust myself with the treatment course. I followed 
whatever she said. All her tips were so helpful and helped me to handle the 
treatment. If I hadn't heard her story, I would’ve had a tougher time than 
what I experienced. I would recommend to anyone who wants to go on 
treatment that they listen to the stories of others who have done treatment” 
(male, 49 years). 
Several participants in the treatment group said that their intention to 
undertake treatment was based on hearing about positive experiences and they 
considered it treatment persuasion. They stated that such stories made them 
realise that by undertaking HCV treatment and being without the virus, their 
health and wellbeing would improve and their lives would be prolonged. 
“I was always scared of treatment. After meeting my cousin who did 
treatment and lived in Sydney, I decided to go for the treatment. She was one 
of the treatment motivators for me and she convinced me HCV treatment is 
not a big deal and anyone can do it, otherwise I wouldn't have gone for 
treatment. Hearing positive stories simplified the treatment journey. Being 
free of HCV means living longer and having a healthy life” (female, 50 
years).  
Non-treatment group  
Many participants in the non-treatment group highlighted that HCV treatment 
was one of the most tragic things that had happened to their friends. They 
indicated that hearing about negative experiences of HCV treatment from 
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other IDUs strongly influenced their own treatment intention. Several IDUs 
reported friends discontinuing treatment due to the long duration of the 
treatment and the side effects. 
“My friend has been on HCV treatment for six months. When she started HCV 
treatment, she was working part-time. She experienced very nasty side effects, 
she became very depressed, very isolated, having constant headaches and 
vomiting all the time; she even tried to kill herself. She was meant to finish 
the treatment within forty-eight weeks, but because of experiencing horrible 
side effects, she couldn’t handle it and she stopped after six months. That’s 
why I don’t want to go for it” (female, 40 years).  
“A friend of mine who had to quit his job because of bloody treatment, he 
couldn’t cope with treatment side effects while he was working. Seriously, 
who can afford to be on HCV treatment for one year? One year is a long time. 
You can’t devote yourself for one year to be on treatment” (male, 42 years).  
“I thought after finishing HCV treatment, people can feel free, live without 
HCV and have a better quality of life. However, my friend did complete the 
treatment and did not clear the virus. So that's why I don’t want to go on 
treatment, it is extremely terrible and after being on treatment for one year, 
you can still carry the virus” (male, 38 years).  
One participant in the non-treatment group described the tragic effect of the 
long duration of treatment which, along with the side effects, was suffered by 
a friend of his:  
“If HCV treatment was shorter than one year, my friend’s tragedy wouldn’t 
have occurred. He just ended up committing suicide when there was only one 
month left to finish out of forty-eight weeks’ treatment. I believe being on 
treatment for one year makes people lose their patience and energy, making 
them so exhausted. Why should it take such a long time? One year is a very 
long time and I think only the minority of people can deal with it” (male, 38 
years).  
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Participants in the non-treatment group believed that a mentor who had 
experienced HCV treatment could be helpful to individuals contemplat ing 
treatment. They acknowledged that hearing about negative experiences 
caused them to imagine similar experiences and influenced their intention not 
to undertake HCV treatment. They suggested that exposure to others’ 
experiences opened their minds and gave them a comprehensive picture of 
HCV treatment.  
“I believe sharing other people’s treatment stories is useful for others who 
haven’t experienced treatment yet. I’ve HCV for a long while; I have a 
negative attitude towards HCV treatment. My negative attitude got worse 
when I met one of my mates who went through treatment and had a horrible 
time during treatment. When he was telling me his treatment stories, I did see 
myself in his shoes. Since I met him I did visualise myself in his position, then 
I thought it’s not time to go on it. My friend’s experience definitely influenced 
me not to go for the treatment” (female, 39 years). 
Hearing negative experiences led participants in the non-treatment group to 
become emotional and anxious in anticipation of what would happen if they 
were to undertake HCV treatment. They refused treatment because of 
negative stories from peers who failed to clear HCV. They stated that it was 
hard to trust the treatment. As noted previously, treatment efficacy was a 
major concern:  
“... thinking about what’s gonna happen to me if I go for the treatment is 
killing me. I couldn’t make up my mind to go for it, since my dad had been 
through the treatment and he had to stop in the middle of the treatment 
because he did not respond to treatment. I jumped to the conclusion, what’s 
the point of going on treatment when there is no chance of clearing the virus? 
It’s useless thing to do. To start something you should have hope to get 
through it; when you already know you could fail to clear the virus, of course 
I don’t take it” (female, 41 years).  
“Um, certainly since I’ve heard from my friend who still has the virus after 
tweleve months of being on treatment and tolerating treatment. You know, I 
87 
 
couldn’t believe that. I thought once you on treatment you can get rid of the 
virus. When I saw my friends who were disappointed with the treatment, I 
decided not to go. I’m glad that I met him, otherwise I would be pissed off 
and become mad if that had happened to me”(female, 38 years).  
 Hearing about negative experiences of side effects made the participants in 
the non-treatment group worried and anxious about whether they could 
manage them. That is why most participants in the non-treatment group had 
decided not to undertake HCV treatment.  
“I don't want to go for the treatment, because I have seen my housemate, who 
has been through treatment, and she couldn't handle the side effects because 
they were out of her control. If I face the same side effects that my housemate 
faced, I wouldn't be able to manage them and they could be out of my control. 
So I don't want to go for it” (male, 35 years).  
4.1.3.7 Protecting family, health and wellbeing and career goals 
Some of the participants in the treatment group said that the “benefit of being 
treated” acted as a motivator to undertake HCV treatment. They were at a 
stage in their lives where they wanted to eliminate their concerns about their 
future. They were taking steps toward healthy lives.  
Protecting family  
Concerns related to the transmission of HCV to family members were 
important in deciding to undergo HCV treatment. Protecting partners, 
children and family from HCV transmission was repeatedly mentioned. For 
example: 
“Protecting my kids and my partner against the virus pushed me towards 
treatment. I have two little kids, so I just wanted to keep them safe. I didn’t 
want to pass the virus to them because they’re just kids. We have only one 
toilet and one bathroom in the house they might go and use my toothbrush or 
razor, then catch the virus, so I wouldn’t forgive myself for the rest of my life. 
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To me it is the most horrible thing someone can do to their kids or their 
family” (male, 37years).  
Prior to undergoing treatment, some participants physically isolated 
themselves from the other members of their family, causing emotional 
stress: 
“I couldn’t handle my situation, living every day in hell where I limited myself 
to my bedroom and my own TV. I separated myself physically and emotionally 
from my family. It was very hard for me. I wanted to be with my kids but, 
because of HCV, I couldn’t. I always gave excuses to my kids in order to avoid 
playing with them, even though if I didn’t think about my HCV it was always 
in the back of head of my mind that I’m HCV-positive and my kids and partner 
were not safe around me and I always worried that I could give it to them 
somehow” (male, 37 years).  
Some wanted to maintain strong connections with their grandchildren; they 
considered HCV a barrier to this goal. This perception was very common 
among participants whose children (the parents of their grandchildren) found 
it hard to deal with their parents’ HCV. They felt embarrassed about their 
HCV status. 
“My daughter never trusted me to look after her kid, she always preferred to 
put her kid in day care and pay a fortune rather than letting me look after her 
kid. Even for any social activity she put her kid away from me, she didn't even 
let me feed her, all because of my HCV. She always worried that something 
would happen and her kid would get HCV. That’s why I did treatment and I 
fortunately cleared the virus. Now I can look after my gorgeous grand kid!” 
(female, 48 years).  
On the other hand, two participants in the treatment group looked after their 
grandchildren despite their HCV and believing they were not healthy enough. 
One participant stated: 
“I take care of my grandchildren three days per week. I just want them to be 
safe when they’re with me. I remember when my son was four years old and 
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he put my razor in his mouth. I’d hate something like this happen to my 
grandchildren. So I just wanted to be a healthy person and not carrying the 
virus when I’m with my grandkids” (female, 50 years).  
Another participant described feeling anxious as a grandmother: 
“I had an anxiety attack when I was with my grandkids, it made me feel awful 
and I felt guilty as an HCV-infected person looking after my 
grandkids”(female 50 years).  
Health and wellbeing 
Participants in the treatment group who did not have children or family 
undertook treatment to become healthier and live longer. They perceived 
HCV treatment as a second chance in life which assisted them to return to 
their pre-HCV lifestyle and extended their life expectancy. Being HCV-free 
improved their confidence; they typically described this as giving them a new 
lease on life. The vast majority of treatment-experienced participants spoke 
about becoming HCV-free changing their lives for the better. 
“I’m not old enough to die, I still have life to live. I want to have a better life 
with a better health status and live longer. I can start a new life without HCV, 
so HCV treatment is extremely important for me because it can save my life 
and give me more time to be alive”(male, 49 years). 
“I still have plenty of time to live young. I can have a better quality of life and 
live longer and even have a new life free of HCV, why not? When I can extend 
my life expectancy and have a healthy life by clearing the HCV, why not? I 
would be stupid if I didn't take HCV treatment” (male, 37 years). 
The majority of participants in the treatment group felt unwell and related 
their health problems to having had HCV for a while. Feeling fatigued all the 
time, brain fog, dry eyes and depression were the most common HCV 
symptoms experienced by participants in the treatment group. They 
acknowledged that HCV can have a long-term negative impact on 
individuals’ health and wellbeing, both physically and emotionally, which 
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might stop them from participating in their normal daily routine. Participants 
wanted the energy levels they had before being infected and to have a normal 
life. They spoke about HCV increasing the chance of liver disease such as 
fibrosis, cirrhosis and liver cancer, which could lead to an early death. 
“I want my energy back. I couldn't get up in the morning even when I had 
enough sleep at night, about nine to ten hours, then when I woke up in the 
morning I felt so tired and slept again. Most of the time I had to sleep again 
in the morning or lie down for a while to get my energy back, but I still didn't 
have enough energy. I used to go sailing a lot, but because of being fatigued 
and lack of energy I wasn't able to do it. I wasn't able even to do my daily 
routine. HCV can cause early death as well, as one of my friends died because 
of HCV” (male, 47 years). 
Other participants in the treatment group expressed fear and uncertainty about 
their health status in the near future. They had constant fear of becoming sick 
and being admitted to hospital and requiring high- dependency care. They did 
not want to experience ill health and be hospitalised with debilitating HCV-
related disease in the near future.  
“I always have a fear of ending up in hospital because of my HCV. I don’t 
want to be hooked to a machine and the machine keeps you alive. When I 
think rationally about having a choice whether or not to undergo HCV 
treatment, my common sense told me I should go for it in order to save my 
health and not end up in hospital” (male, 49 years ).  
 Some participants in the treatment group averred that HCV treatment had 
brought positive and healthy changes in their lives. Their intention to 
undertake HCV treatment had increased since they were diagnosed with 
HCV. They added that they were fortunate in having an option to undertake 
HCV treatment to clear the virus and live healthier lives. Living HCV-free 
gave them a greater sense of value, as well as tranquillity and pleasure. 
 
“HCV treatment is a free gift for infected people, and it brings a positive and 
healthy change into people’s lives. I always wanted to go on HCV treatment 
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over the past years since I was diagnosed. I also believed that infected people 
could improve their lives without suffering with HCV every day in their life 
by going on HCV treatment. Once the virus is cleared, joy and happiness 
comes into your life” (female, 50 years). 
  
Career  
A desire to become healthy was not the only reason that encouraged IDUs to 
take up treatment. Those participants in the treatment group who were 
employed stated that their careers were a major motivation for HCV treatment 
uptake. They were satisfied with their current jobs, and did not want to 
become unemployed due to HCV. One female IDU who worked as a nurse 
said that her job motivated her to commence HCV treatment.  
“The main motivation for me to go on HCV treatment was keeping my current 
job. I really love my job, I don’t want to lose it because of HCV. I just wanted 
to be free from the HCV while I am working as a nurse and dealing with 
patients. In a psychiatric ward two years ago, one of my patients bit me and 
I had bleeding. His mouth was full of blood. I felt awful and dirty. After that, 
I decided to go on HCV treatment, because I was worried that I could pass it 
to my patients, particularly during some procedures” (female, 48 years). 
The participants who worked in settings where there was a high chance of 
transmitting HCV to others did not disclose their HCV. They just wanted to 
clear the virus to put themselves at peace and without worry while they 
worked. One participant who worked as a chef in a city restaurant pointed 
out: 
“You know, over the top of everything, my job was a key motivator to push 
me into the treatment. You know, working as a chef is really hard and 
stressful, especially with HCV; I was so under stress and pressure while I was 
working due to HCV. One day when I was working, I cut my hand very badly 
and blood was all over the place and my colleague wanted to help me, then I 
told him, ‘please don’t help me’. He insisted on helping me, then I had to tell 
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him I had HCV. It was so hard for me; I couldn’t handle it anymore, so I 
decided to go on HCV treatment” (male, 37 years).  
HCV symptoms were an extra burden for the employed participants in the 
treatment group, and this interfered with their working responsibilities. They 
perceived it as potentially jeopardising their lives, as all of them were the 
primary breadwinners in their families. As their HCV symptoms worsened 
and became unpredictable, the increasing hindrance to their work 
performance influenced their intention to undergo HCV treatment. 
"I believe for me, my motivation or encouragement to go on HCV treatment 
is my job. My job is physical work and in the middle of the day I didn't have 
the energy to continue my job and I was so lethargic, with no energy. I wasn’t 
able to manage my work while dealing with HCV symptoms at the same time. 
So I lost my job. It was a big loss for me because I am the only income source 
to my family. Then I thought it was now time to kill the virus, so I could get 
back to work. I am happier than ever now that I am with no HCV. I can work 
properly and earn good money” (male, 37 years).  
Other participants were constantly exhausted due to experiencing HCV 
symptoms: 
"Let me tell you that my job was the key to inspire me towards treatment. I 
worked as an assistant manager, full-time, and I tried a lot to keep my job. 
But because of having HCV for ages, I started showing symptoms such as 
constant fatigue and nausea every day, and the worst one was when I became 
forgetful with low focus" (female, 38 years).  
4.1.3.8 Unstable housing 
Participants in the non-treatment group who were homeless at interview 
described homelessness as increasing the likelihood of them engaging in risky 
behaviours such as sharing injecting equipment, exchanging sex for drugs and 
unprotected sex, which could expose them to other blood-borne viruses. They 
expressed their frustration with their lack of healthy food, sleep, showers, 
washing machines and particularly refrigerators for keeping HCV 
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medications. They did not have the resources to undertake HCV treatment 
and it did not make sense for them to do so while they lived in this unstable 
environment. They perceived the ongoing struggle of being homeless as a 
demotivating factor with respect to HCV treatment. 
“You know, I’m homeless over the last two years. How can I go on HCV 
treatment while I am homeless, how can I keep my medication? As a homeless 
person, I do everything to earn money for my expenses, such as sleeping with 
any drug dealer at any time without using a condom. When I am desperate 
for the drugs and I don’t have a clean needle, I use other users’ needles. I 
don’t eat, sleep and shower properly. At the moment, without a house, I just 
want to live and spend my life. HCV treatment doesn’t mean anything to me. 
What sort of motivation is left for me to go on HCV treatment? Because of 
these reasons that I told you earlier, I can’t go on HCV treatment” (female, 
40 years).  
Living on the street without permanent shelter caused depression and suicida l 
tendencies. Participants’ mental illnesses eroded their ability to maintain a 
positive mindset towards HCV treatment, but in any case, they knew 
treatment with pegylated interferon could make their situation even worse. 
They stated that without shelter, they felt unable to look after themselves or 
care about their HCV. 
“I am homeless over the last two years. How do you expect me to take HCV 
treatment? I’m struggling with living on the street where my depression got 
intense and worse. Often, I visit a GP for a prescription; without my 
depression medicine I wouldn’t be alive. But sometimes I tried to kill myself 
because I’m tired of living on the street, so with the attitude of killing myself 
and my depression, I don’t have a hope to kill the virus, especially with 
interferon treatment, which makes my depression worse and worse. I can’t 
deal with my current situation, how I can deal with treatment while I am 
homeless? You know, based on my experience for nearly two and half years 
on the street, I would say all homeless are depressed, regardless of HIV and 
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HCV. The only disease you could generalise for the homeless is depression” 
(male, 37 years).  
Homeless participants noted that they could not register themselves with 
health care providers (clinical nurses, support services and doctors) in order 
to commence HCV treatment without a stable address and contact number. 
“I have been living on the streets for the past three years. As you know, I need 
stable accommodation with a stable address and contact number to be able 
to enrol in HCV treatment. So if I want to take HCV treatment, I need to go 
through a registration process. At this stage, it is not possible. Having a 
stable address is one of the key parts to go on HCV treatment. As long as I’m 
homeless, I can’t be registered for HCV treatment” (male, 34 years).  
Some participants claimed that health care providers’ negative perceptions of 
homeless clients resulted in homeless IDUs going without HCV treatment, 
which could lead to an increased risk of developing liver damage or liver 
failure. Feelings of mistreatment contributed to their low intention to 
undertake HCV treatment.  
“I don’t have shelter over my head since three years ago. I’ve had HCV for 
about eighteen years. I tried to go on HCV treatment; when I asked my GP 
about going on HCV, he didn’t give me a referral for HCV treatment because 
of my depression. He already knew my liver is not good, I don’t know what 
the problem is with my liver, but I know my liver is not okay. Without giving 
me a treatment choice, I will die soon from liver disease. I try my best to stay 
alive without having any proper health care” (male, 42 years).  
 
Fear of unpleasant side effects was expressed by some homeless participants. 
Thoughts of encountering psychological and physical side effects of 
treatment while living on the streets were powerful disincentives. They 
expressed serious concerns about their capacity to cope with treatment side 
effects, especially while struggling with drug addiction. 
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“As a homeless person, I don't have a bed to sleep in, I don’t bathe or shower. 
I love a shower because it makes me calm, it’s the only place that I don’t think 
about anything. It may sound silly to you, but I love it. I don’t have a stove to 
cook on and I don’t have my own peace. How can I deal with the HCV 
treatment side effects or how can I manage the side effects while I live on the 
street? Without a peaceful place and peaceful mind, I can’t deal with 
interferon side effects which can affect my mental and physical health as 
well” (male, 36 years).  
Two homeless participants described drinking large amounts of alcohol and 
injecting drugs in particularly risky ways. They confirmed that without shelter 
they did not have control of their lives, so they did not intend to undertake 
HCV treatment as their homelessness could jeopardise the outcome. 
“I didn’t have a stable place to live. I was homeless for seven months until a 
friend of my brother-in-law offered me a place to live without paying. This 
place is not good, because all the housemates are encouraging me to drink 
alcohol, try different drugs, injecting more than I used to, we even shared 
needles, especially on the weekend when we run out of needles, also using 
homebake as well. I would be stupid if I went on HCV treatment”(male, 42 
years). 
4.2 Focus groups  
Focus groups were held to follow up and confirm the themes identified in 
individual interviews, as well as to explore HCV-positive current IDUs’ 
perceptions about triple treatment. The results allowed the researcher to 
develop an instrument for assessing the factors that influence intention of 
HCV-infected IDUs to undertake HCV treatment. This section describes the 
focus group participants and the findings from the focus group discussions. 
The themes emerging from the focus groups were treatment side effects; 
treatment duration; treatment effectiveness; stigma; and lack of support.  
96 
 
4.2.1 Sample characteristics of focus groups  
The five focus groups brought together 25 individuals (five in each group) 
who were current IDUs living with HCV and with no experience of HCV 
treatment. Table 4.2 provides the socio-demographic and drug-use history of 
participants. In summary, just over half of the participants were female; 
participants were aged from 33 to 47 with a median age of 39 years. Most had 
stable accommodation and just over half (52%) had completed Year 12 or 
TAFE/university (Table 4.2). A small percentage identified as Aborigina l. 
Most participants lived alone. More than half of the participants were 
unemployed and derived their income from government benefits (Table 4.2).  
As indicated in Table 4.2, methamphetamine was the drug of choice and the 
most commonly drug injected in the last six months for just over half of the 
focus group participants, while the remainder nominated heroin. A large 
majority of participants reported injecting once a day. Injecting drug use 
histories were largely of more than 10 years. Most participants had not 
consumed alcohol in the past year.  
Table 4.2 Characteristics of focus groups 
Socio-demographic  
and drug characteristics  
 
 n % 
Gender 
 Male 
 Female 
 
12 
13 
 
48 
52 
 
Accommodation  
 Homeless  
 Non-homeless  
 
 
8  
17 
 
 
32 
68 
 
Live with 
 Alone 
 partners /Family  
 
 
16 
9 
 
 
64 
36 
 
Education  
 ≤ Year11 
 Year 12  
 TAFE/Uni 
 
 
12 
11 
2 
 
 
48 
44 
8 
 
Ethnicity 
 Aboriginal  
 Non-Aboriginal  
 
 
2 
23 
 
 
8 
92 
 
Marital status  
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 Single 
 Married/lived with sexual partner 
9 
16 
36 
64 
 
Employment status  
 Non-Employed  
 Employed  
 
 
11 
14 
 
 
44 
56 
 
Source of income 
 Employed  
 Government benefits  
 
 
11 
14 
 
 
44 
56 
 
Preferred drug and drug used most often in the last 6 months 
 methamphetamine 
 Heroin 
 
 
13 
12 
 
 
52 
48 
Frequency of injection  
 More than daily  
 once a day  
 
2 
23 
 
8 
92 
Drug use duration 
 8-10 years 
 >10 years  
 
5 
20 
 
20 
80 
Consumed alcohol in the past year 
 Yes 
 No 
 
6 
19 
 
24 
76 
 
4.2.1 Themes from focus groups  
This section presents the results of thematic analysis of the transcripts of the 
focus group discussions involving HCV-infected current IDUs. Participants ’ 
verbatim quotations are included in the text to illustrate the primary themes. 
The themes presented describe the factors that contributed to these non-
treatment-experienced participants’ perceptions of HCV triple treatment. The 
findings from the focus group discussions are only from IDUs infected with 
HCV genotype 1.  
Analysis revealed new insights into IDUs’ perceptions of triple therapy. 
Focus group discussions revealed that efficacy, duration and side effects were 
mentioned as influences on intention to undertake HCV treatment. In most 
focus groups, participants were unanimous about the importance of these 
factors.  
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4.2.1. Treatment side effects  
Most of the focus group participants asserted that the new triple therapy added 
a third drug and so added more side effects to the pegylated interferon and 
ribavirin. They cited dermatological side effects of the new drug as a factor 
which discouraged them from undertaking treatment. Most female 
participants were concerned about these side effects and their appearance. 
They mentioned skin rashes, irritation and itchiness that could damage their 
skin and that their skin might be affected for a long time, even after the 
completion of treatment. They believed the dermatological damage would be 
embarrassing in public, particularly in the workplace.  
“I tried to look after my face and my body very well, because as a drug user 
I don’t want people to judge me because of my appearance. So why should I 
go through a treatment that will affect my skin badly? The rashes might be 
itchy, which is so annoying. If the rashes stay on my skin for a while, I can’t 
feel comfortable to go out in public” (female, 36 years). 
Most focus group participants asserted that changes in physical appearance 
because of skin side effects, along with other physical side effects of 
pegylated interferon, could affect their functioning and particularly their 
working lives. 
“I’m so scared to go through new treatment. How am I to face the new side 
effects? New meds mean more side effects, plus the interferon side effects, can 
affect my daily activities or limit my life in general. I know how the interferon 
affects you badly, plus the new side effects make us so sick for about one year. 
I really don't want to become sick” (female, 39 years).  
The employed participants claimed that it was hard for IDUs to mainta in 
permanent employment. They were worried that undertaking triple therapy 
might jeopardise their employment due to their inability to cope with harsh 
side effects while working full time. This led them to reject treatment. They 
believed that treatment side effects such as becoming anaemic, constant 
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headaches, vomiting and other side effects would be very difficult to tolerate 
while they were working. 
“I can’t lose my job because of the treatment side effects, as I have a 
permanent job. We are drug users; you should know that these days getting a 
job is very difficult especially for us drug users. We are not silly to put 
ourselves in a position where we have to think every day about losing our 
jobs because of not coping with the treatment side effects very well. Coping 
with the side effects such as headache, vomiting and et cetera is not easy to 
handle while working” (male, 38 years).  
Participants received a powerful sense of personal satisfaction from their 
current jobs. It was very important for them to maintain their employment and 
keep their positions. They did not want to struggle to meet their work 
responsibilities while coping with HCV treatment.  
“I’ve been working for a while, and as long as I’m very happy with it I can't 
see any point to lose my job because of HCV treatment. When I already know 
the physical side effects could debilitate my physical health, why should I lose 
my job because of HCV treatment? Why should I put myself in a situation 
where I have to struggle to do my work because of these side effects? Also, I 
can earn money which puts me away from financial pressure. To me, HCV 
treatment makes people lose their job, so why should I do it?” (male, 47 
years). 
Those participants who had a history of depression asserted that as long as 
interferon is involved in the HCV treatment course, they would encounter 
psychiatric side effects which could worsen their condition. One participant 
commented:  
 
“I think as long as the interferon is attached to the HCV treatment, we are at 
risk of facing psychiatric side effects, so what’s the point? To me it’s not worth 
it; I’ve been dealing with my depression over the last six years. By going on 
HCV treatment, my depression can get worse” (male , 40 years). 
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However, those who reported no mental health problems similarly did not 
want to experience psychiatric side effects of treatment, which could disrupt 
their daily lives. They were also worried that psychiatric side effects might 
persist long after the treatment was completed. They perceived their drug 
addiction as a mental health issue which they were already struggling with; 
they did not have the capacity to deal with another psychiatric issue which 
might exacerbate their addiction. 
“I never had any mental health issues except my drug issue. I believe if you 
don’t face a mental health issue, you have it for a long time. It also can 
interrupt your daily life as well. You can’t get rid of it easily. Already I have 
to deal with my drug addiction, so I don't want to deal with any other mental 
or psychiatric issue, which could intensify my addiction and I don't have the 
capability to handle it” (male, 42 years).  
4.2.2 Treatment duration  
A long treatment period was another hurdle identified by most of the focus 
group participants. They knew it may take 44 or 48 weeks because of their 
genotypes. They had no desire to make the commitment to undergo the triple 
therapy and in turn had a low level of intention to undertake this treatment. 
“I believe the new triple treatment is still time-consuming and it is one of the 
main barriers which stops people from taking HCV treatment. This triple 
HCV treatment takes a long time and I think because of our genotype, which 
is type one, we have to be on treatment for nearly one year even with this new 
treatment of interferon, ribavirin with either telaprevir or boceprevir. This 
means we have to give commitment for a certain period to be on treatment. 
So at this stage we would not consider to go on HCV treatment until 
something comes up with a shorter duration” (female, 43 years). 
Most of the focus group participants agreed that a commitment to 44 or 48 
weeks of triple HCV treatment risked consequences such as loss of jobs, and 
hence income. They asserted that they would not be able to manage their HCV 
treatment while they were working. They spoke negatively of the time 
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required to attend clinics and undergo blood tests, which would interfere with 
their working lives. 
 “…Um everybody knows you can't handle treatment while you’re working, 
especially those who have permanent jobs. There’s a possible chance of 
losing your income, which drains you economically. As everybody disclosed 
their status at the beginning of this group discussion that we have a 
permanent job so for all of us taking HCV treatment with a permanent job is 
very hard. We can't give commitment to two things at the same time. Because 
HCV treatment is a long commitment, of forty-eight weeks, which we have to 
attend clinic appointments, blood tests and see the doctor or nurse on a 
regular basis which is not manageable while working on a full time basis and 
it can interrupt our work” (male, 40 years). 
Some participants talked about the possibility of having to reduce their 
working hours during treatment, which might put them in a difficult financ ia l 
position.  
“It’s hard to get through treatment while we’re working. We have to be 
working at least on a part-time basis to be able to go on HCV treatment, and 
otherwise we have to deduct working hours. We don’t want to earn less 
because of HCV treatment. This treatment needs a long commitment, which 
can have a negative impact on our work” (female, 42 years). 
Problems related to duration of treatment were reported by other participants 
as influencing their intention to undertake HCV treatment. They affirmed that 
to be on treatment for 48 weeks or 44 weeks made them vulnerable to 
exhaustion, which would make them lose faith that they would be able to clear 
the virus. One participant stated: 
“To be on HCV treatment for such a long time make us so exhausted and tired 
mentally and emotionally, also it make us negative about the result  of 
treatment, thinking we won’t get rid of the virus. It can get to the stage where 
we’re sick of being on the treatment and we can’t handle treatment , then we 
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have to pull out of treatment earlier than what is expected to finish” (male, 
41 years).  
 
Few thought they could stay on HCV treatment for 44 or 48 weeks; some said 
they would probably withdraw after a couple of weeks or in the middle of the 
course. Lengthy treatment duration is clearly one of the main reasons why so 
few HCV-positive IDUs undertake triple HCV treatment. 
4.2.3 Treatment effectiveness  
Another important theme common in the focus group discussions was the low 
efficacy of treatment. Lack of treatment efficacy led participants to feel 
uncertain and apprehensive about the uptake of HCV treatment, and the 
majority of the participants were hesitant about treatment and their chances 
of clearing the virus. They noted that there was a possibility that their HCV 
infection would rebound after treatment; this was because all focus group 
participants had genotype 1, and they believed that it is very hard to attain 
SVR through treating this genotype with interferon. Ultimately, they stated 
that they were unlikely to undertake triple therapy due to concerns about the 
efficacy of treatment. 
“You know, I didn't know there is a new treatment for HCV until you informed 
us at the beginning of this group discussion. As you mentioned, the chances 
of success rate has increased with this new triple treatment compared to the 
old treatment, but it still doesn’t guarantee 100% to get rid of the virus. So I 
don't see a specific point to go through such a journey while feeling insecure 
and unsure about the results. I believe as long as the treatment is not enough 
effective, the chances of clearing the virus is low, especially with our 
genotype. To me the most efficient treatment is a therapy which gives me a 
100% guarantee to kill the virus, otherwise it is useless” (male, 37 years).  
Participants in the non-treatment- group described HCV treatment as 
gambling. Likewise, the vast majority of focus group participants considered 
HCV treatment as gambling and as a risk that could result in emotional trauma 
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if they failed to clear the virus or pay off big if they succeeded in attaining 
SVR. In other words, it placed individuals in the stressful position of not 
knowing whether they would be a winner or loser. This is illustrated in the 
following quote: 
“HCV treatment is like gambling, taking a risk. What I mean is you’re taking 
a risk on whether or not you’re going to be able to remove the virus from the 
body. Why should we put ourselves under pressure for something that we 
don’t know if we will become a loser or a winner? If you think rationally, is 
it the right thing to do at this stage?” (female, 39 years). 
They perceived HCV treatment as an investment and believed that this 
investment should produce a return, but were pessimistic about investing in it 
due to the low probability of eliminating HCV from their bodies. None was 
willing to pursue triple therapy. As another participant said: 
“For me, if I go on HCV treatment, it is like investing my money on something. 
For any investment you put input and expect output. But if you look at the 
HCV treatment you just input, putting more effort and hard work for 
something that you don’t know that you’ll get something out of it. As my mate 
said, we can't do anything now about it. Of course nobody wants to waste 
their money and energy for something that there is no guarantee to clear it” 
(female, 42 years).  
The vast majority of participants were not motivated to undertake HCV 
treatment due to having no guarantee of success. They claimed that they 
would undergo HCV treatment when a guarantee of eliminating the virus was 
given. 
“Do you know why there are still lots of HCV cases? Users are still reluctant 
to undergo HCV treatment, because of fear of not clearing the virus. We don't 
want to experience HCV treatment and then at the end of treatment face a 
null response. This is so annoying, especially for us as active drug users, 
without an assurance to clear the virus, it is disappointing. That's why we are 
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still hesitant to go for HCV treatment; even the new treatment still doesn't 
have 100%” (male, 43 years).  
“The issue with HCV treatment, even with the new treatment, is it is not 
medically developed enough to eradicate the virus. Also, we don’t trust HCV 
treatment in general, even with the new triple treatment, so we don't have 
confidence in the treatment to actually get rid of the virus” (female, 40 years).  
4.2.4 Stigma  
All focus group participants acknowledged that they were susceptible to 
stigma because of HCV. They stated that there is a stigma associated with any 
HCV treatment. They described stigma as inseparable from HCV, which was 
a powerful barrier to undertaking HCV treatment. One participant had the 
following to say about stigma and treatment: 
“Stigma is an important issue for people who are infected with HCV. We are 
at risk to be stigmatised and discriminated against. Stigma is always with 
HCV, old or new treatment doesn't make any difference and doesn't reduce 
the level of stigma. Stigma is still with HCV, as long as HCV exists, stigma is 
linked to it. Stigma can challenge us, when we have to perceive ourselves as 
new persons infected with HCV. This challenge may reduce our ability and 
intention to join with our social networks as well as disturbing our social 
activity. In order not to avoid this stigma and discrimination, we do not 
undergo treatment, even this new treatment” (female, 42 years).  
Experience and fear of HCV-associated stigma were widely acknowledged in 
the focus groups. Most participants, who perceived stigma as a significant 
issue in their communities, brought up fears of being isolated from friends 
and family. They hid their HCV status, as they did not want to become 
socially isolated and suffer prejudice and stigmatisation.  
“I don't want to tell anyone I’m HCV positive because I fear it will be revealed 
to my family and friends. I prefer not to tell anyone about my HCV status, 
because I can't handle the isolation and not being able to interact with my 
community, family and friends. This is hard and painful for me I don't feel 
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comfortable, because this is not who I am. I have to hide my status for 
avoiding stigma and discrimination” (male, 35 years). 
 
In particular, employed participants resisted disclosing their status, as they 
believed that revealing their HCV status in the workplace would risk them 
being labelled and judged by their colleagues. Hence, they attempted to 
interact normally with their colleagues in order to avoid negative reactions 
associated with the HCV stigma. 
 
“I am employed and it is not rational to reveal that we’re HCV-positive so we 
are not stupid to disclose our status in the workplace, where others judge and 
label us. We attempt to have normal communication with our colleagues so 
we don't have to face a negative reaction in the workplace” (female, 38 years).  
 
Concern about HCV-associated stigma was especially emphasised by those 
who had been discriminated against and stigmatised by their families and 
friends. They experienced social isolation and negative behaviour and 
reactions once they disclosed their HCV status. They experienced feelings of 
sadness, shame and particularly loneliness, and reduced self-esteem. They 
had lack of interaction with their family and their social network and so they 
felt like unvalued members of their community. This rejection by family and 
friends damaged their social functioning and their mental health; as one 
participant commented:  
 
 “I did the big mistake in my life that I told my family and my friend I have 
HCV. Since then I’m so sad, embarrassed and I felt so lonely because I’m 
judged all the time. Day by day the distance between me and my family gets 
bigger and I don’t feel close to them anymore. I don’t have confidence 
anymore to hang out with my friends or family. My family doesn’t want me 
anymore, they never asked me for any social events such as birthdays and 
even New Year I always have to be on my own. I can’t see myself as a valuable 
person within my family. When I see my family avoid me, what should I expect 
from others? It really hurts me mentally” (male, 37 years). 
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4.2.5 Lack of support  
All of the focus group participants highlighted family as the most important 
source of support for enrolling in and completing HCV treatment. Without 
family support during HCV treatment, they felt they were likely to become 
exhausted and lose capacity for self-care and develop a sense of hopelessness, 
feelings of loneliness, isolation and depression. In other words, they believed 
that without a supportive family, they were more at risk of the psychologica l 
side effects of the treatment and the intensification of their mental health 
issues. They claimed that they do not wish to undertake HCV treatment if 
they did not have support from their family.  
“The important thing is to have family support if we want to go on HCV 
treatment. I didn't tell my family I’m HCV positive, so I can't tell them if I go 
on treatment and I don't have a partner. With no family support, I can become 
so exhausted because I have to do everything on my own and this end up at 
the stage where I won't be able to take care of myself. Also I’ll feel lonely, 
depressed, isolated and hopeless, plus the psychiatric side effect of interferon, 
which could amplify the effects. But if I had my family they could support me 
to cope with the treatment side effects, help me to adjust to the treatment and 
help me not to suffer from the emotional burden"  (male, 38 years).  
“How can I go on treatment when I don’t have anyone to support me? I’m 
already depressed and isolated, so my mental health issue can get worse by 
undergoing HCV treatment. I don't have the capacity to handle everything on 
my own, so I’ll be drained with no energy, become tired and not be able to 
care for myself. However, with family support you don’t feel hopeless, 
depressed, and you don't suffer from emotional pain” (male, 43 years).  
Participants placed great emphasis on family support as providing a strong 
and sustainable environment which can diminish the stress of HCV treatment 
and provide long-term emotional support, making it easier for them to cope 
with treatment side effects and other challenges. 
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 “I believe that family support can provide a resilient, solid and defensible 
environment where they help to remove the stress and pressure from the 
treatment and make a peaceful environment for us. Family support is a 
reliable source of support which can help us to adjust with treatment” (male, 
42 years).  
The most important element of having a supportive family is the enhancement 
of self-esteem and hope for achieving SVR. Family support can also reinforce 
incentive to undertake HCV treatment. 
 
“When people want to go on treatment they should make sure they have 
support from their family, have a close relationship and high interaction with 
their family. Because this boosts their self-esteem and their confidence to go 
for the treatment and give them hope to obtain a good outcome by 
strengthening their mental health, motivating and encouraging them to go for 
the treatment” (female, 34 years). 
Besides emotional support, the participants agreed that family could play an 
important role in assisting them with daily activities. 
“Having a supportive family gives a peaceful place where they are next to 
you, side by side, especially in daily activity. This is very important during 
HCV treatment, that you don’t need worry about your daily tasks” (female, 
38 years).  
Finally, focus group participants concluded that a supportive family would 
enable them to express their frustration with HCV treatment and its side 
effects, talk about problems coping with side effects during treatment, and 
discuss anxiety and concern about clearing the virus during the treatment. 
Having a supportive family physically and emotionally during the treatment 
journey can help them to accomplish the full treatment course. 
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4.3 Summary  
The results of the qualitative phase of the study were reported in this chapter. 
Analysis of the data collected through semi-structured interviews and focus 
group discussions found that HCV-infected IDUs who had experienced HCV 
treatment and those who had not experienced treatment maintained simila r 
perceptions the treatment. While IDUs in the treatment group spoke about the 
factors that motivated them to undertake treatment, the entire qualitat ive 
sample reported common factors leading to treatment discontinuation and 
treatment refusal. There were no further themes that emerged from the focus 
groups, even though the efficacy of treatment was enhanced by triple therapy.  
The characteristics of the treatment, lack of support and stigma were the most 
common factors identified by these groups. The primary motivations for 
treatment uptake reported by the treatment group were to protect family, to 
increase personal quality of life and to preserve their careers. Hearing positive 
peers’ experience of treatment or encountering peers who had cleared the 
virus motivated participants in the treatment group, while hearing negative 
stories from peers discouraged participants in the non-treatment group. In 
addition, some participants in the non-treatment group reported unstable 
housing as the most decisive factor determining their intention not to 
undertake HCV treatment. The results of the qualitative study contributed to 
the quantitative survey development to examine the factors that influence the 
intentions of IDUs infected with HCV to undertake treatment 
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Chapter 5: Quantitative Results 
This chapter presents the findings of the quantitative phase of the research: a 
cross-sectional survey of HCV-infected IDUs who had not experienced HCV 
treatment. The quantitative phase assessed the prevalence rate of intention to 
undertake HCV treatment and determined the association between the 
independent variables and intention to undertake HCV treatment (the 
dependent variable). This chapter has three sections. The first section 
describes the socio-demographic characteristics of the quantitative sample 
and the responses from participants to the characteristics of treatment, stigma 
and support. The second section provides the results of univariate analysis of 
the associations between socio-demographic characteristics, drug-use history, 
health-care-seeking characteristics, characteristics of treatment, stigma and 
support and intention to undertake HCV treatment. Finally, multivariate 
logistic regression analysis identifies the independent predictors of intent ion 
to undertake HCV treatment.  
No questionnaires had missing data or invalid responses. A total of 336 HCV-
infected IDUs participated in the cross-sectional survey. Of these, 125 
participants (37%) indicated that they had no intention to undertake HCV 
treatment and the remainder (n=211; 63%) indicated that they intended to 
undertake HCV treatment in the future.  
5.1. Descriptive results 
5.1.1 Socio-demographic characteristics 
As indicated in Table 5.1, the sample contained almost equivalent numbers 
of males and females and the median age of participants was 40 years (range 
24–60 years). Most participants had a stable home and lived with their partner 
or shared with others. A large minority (40%) of participants had left school 
at or prior to completing Year 11. A small proportion described themselves 
as Aboriginal. Just over half of all participants were married or in a 
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relationship. Most participants described themselves as unemployed and 
derived their main source of income from government benefits (Table 5.1). 
Table 5.1 Socio-demographic data of survey participants 
Socio-demo characteristics  
 
n 
 
% 
Gender 
 Male 
 Female 
 
162 
174 
 
48 
52 
 
Median age (range)  
 
40 (24-60) 
 
 
Accommodation  
 Homeless 
 Not homeless  
 
 
67 
269 
 
 
20 
80 
 
 Live with 
 Alone 
 Living with others or partners  
 
 
34 
235 
 
 
10 
70 
 
Education  
 ≤Year11 
 Year 12 / 
 TAFE/Uni 
 
 
134 
202 
 
 
 
40 
60 
 
Ethnicity 
 Aboriginal 
 Not Aboriginal 
 
 
41 
295 
 
 
12 
88 
 
Marital status  
 Single 
 Married/lived with sexual partner 
 
 
150 
186 
 
  
44.6  
61.3  
 
Employment status and source of income 
 Employed and employment  
 Not employed 
 and government benefits 
 
 
130 
206 
 
 
38.7 
61.3 
 
5.1.2 Drug -history characteristics 
Participants identified heroin or methamphetamine as their preferred drug and 
these were the only commonly injected drugs in the six months prior to 
interview. A majority of participants reported methamphetamine as their 
preferred drug and the drug they had injected most often in the last six months. 
Most participants reported injecting once a day (Table 5.2). 
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The duration of injecting drug use for the participants ranged from 8 to more 
than 11 years. None of the participants reported injecting for less than 8 years. 
More than half of participants reported injecting for 8-10 years. About a third 
of participants indicated that they drank alcohol in the past year (Table 5.2). 
Table 5.2 Drug-history characteristics of survey participants 
Drug history n % 
Preferred drug 
 Heroin   
 methamphetamine 
 
139 
197 
 
41.4 
58.6 
 
Drug most often used in the last 6 months 
 Heroin 
 methamphetamine 
 
 
139 
197 
 
 
 
41.4 
58.6 
 
Frequency of injection  
 Once a day  
 > than once a day  
 
 
135 
201 
 
 
40.2 
59.8 
 
Drug duration 
 8-10 years 
 ≥11 years 
 
 
182 
154  
 
 
54.2 
45.8 
 
Alcohol  
 Yes 
 No  
 
 
119 
217 
 
 
35.4 
64.6 
 
5.1.3 Health-care- seeking characteristics 
Of the 336 participants, nearly two thirds did not know their HCV genotype 
(Table 5.3). Just over half of all participants had been diagnosed with active 
HCV between 5–10 years before the survey, the remainder being diagnosed 
more than 10 years previously. A large minority of participants were unaware 
of HCV standard treatment and triple therapy before commencing the survey. 
Over half of participants reported that they had had a discussion about their 
liver health with their GP (Table 5.3).  
Table 5.3 Health-care-seeking characteristics of survey participants 
Healthcare-seeking characteristic  n % 
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Knows HCV genotype , 
 No 
 Yes 
 
214 
122 
 
63.7 
36.3 
 
Years ago diagnosed HCV positive,  
 5-10 years 
 >10 years 
 
188 
148 
 
56 
44 
 
Being aware of HCV treatment before commencing the survey 
 No  
 Yes 
 
 
140 
196 
 
 
41.7 
58.3 
 
Had a discussion with GP about liver health status , 
 No 
 Yes 
 
 
148 
188 
 
 
44 
56 
 
5.1.4Participants’ perceptions of characteristics of treatment, stigma 
and support 
As detailed in Chapter 3, an overall measure (combined median score) of 
perceptions of the characteristics of treatment, stigma and support in relation 
to the uptake of HCV treatment was computed and used in the analysis. A 
summary of participants’ responses to these variables is presented in Table 
5.4, which shows more than half of the participants (69.6%) agreed with the 
statement that they ‘assumed that HCV treatment has a guaranteed cure’ and 
‘once they clear the virus, the virus does not come back to them’. More than 
two-thirds (71%) stated that they assumed HCV treatment takes less than 
either 6 or 12 months, and does not involve harsh side effects. A simila r 
proportion of the participants were concerned about the stigma associated 
with IDU and HCV. The vast majority of participants reported that they had 
a network of family and friends who could support them if they chose to 
undertake treatment.  
Table 5.4 Proportions of IDUs’ perceptions of characteristics of 
treatment, stigma and support 
 
Statements  Strongly 
disagree 
Disagree  neutral Agree  Strongly 
agree  
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I assumed hepatitis C 
treatment has a guaranteed 
cure.  
 
44(13) 
 
50(15) 
 
8(2.3) 
 
89(26.4) 
 
145(43.1) 
 
I assumed once I clear 
hepatitis C virus, it does 
not come back.  
 
44(13) 
 
40(12) 
 
18(5.3) 
 
89(26.4) 
 
145(43.1) 
 
I assumed hepatitis C 
treatment takes less than 6 
months. 
 
35(10.4) 
 
39(11.6) 
 
22(6.5) 
 
138(41) 
 
102(30.3) 
 
I assumed hepatitis C 
treatment takes less than 12 
months. 
 
45(13.4) 
 
39(11.6) 
 
12(3.5) 
 
138(41) 
 
102(30.3) 
 
I assumed hepatitis C 
treatment does not involve 
harsh physical side effects. 
 
20(6) 
 
36(10.7) 
 
40(12) 
 
136(44.6) 
 
104(30.9) 
 
I assumed hepatitis C 
treatment does not involve 
harsh psychological side 
effects. 
 
21(6.2) 
 
35(10.4) 
 
40(12) 
 
130(38.6) 
 
110(32.7) 
 
I assumed hepatitis C 
treatment does not involve 
severe skin problems. 
 
21(6.2) 
 
30(9) 
 
45(13.3) 
 
120(35.7) 
 
120(35.7) 
 
I assumed hepatitis C 
treatment does not involve 
post- treatment side effects.  
 
21(6.2) 
 
35(10.4) 
 
40(12) 
 
130(38.6) 
 
110(32.7) 
  
I feel I need to hide the fact 
that I am a drug user and 
have hepatitis C. 
 
48(14.3) 
 
52(15.5) 
 
0 
 
130(38.6) 
 
106(31.5) 
 
I believe injecting drug 
users with hepatitis C are 
treated like outcasts. 
 
48(14.3) 
 
52(15.5) 
 
0 
 
130(38.6) 
 
106(31.5) 
 
I feel I wouldn’t get as 
good health care if health 
care providers knew about 
my drug status.  
 
47(14) 
 
53(15.8) 
 
0 
 
131(39) 
 
105(31.3) 
 
I fear my family and my 
friend would reject me if 
they learned about my 
illness. 
 
48(14.3) 
 
52(15.5) 
 
0 
 
130(38.6) 
 
106(31.5) 
 
There is a special person 
who is around when I am 
in need with my daily 
chores. 
 
40(12) 
 
50(14.8) 
 
50(14.8) 
 
94(28) 
 
102(30.3) 
  
40(12) 
 
45(13.3) 
 
55(16.3) 
 
94(28) 
 
102(30.3) 
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There is a special person 
with whom I can share my 
joys and sorrows. 
 
I have a special person who 
is a real source of comfort 
and help to me. 
 
40(12) 
 
50(14.8) 
 
50(14.8) 
 
94(28) 
 
102(30.3) 
 
I get the emotional help 
and support I need from 
either family or friends. 
 
40(12) 
 
50(14.8) 
 
50(14.8) 
 
94(28) 
 
102(30.3) 
5.2 Univariate analysis  
5.2.1Univariate analysis of socio-demographic characteristics by HCV 
treatment intention  
Table 5.5 shows the characteristics of the study sample by intention to treat 
status. A large majority of women (84.5%) indicated an intention to undertake 
treatment, compared to men (39.5%) (p<0.001). Participants aged 40 or over 
(72%) were more likely to report an intention to undertake HCV treatment 
than those who were less than 40 years old (53.5%) (p<0.001). Seventy-six 
per cent of participants who had stable housing described an intention to 
undergo treatment compared to a small fraction of homeless participants 
(7.5%) (p<0.001). Most IDUs (78%) who lived with their partners or shared 
housing with others indicated an intention to undertake HCV treatment 
compared to those who lived alone (29%) (p<0.001). IDUs with a secondary 
school education or education beyond secondary school (91%) were more 
likely to report intention to undergo treatment than less educated participants 
(19%) (p<0.001) (Table 5.5).  
Non-Aboriginal IDUs (70%) were more likely to indicate an intention to 
undergo HCV treatment than Aboriginal IDUs (12%) (p<0.001). Most IDUs 
(84%) who lived with their sexual partner or were married expressed their 
intention to undertake HCV treatment in contrast to (37%) of those who were 
either single or divorced (p<0.001). Non-employed IDUs who derived their 
major source of income from government benefits (67%) had higher levels of 
intention to undertake HCV treatment than employed IDUs who received 
their major source of income from their jobs (56%) (p=0.045) (Table 5.5).  
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Table 5.5 Univariate analysis of socio-demographic characteristics by 
HCV treatment intention 
Demographic 
characteristics 
Overall  
336(100%) 
Intention to 
undertake 
HCV 
treatment  
211(63%) 
No 
intention to 
undertake 
HCV 
treatment  
125(37%) 
p-value 
&Chi-
square 
Odds Ratio& 
95% CI 
Gender 
 Male 
 Female 
 
162 (48) 
174 (52) 
 
64 (39.5) 
147 (84.5) 
 
98 (60.5) 
27 (15.5) 
 
p<0.001 
χ2=72.64 
 
 
OR:8.33 
CI:4.97,13.98 
Age group 
 < 40 years 
 ≥40 years  
  
 
 
170 (50.6) 
166 (49.5) 
 
91 (53.5) 
120 (72.3) 
 
79 (46.5) 
46 (27.7) 
 
p<0.001 
χ2= 12.65 
 
OR:2.26 
CI:1.42,3.56 
Accommodation  
 Homeless 
 Not homeless
  
 
67 (20) 
269 (80) 
 
5 (7.5) 
206 (76.6) 
 
62 (92.5) 
63 (23.4) 
 
p<0.001 
χ2=109.68 
 
 
OR:40.54 
CI:15.62,105.
2 
Living:  
 Alone 
 With others or 
 partners  
 
34 (10) 
235 (70) 
 
10 (29.4) 
183 (78) 
 
20 (58.8) 
52 (22.1) 
 
 
p<0.001 
χ2=76.04 
 
 
OR:9.17 
CI:5.38,15.64 
 
Education  
 ≤11 
 Year 12/ 
 TAFE/Uni 
 
 
134 (40) 
202 (60) 
 
 
 
26 (19.4) 
185 (91.6) 
 
 
 
108 (80.6) 
17 (8.4) 
 
 
 
p<0.001 
χ2=179.66 
 
 
 
OR: 40.2 
CI:23.46,87.0 
 
Ethnicity 
 Aboriginal 
 Non-
 Aboriginal  
 
 
41 (12) 
295 (88) 
 
 
5 (12) 
206 (70) 
 
 
36 (88) 
89 (30) 
 
 
p<0.001 
χ2= 51.18 
 
 
OR:52.17 
CI:26.49,102 
 
Marital status  
 Single 
 Married/lived 
with sexual partner 
 
 
150 (44.6) 
186 (61.3) 
 
 
55 (36.7) 
156 (84)  
 
 
95 (63.3) 
30 (16.1) 
 
 
p<0.001 
χ2=79.19  
 
 
OR: 8.98 
CI:5.37,14.9 
 
Employment status  
 Employed  
 Not employed 
 
 
130 (38.7) 
206 (61.3) 
 
 
73 (56.2) 
138 (67) 
 
 
57 (43.8) 
68 (33) 
 
 
p=0.045 
χ2=4.006  
 
 
 
OR:1.58 
CI:1.0,2.49 
Source of income 
 Employment  
 Government 
 benefits 
 
130 (38.7) 
206 (61.3) 
 
73 (56.2) 
138 (67) 
 
57 (43.8) 
68 (33) 
 
p=0.045 
χ2=4.006  
 
 
OR:1.58 
CI:1.02,2.49 
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5.2.2 Univariate analysis of drug-history characteristics by HCV 
treatment intention  
Table 5.6 provides an overview of the univariate analysis of drug-history and 
intention to treat. Methamphetamine users (those who nominated 
methamphetamine as their drug of choice and injected it most often in the last 
six months) were more likely to express an intention to undergo HCV (68%) 
treatment than heroin users (55.5%) (p=0.018). A significantly higher 
proportion of IDUs who had injected for between 8 and 10 years (77%) 
reported an intention to undergo HCV treatment than IDUs who had injected 
for more than 11 years (50.5%) (p<0.001). IDUs who did not drink alcohol in 
the past year (88%) were more likely to intend to undertake HCV treatment 
than IDUs who had consumed alcohol (17%) (p<0.001) (Table 5.6).  
Table 5.6 Univariate analysis of drug-history characteristics by HCV 
treatment intention 
Drug history Overall  
336(100%) 
Intention to 
undertake 
HCV 
treatment  
211(63%) 
No intention 
to undertake 
HCV 
treatment  
125(37%) 
p-value 
&Chi-
square 
Odds Ratio& 
95% CI 
Preferred drug and 
drug most often used 
in the last 6 months 
 Heroin   
 Methampheta
 mine 
 
 
 
139(41.4) 
197(58.6) 
 
 
 
77(55.4) 
134(68) 
 
 
 
62(44.6) 
63(32) 
 
 
 
p=0.018 
χ2=5.56 
  
 
 
 
OR:1.71 
CI:1.09,2.68 
 
Frequency of injection  
 Once a day  
 > than once a 
 day  
 
 
135(40.2) 
201(59.8) 
 
 
79(58.5) 
132(65.7) 
 
 
56(41.5) 
69(34.3) 
 
 
p=0.18 
χ2=1.76 
 
 
OR:1.35 
CI:0.865,2.12 
 
Drug duration 
 8-10 years 
 >11 years 
 
 
182(54.2) 
154 (45.8) 
 
 
92(50.5) 
119(77.3) 
 
 
90(49.5) 
35(22.7) 
 
 
p<0.001 
χ2=25.49 
  
 
 
OR:3.32 
CI:2.067,5.35 
 
Alcohol  
 Yes 
 No  
 
 
119(35.4) 
217(64.6) 
 
 
20(16.8) 
191(88) 
 
 
99(83.2) 
26(12) 
 
 
p<0.001 
χ2=166.82 
 
 
 
OR:36.36 
CI:19.33,68.3
7 
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5.2.3 Univariate analysis of healthcare-seeking characteristics by HCV 
treatment intention  
Table 5.7 provides an overview of the univariate analysis of health care 
seeking behaviour and intention to treat. IDUs who were aware of both HCV 
genotype (97%) and HCV treatment before commencing the survey (92%) 
were more likely to report an intention to undertake HCV treatment compared 
to those who were unaware of their genotype (43.5%) and HCV treatment 
(21.4%) (p<0.001). IDUs diagnosed with HCV infection more than 10 years 
before the survey (76.5%) were more likely to report an intention to undergo 
HCV treatment than those who were diagnosed from 5 to 10 years previous ly 
(52%) (p<0.001). A higher proportion of IDUs (97%) who had discussed their 
liver health status with their GPs had more intention to undertake treatment 
than IDUs who did not have discussion (19.6) (p<0.001) (Table 5.7). 
Table 5.7 Univariate analysis of healthcare -seeking characteristics by 
HCV treatment intention  
Health-care-
seeking 
characteristic 
Overall 
336(100%) 
Intention 
to 
undertake 
HCV 
treatment 
211(63%) 
No 
intention to 
undertake 
HCV 
treatment 
125(37%) 
p-value & 
chi-square 
Odds Ratio 
& 95% CI 
Knows HCV 
genotype  
 No
 Yes 
 
 
214 (63.7) 
122 (36.3) 
 
 
93 (43.5) 
118 (96.7) 
 
 
 
121 (56.5) 
4 (3.3) 
 
 
p<0.001 
χ2=94.35 
 
 
 
OR:38.38 
CI:13.66,107
.7 
Years since 
diagnosed HCV 
positive  
 5-10 years 
 >10 years 
 
 
 
188 (56) 
148 (44) 
 
 
 
98 (52.1) 
113 (76.4) 
 
 
 
90 (47.9) 
35 (23.6) 
 
 
 
p<0.001 
χ2=20.79 
 
 
 
 
OR:2.95 
CI:1.84,4.76 
Awareness of HCV 
treatment  
 No  
 Yes 
 
 
140 (41.7) 
196 (58.3) 
 
 
30 (21.4) 
181 (92.3) 
 
 
110 (78.6) 
15 (7.7) 
 
 
p<0.001 
χ2=175.81 
 
 
OR:44.24 
CI:22.78,85.
9 
Having had a 
discussion with GP 
about liver health  
 No 
 Yes 
 
 
 
148 (44) 
188 (56) 
 
 
 
29 (19.6) 
182 (96.8) 
 
 
 
119 (80.4) 
6 (3.2) 
 
 
 
p<0.001 
χ2=211.3 
 
 
 
 
OR:124 
CI:50.15,308
.88 
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5.2.4 Univariate analysis of characteristics of treatment, stigma and 
support by HCV treatment intention  
Table 5.8 shows the results of the univariate analysis using the combined 
explanatory variables and intention to undertake treatment. A majority of 
participants (87%) who assumed that the treatment provides a guaranteed cure 
with protection against relapse (treatment effectiveness) were more likely to 
intend being treated than those who did not assume these (p<0.001). 
Participants who assumed that HCV treatment takes less than either 6 or 12 
months (treatment duration) (76 %) were more likely to report an intention to 
undertake HCV treatment than those who did not assume (29%) (p<0.001).  
The same proportion of participants who assumed that treatment does not 
involve harsh side effects (76 %) reported an intention to undergo HCV 
treatment compared to 29% of those who did not make this assumption 
(p<0.001). IDUs who were concerned about stigma attached to IDUs and 
HCV (58.5%) were less likely to intend being treated than those who were 
not concerned (73%) (p=0.012). A higher proportion of participants who had 
social support for HCV treatment (92%) described an intention to undertake 
treatment, than those who did not have such support (12% ) (p<0.001) 
Table 5.8 Univariate analysis of characteristics of treatment, stigma and 
support by HCV treatment intention 
Variables  Overall  
336(100%) 
Intention to 
uptake HCV 
treatment 
211(63%) 
No intention 
to uptake 
HCV 
treatment 
125(37%) 
P-value 
&chi-
square 
Odds Ratio & 
CI 
(Treatment effectiveness) 
Assumption HCV treatment 
provides both a guaranteed cure 
and protection against relapse  
 Disagree 
 Agree 
 
 
 
 
102 (30.4%) 
234 (69.6%) 
 
 
 
 
8 (7.8) 
203 (86.8) 
 
  
 
 
94 (92.2) 
31 (24.8) 
 
 
 
 
P<0.001 
χ2=189.32 
 
 
 
 
OR:76.9 
CI:34, 173.7 
(Treatment duration) 
Assumption HCV treatment 
duration takes less than either 6 
or 12 months .  
 Disagree 
 Agree  
 
 
 
 
96 (28.6) 
240 (71.4) 
 
 
 
 
 
28 (29.2) 
183 (76.3) 
 
 
 
 
68 (70.8) 
57 (23.8) 
 
 
 
 
P<0.001 
χ2=65.06 
 
 
 
 
 
OR:7.7 
CI:4.5,13.2 
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(Treatment side effects) 
Assumption HCV treatment 
does not involve harsh side 
effects  
 Disagree 
 Agree 
 
 
 
 
96 (71.4) 
240 (28.6) 
 
 
 
 
28 (29.2) 
183 (76.3) 
 
 
 
 
68 (70.8) 
57 (23.8) 
 
 
 
 
P<0.001 
χ2=65.06 
 
 
 
 
OR:7.7 
CI:4.5,13.2 
 
Concern about Stigma  
 Disagree 
 Agree 
 
 
100 (29.8) 
236 (70.2) 
 
 
73 (73) 
138 (58.5) 
 
 
27 (27) 
98 (41.5) 
 
 
P<0.012 
χ2=6.34 
 
 
OR:0.521 
CI:0.31, 0.86 
 Having Support  
 No 
 Yes 
 
140 (41.7%) 
196 (58.3%) 
 
30 (21.4%) 
181 (92.3%) 
 
110 (78.6%) 
15 (7.7%) 
 
P<0.001 
χ2=175.81 
 
OR:44.24 
CI:22.78,.85.9 
 
 
5.3. Multivariate analysis 
5.3.1 Intention to undertake treatment and socio demographic, drug-
history and health-care-seeking characteristics  
The factors that were associated with intention to undertake treatment in the 
univariate analysis at a significance level of p<0.10 were included in a 
multivariate logistic regression model to determine the independent 
predictors of intention to undertake HCV treatment.  
The variables included in the model were gender, age group, accommodation 
status, living arrangements, marital status, ethnicity, education, employment, 
source of income, methamphetamines and heroin users, drug duration, 
drinking alcohol in the past year, awareness of HCV treatment and genotypes, 
knowing about HCV status and having discussion about their liver health 
status with a GP. Interaction terms were examined by the following: drinking 
alcohol in the past year and having discussion about their liver health status 
with a GP; awareness of HCV genotypes and having discussion about their 
liver health status with a GP; and awareness about HCV treatment and having 
discussion about their liver health status with a GP, to eliminate potential 
multicollinearity effects (Aiken and West 1991). The level of significance for 
the retention of variables in the multivariate model was set at p<0.05.  
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The factors that remained significantly associated with intention to take up 
HCV treatment among HCV-infected IDUs included accommodation status, 
drinking alcohol in the past year and ethnicity (Table 5.9). The model was 
statistically significant, χ2=310.741, indicating that it was able to distinguish 
between participants who intended and did not intend to undertake HCV 
treatment. The model as a whole explained between 60.3% (Cox and Snell R 
squared) and 82.3% (Nagelkerke R squared) of the variance in intention status 
and correctly classified 91.4% of cases. IDUs with intention to treat were 
more likely not to be Aboriginal (AOR: 8.07, 95% CI: 3.17, 20.54) and to 
have stable accommodation (AOR: 6.59, 95% CI: 2.302, 18.88). Also, those 
participants who intended to treat were more likely not to have drunk alcohol 
in the previous year (AOR: 6.32, 95% CI: 2.47, 16.15). The interaction terms 
described above were not significant and were not included in the final model. 
Table 5.9 Multivariate analysis of socio-demographic, drug-history and 
HCV related characteristics associated with HCV treatment intention 
Characteristics  n p  AOR 95%CI 
Ethnicity 
 Aboriginal 
 Not Aboriginal 
 
 
37 
301 
 
 
<0.001 
 
 
8.07 
 
 
3.176,20.54 
 
Accommodation  
 Homeless 
 Not homeless 
 
67 
269 
 
 
<0.001 
 
 
6.59 
 
 
2.302,18.88 
 
Drinking Alcohol 
 Yes  
 No 
 
 
119 
217 
 
 
 
<0.001 
 
 
 
6.32 
 
 
 
2.476,16.15 
 
5.3.2 Intention to undertake treatment and treatment effectiveness, 
treatment side effects, treatment duration, support and stigma 
All the variables shown in Table 5.10 (treatment effectiveness, treatment side 
effects, treatment duration, support and stigma) were significant (p < 0.10) in 
the univariate analysis and were included in the multivariate analysis to 
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determine the independent predictors of intention to undertake HCV 
treatment adjusting for potential confounding.  
In the multivariate analysis, variables were retained in the final model if 
p<0.05. All except treatment duration remained significantly associated with 
intention to undertake HCV treatment among HCV-infected IDUs (Table 
5.10). The model was statistically significant, χ2= 297.649 indicating that it 
reliably distinguished participants with and without intention to undertake 
HCV treatment. The model as a whole explained between 58.8% (Cox and 
Snell R square) and 80.2% (Nagelkerke R squared) of the variance in 
intention to undertake treatment and correctly classified 88.4% of cases. 
Significant predictors of intentions to undertake HCV treatment among IDUs 
were support, side effects, effectiveness, and stigma. IDUs with intention to 
treat were more likely to have social support (AOR: 51.75, CI: 12.47, 214.73), 
to assume no harsh side effects are involved in HCV treatment (AOR: 22.73, 
CI: 5.91, 87.47) and to assume treatment provides a guaranteed cure with 
protection against relapse (AOR: 10.675, CI: 3.889, 29.301). However, IDUs 
with intention to undergo treatment were less likely to express concern about 
stigma associated with HCV and IDU (AOR: 0.03, CI: 0.007, 0.19). 
Table 5.10 Multivariate analysis of characteristics of treatment, stigma 
and support associated with HCV treatment intention  
Characteristics  n p  AOR  CI 
Support  
 No 
 Yes 
 
140 
196 
 
 
<0.001 
 
 
51.75 
 
 
12.472,214.73 
 
Treatment side effects  
 Disagree 
 Agree 
 
96 
240 
 
 
<0.001 
 
 
22.73 
 
 
5.910,87.474 
 
Treatment Effectiveness  
 Disagree 
 Agree 
 
 
102 
234 
 
 
 
<0.001 
 
 
 
10.67 
 
 
 
3.889,29.301 
 
Stigma  
 Disagree 
 Agree 
 
 
100 
236 
 
 
 
<0.001 
 
 
 
0.36 
 
 
 
0.007,0.198 
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5 .4 Summary  
This chapter has demonstrated the results from the analysis of data collected 
from a survey of 336 participants recruited in the Perth metropolitan area. The 
quantitative analysis found a number of associations between intention to 
undertake HCV treatment and other variables. Several of these associations 
were statistically significant. After adjustment for confounding variables, the 
multivariate analysis of the factors associated with intention to undertake 
HCV treatment revealed several factors, including: the assumption that HCV 
treatment provides both a guaranteed cure and protection against relapse; the 
assumption that HCV treatment takes less than 6 or 12 months; the 
assumption that HCV treatment does not involve harsh side effect; concern 
about stigma; having social support; not drinking alcohol in the past year; 
non-Aboriginal ethnicity; and having stable housing status. Sixty-three 
percent of participants expressed their intention to undertake HCV treatment 
in the study sample. The next chapter of the thesis provides a discussion of 
these findings.  
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Chapter 6: Discussion  
This chapter contains a discussion of the study findings of the factors 
influencing the intentions of HCV-positive IDUs in the Perth metropolitan 
area with respect to HCV treatment. The study was based on the standard 
combination treatment of pegylated interferon and ribavirin and triple 
treatment. The aim of the study was to gain a better understanding of what 
factors influence the intention of HCV-infected IDUs to undertake HCV 
treatment. The study involved both qualitative and quantitative methods: 
semi-structured interviews, focus groups and a cross-sectional survey. This 
mixed-methods approach enabled the researcher to gain a comprehensive 
understanding of the factors influencing the uptake of treatment. Although 
there were some inconsistencies between the qualitative and quantitat ive 
findings, there were also many complementary findings. 
 
This chapter considers the empirical evidence produced in the current study 
in the context of other research in the area of HCV treatment. The chapter 
begins with a summary of the combined qualitative and quantitative findings 
in which the common factors (treatment side effects, treatment effectiveness, 
support, stigma and housing status) are discussed. Then, the remaining factors 
(treatment duration, peer experiences, the benefits of treatment, alcohol 
consumption and ethnicity are discussed separately because they were not 
common across all three data collection methods. Finally, the prevalence rate 
of intention to undertake treatment is discussed.  
 
6.1 Summary of key findings in relation to research 
field  
6.1.1 Treatment side effects  
One the most important findings from the qualitative study was that the side 
effects of HCV treatment were the main reason for treatment discontinuation 
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and treatment refusal. The critical side effects reported by study participants 
in the treatment group were physical, psychological and dermatological. The 
physical side effects most frequently reported by participants in the treatment 
group were nausea with vomiting, anorexia, dry mouth, and flu-like 
symptoms (fatigue, body and muscle pain, and headaches). The psychiatr ic 
side effects most frequently reported were depression, mood swings, anxiety, 
insomnia and suicidal thoughts. Cognitive side effects were reported by 
several participants in the treatment group. These included forgetfulness, poor 
concentration, attention difficulties, and poor recall. Skin rashes, itching and 
skin dryness were also reported by some female participants in the treatment 
group. The importance of these physical and psychological side effects of 
treatment were confirmed by most participants in the non-treatment group 
and focus groups, who reported that fear of these side effects was one of the 
main reasons for not intending to undertake HCV treatment.  
Physical side effects, particularly gastrointestinal disturbances (nausea, 
vomiting, decreased appetite) and flu-like symptoms, have been identified as 
key factors for treatment withdrawal and treatment refusal in similar studies 
(Fried et al. 2002, Hopwood and Treloar 2005), which noted between 43% 
(Fusfeld et al. 2013) and 69.5% (Manos et al. 2013) of patients reporting 
physical symptoms that resulted in early treatment discontinuation. 
Psychiatric side effects, particularly feelings of depression, decreased interest 
and pleasure, feelings of worthlessness, anxiety, insomnia and suicida l 
thoughts, have been identified as significant factors for treatment 
discontinuation and treatment refusal in other studies, occurring in 30% to 
70% of patients (Schaefer et al. 2012 , Manos et al. 2013).  
 
Scholars have reported the incidence of impaired concentration or “brain fog” 
ranging between 15% (Schaefer et al. 2012 ) and 53% (Manos et al. 2013). 
These and other cognitive side effects have resulted in early treatment 
discontinuation (Lotrich 2009, Janssen et al. 1994, Schaefer et al. 2012, Trask 
et al. 2000), as has experience of skin problems (Hopwood, Treloar, and 
Redsull 2006, Hopwood 2009, Sgorbini, O'Brien, and Jackson 2009, Veluru 
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et al. 2010), which were not physically painful but distressing to female 
participants in the treatment group in the current study.  
 
Qualitative study highlights of the impact of physical and psychiatric side 
effects on treatment cessation and the fear of these side effects leading to 
treatment refusal. Several participants in the treatment group reported taking 
anti-nausea, antidepressants, pain relief and anti-inflammatory medications 
and resting thoroughly, but reported that these measures were ineffective and 
they were still unable to eat, experienced depressive symptoms and had 
fatigue and headaches. Impaired cognitive performance, such as difficulty in 
concentrating and forgetfulness, were very discouraging for several 
participants, leading to additional stress such as inability to remember job 
duties or recall required daily actions or tasks. The few participants who used 
moisturising lotions and topical steroid creams to relieve skin conditions 
reported that these were ineffective and they had still distressing skin 
problems. These treatment experiences reflected the expectations of non-
treatment group and focus group participants’ concerns about being unable to 
cope with treatment side effects.  
 
The current study showed that physical and psychiatric side effects are 
associated with discontinued and refused treatment at least partly due to their 
negative impacts on ability to function, maintain a social life and mainta in 
mental health and emotional stability. Several other studies have reported that 
HCV treatment can significantly decrease quality of life and affect lifestyle 
(Fusfeld et al. 2013, Doab, Treloar, and Dore 2005, Treloar and Hopwood 
2008, Treloar, Newland, et al. 2010, Treloar et al. 2014), and that psychiatr ic 
side effects of HCV treatment can impair mental health and decrease patients’ 
social engagement (Hopwood and Treloar 2005, Fraenkel et al. 2006, Russo 
and Frie 2003, Fried 2002, McNally, Sievert, and Pitts 2006, Fusfeld et al. 
2013).  
 
Participants in the treatment group reported that their reduced ability to 
function and to maintain social interactions, routine daily life and mental 
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health stability had an impact on work, home/family life and social life. 
Concern about the dermatological effects of treatment adversely affecting 
participants’ appearance was also expressed by some. Participants in the non-
treatment and focus groups reported a similar struggle and expectations of 
difficulties in fulfilling their day-to-day responsibilities due to the physica l 
and psychiatric side effects of HCV treatment. Likewise, expected negative 
effects on family functioning, daily routines, work, finances and mental 
health were also reported by non-treatment and focus group participants. For 
example, several participants in the non-treatment group and focus groups 
who had pre-existing psychiatric illnesses such as depression expressed their 
concern about treatment exacerbating their mental health issues. Those with 
no history of mental health issues were concerned about becoming depressed 
or experiencing anxiety and mood swings and of the consequences of being 
prescribed and taking antidepressants for long periods. 
 
Treatment group participants who were employed were often unable to 
maintain a balance between work, home life and treatment, finding it harder 
to plan their schedules, perform routine tasks and maintain their social 
contacts. This often resulted in isolation, lack of desire or interest to engage 
in social interaction, and poor work performance. Many reported a need to 
reduce their work hours, while others were forced to take sick leave. 
Employed participants in the non-treatment group and focus groups similar ly 
reported that they did not want to jeopardise their employment status by 
undertaking HCV treatment. In particular, those who had re-entered the 
workforce in recent years were worried they might need to reduce or cease 
work due to the physical side effects of HCV treatment, and asserted that they 
had more pressing concerns and challenges in their lives.  
 
Both univariate and multivariate analyses found that the expectation of not 
involving harsh side effects in HCV treatment increased intention to take up 
treatment. The qualitative analysis revealed that a significant proportion of 
non-treatment group and focus group participants had no or low levels of 
intention to undertake HCV treatment, either actively through refusal or 
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passively through deferring due to a very high incidence of unwanted side 
effects which were associated with poor quality of life. Therefore, it is clear 
that treatment side effects influenced intention to undertake HCV treatment. 
These results support the need for more refined treatment regimens that 
reduce treatment side effects.  
 
Previous research has not determined treatment side effects as a potential 
predictor of intention to undertake HCV treatment. Nevertheless, further 
national study in this area is needed, particularly with the recent availabil ity 
of new interferon-free treatments (DAAs) to confirm this predictor. As 
reported above, most of the treatment side effects were associated with 
interferon, so DAAs when given without interferon greatly reduce the 
occurrence and severity of adverse side effects. This greater tolerability 
makes HCV treatment more appealing and improves people’s ability to 
comply with the prescribed regime, and is resulting in increased uptake and 
successful completion of treatment (Jensen and Holle 2016). It also reduces 
the need for lifestyle modifications, such as using adaptive or resilience 
techniques, and prescription medications. DAAs eliminate problems for 
patients with pre-existing psychiatric disorders, and employed individuals can 
undertake treatment without being concerned about their work performance.  
 
Despite the vast improvements in tolerability associated with DAAs, a recent 
study showed that side effects such as fatigue, nausea, headache and anaemia 
still occurred in 19% of patients who were treated with sofosbuvir–velpatasvir 
for 12 weeks, 18% of those who were on sofosbuvir–velpatasvir for 24 weeks, 
and 16% of those who received 12 weeks of sofosbuvir–velpatasvir in 
combination with ribavirin (Curry et al. 2015). Treatment for genotype 4 still 
involves pegylated interferon in combination with the new HCV treatments 
(see Figure 2.1), which means some HCV patients will continue to suffer the 
harsh side effects of pegylated interferon.  
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6.1.1 Treatment effectiveness  
Poor treatment effectiveness was one of the main reasons for treatment 
discontinuation and refusal by the qualitative study participants. Most 
treatment group participants reported at least one episode of treatment in 
which they had failed. Lack of treatment efficacy has been identified as a 
significant reason for withdrawal from treatment and treatment refusal in 
previous studies (Doab, Treloar, and Dore 2005, Treloar and Holt 2008, 
Treloar and Hopwood 2008, Treloar and Rhodes 2009, Treloar, Newland, et 
al. 2010, Treloar et al. 2012 , Treloar et al. 2014). Lower adherence to HCV 
treatment is seen among HCV-infected IDUs concerned about treatment 
efficacy (McNally, Sievert, and Pitts 2006, Treloar, Newland, et al. 2010, 
Khokhar and Lewis 2007, Parkes et al. 2006, Treloar and Holt 2008, Lally et 
al. 2008, Kinder 2009), ranging from 26% (Fusfeld et al. 2013) to 47% 
(Zeremski et al. 2014). 
The results related to this finding provide additional insights into the lack of 
treatment effectiveness leading to treatment refusal and treatment cessation. 
For example, several treatment group participants were not satisfied with their 
treatment regime as they did not achieve SVR by the halfway mark, and some 
participants with genotype 3 relapsed after completion of treatment. Most 
treatment-naïve participants reported that lack of treatment effectiveness – as 
they saw it, too low a probability of clearing the virus – generated substantia l 
uncertainty over whether to undertake treatment. 
 
The qualitative findings highlight that fear of HCV relapse and having to 
undergo treatment again were the primary reasons that low treatment 
effectiveness led to treatment cessation or treatment refusal. In an Australian 
study, HCV-positive individuals under an opiate substitution treatment also 
questioned the efficacy of HCV treatment (Treloar, Newland, et al. 2010). 
Mehta et al. (2008) showed that 87% of participants who remained concerned 
about the efficacy of treatment refused to undertake HCV (Mehta et al. 2008). 
Studies have also reported that fear, scepticism and mistrust about treatment 
efficacy reduced adherence, while trust in drug efficacy and positive 
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expectations increased adherence (Mishra et al. 2011, Mohan et al. 2013). In 
this study’s treatment group, participants with genotypes 1 and 3 reported that 
being unable to achieve SVR led to loss of hope about clearing the virus; in 
contrast, one male participant accepted the unpredictability of HCV treatment 
despite three failures.  
Participants in the qualitative phase of the research agreed that they had to 
wait for another round of treatment to have a near-guarantee of achieving 
SVR. The necessity of a very high probability of cure was a strong theme 
across the qualitative phase of the study, and the lack of it caused much 
dissatisfaction and distrust with the HCV treatment process. The quantitat ive 
survey data fully supported this finding. Univariate and multivariate analyses 
found that the idea of a guaranteed cure with protection against relapse 
increased intention to undertake HCV treatment. Treatment effectiveness 
identified as a predictor of intention to undertake HCV treatment in this study. 
However, there is no published literature in the context of treatment efficacy 
as a potential predictor of intention to undertake HCV treatment.  
 
Despite DAAs’ huge improvement in treatment efficacy, a small proportion 
of HCV patients do not respond (Sarrazin 2016, Colpitts and Baumert 2016), 
particularly patients with advanced liver disease, HIV/HCV coinfect ion 
(Sarrazin 2016) or poor adherence, when the medications are not taken as 
prescribed and on schedule, and individuals miss doses (Smith, Chan, and 
Mohammad 2015). Factors influencing poor adherence to HCV treatment 
include unstable housing, forgetfulness, lack of priority, patients’ lack of 
control in their lives, and pre-existing psychiatric illness (Weiss et al. 2009, 
Marcellin et al. 2011, Mishra et al. 2011), confirmed by the qualitative phase 
of the current study. These factors may create some restriction to full 
adherence to the prescribed new HCV treatment as instructed, and 
subsequently could increase the likelihood of developing drug resistance and 
treatment failure (Colpitts and Baumert 2016). Treatment adherence poses a 
similar challenge for DAAs as it did for interferon-based HCV medications ; 
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further research needs to be undertaken to determine how to maximise 
adherence.  
6.1.2 Support 
Lack of support was another main reason for treatment discontinuation and 
treatment refusal specified by the qualitative phase participants. For example, 
several participants in the treatment group reported that their family did not 
respond to their negative thoughts and stressors, nor did they create a 
sympathetic environment. The absence of social support has been identified 
as a key factor for treatment withdrawal treatment and treatment refusal in 
similar studies (Evon et al. 2011, Phillips and Barnes 2016 ).  
 
A lack of support increases the burden on the individual and can lead to 
treatment discontinuation, refusal or deferral of HCV treatment (Evon et al. 
2011, Sgorbini, O'Brien, and Jackson 2009). Study participants lacking 
support reported reduced ability to cope with treatment side effects, to 
function and to maintain emotional stability. Other studies have reported that 
lack of social support can lead to increased depressive symptoms, decreased 
ability to cope with treatment side effects, and reduced motivation to 
undertake and complete treatment (Evon et al. 2011, Rifai et al. 2006). Studies 
have also reported that in the absence of support, maintaining stability, a 
normal lifestyle, daily routines and healthy behaviour is difficult (Blacklaws 
et al. 2009, Fraenkel et al. 2006, Evon et al. 2011). Due to a perceived lack of 
support, participants in the treatment group reported that they relied on their 
own efforts and ability during treatment, which imposed a burden of self-
control, increased distress and depression, and lost confidence in their ability 
to complete treatment.  
 
Qualitative phase participants reported their beliefs that lack of solid 
supportive networks (providing care, love, respect, understanding, hope, 
encouragement and physical support, such as help with household tasks and 
child care) would make the treatment journey even more challenging. 
However, the quantitative data indicated that 58% believed they would have 
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social support if they undertook HCV treatment. A possible reason for this 
discrepancy between the qualitative and quantitative outcomes is that more 
IDUs in the qualitative study lived alone and had experienced family 
breakdown, so lacked strong and intimate relationships with their familie s. 
Additionally, the family members of some of the qualitative phase 
participants suffered from drug addiction or chronic illness or were concerned 
about becoming infected with HCV, further reducing support. In the 
quantitative study, 70% of study participants lived with their families and 
placed great value on a supportive family in relation to the uptake of HCV 
treatment.  
 
Similarly, the few participants in the treatment group who had cleared HCV 
reported that they obtained constant and full support from their family during 
treatment. They reported that their families sacrificed aspects of their own 
lives, resigning from their jobs and committing significant time and effort to 
keep them motivated to complete the treatment. HCV patients who perceived 
satisfying levels of social support experienced fewer adverse side effects 
during treatment, resulting in improved treatment outcomes due to reduced 
psychological distress (Evon et al. 2011, Sgorbini, O'Brien, and Jackson 
2009). Support was identified as a predictor of intention to uptake HCV 
treatment in both univariate and multivariate analyses. This is line with other 
studies, which found that family support was independently associated with 
HCV treatment (Alavi et al. 2013 , Alavi et al. 2015, Wilson et al. 2010) 
 
The quantitative study suggested that IDUs who intended to undergo HCV 
treatment in the future were many times more likely to have social support. 
This is congruent with previous studies which have reported that individua ls 
with greater social support from family and/or friends are more willing and 
better equipped to manage HCV treatment and hence more likely to be 
assessed for treatment and to commence therapy (Grebely, Bryant, et al. 2011, 
Alavi et al. 2013 , Alavi et al. 2015). The role of family is important even 
with the new interferon-free treatments; for while the side effects of the new 
DAA treatment are less severe than with interferon-based treatments, they do 
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still occur, adherence is crucial. Family members can remind patients to take 
their medications on schedule, support them to remain engaged in treatment 
and provide positive energy and emotional closeness. The availability of a 
safe and supportive network is associated with high adherence to HCV 
treatment, mainly because IDUs are cushioned against missing doses 
(Newman et al. 2013 , Edlin 2002).  
6.1.3 Stigma  
Stigma was identified in the qualitative phase of this study as an important 
factor in relation to HCV treatment uptake. Almost all participants in the 
treatment group had hidden their current IDU status from their health care 
providers due to fear of being judged and labelled as dirty or second-class 
citizens and not being treated like other patients with HCV. Also, some 
participants in the treatment group were stigmatised by their own family for 
being IDUs and concealed their HCV status and treatment status due to fear 
of additional stigma. Similarly, most participants in the non-treatment group 
and focus groups reported fear of being judged by health care providers, their 
families and even friends, which made them reluctant to undertake HCV 
treatment. Stigma associated with IDU and/or HCV has been identified  
previously as a key reason to conceal IDU and/or HCV status, as well as for 
reduced intention to engage with HCV treatment. Family (Hopwood 2009, 
Wilson et al. 2010, Treloar, Rance, and Backmund 2013 , Grebely et al. 2009) 
and health care settings can be significant sources of stigma for IDUs with 
HCV (Harris 2009, Tinda, Cook, and Foster 2010, Treloar, Rance, and 
Backmund 2013 , Sgorbini, O'Brien, and Jackson 2009, Grebely et al. 2009).  
 
In this study, most participants in the treatment group reported that they did 
not believe they could be honest about their IDU status and HCV status and 
therefore continued to interact normally with health care providers and their 
families. Many participants in the non-treatment group and focus groups 
reported that health care services treated them differently from people with 
other chronic diseases; they did not meet their needs and their expectations, 
and they inevitably assumed that the ineffective care they received was 
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because of being an IDU. Several other studies have reported that stigma 
reinforces perceptions of being poorly treated, isolates individuals and leads 
to unwillingness to seek HCV care and disclose HCV or drug status (Sgorbini, 
O'Brien, and Jackson 2009, Tinda, Cook, and Foster 2010, Harris and Rhodes 
2013). Several participants in the treatment group reported that they did not 
obtain family and health care providers’ support due to fear of rejection, 
verbal, physical and emotional abuse and disgrace. Some participants in the 
non-treatment and focus groups reported that they lost social interaction and 
social networks once they disclosed their HCV status.  
 
Most qualitative participants reported that they perceived negative attitudes 
towards them in health care settings, particularly the GP setting, where they 
perceived both a lack of trust and unwillingness to treat IDUs with HCV. This 
finding is similar to several previous studies (Tinda, Cook, and Foster 2010, 
Marinho and Barreira 2013 , Treloar, Rance, and Backmund 2013 ). These 
results were confirmed in the analysis of the survey data. IDUs who were 
concerned about stigma were less likely to intend undertaking treatment. 
However, this is in contrast to a study by Wilson et al., the only quantitat ive 
study which assessed the association between stigma and undertaking HCV 
treatment (Wilson et al. 2010). Wilson and his colleagues showed that 
participants who were most concerned about the risks associated with 
disclosing their HCV status were more likely to consider treatment (Wilson 
et al. 2010). This discrepancy could be because only 44.5% of participants in 
that study were current IDUs, while the remainder were past IDUs and 
haemophiliacs. Unfortunately, further analysis was not conducted to identify 
which group of participants considered undertaking treatment, indicat ing 
greater concern with disclosing their HCV status.  
 
Despite the significant impact of stigma on the uptake of HCV treatment, no 
previous research has examined stigma as a predictor of intention to 
undertake treatment. The current study identified that concern about stigma 
is a potential negative predictor of intention to undertake treatment. The 
results of this study show that stigma could remain a major factor influenc ing 
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the intention of IDUs to undertake treatment, particularly with respect to GPs’ 
attitudes to IDUs, as new HCV medications can be prescribed by GPs. In 
addition, previous studies reported that stigma in health care settings leads to 
poor HCV treatment adherence and a lack of willingness to report missed 
doses, and was a common issue among IDU (Harris and Rhodes 2013, 
Marcellin et al. 2011). The new HCV treatments will not be immune from the 
effects of stigma. The new HCV treatments will not be immune from the 
effects of stigma. However, further quantitative studies need to be undertaken 
to verify the results of the present study, particularly with respect to the new 
DAAs. Moreover, further research should examine the impact of stigma on 
the disclosure of HCV status and the uptake of DAAs. 
6.1.4 Unstable housing 
Unstable housing was identified as an important reason for treatment refusal. 
Homeless participants stated that their highly precarious situation along with 
pre-existing mental health problems, made them anxious about meeting their 
basic survival needs, let alone considering HCV treatment. For many, lack of 
a safe place to live, clean clothing, healthy food, showers, toilets, clothes-
washing machines and refrigerators to store medication made it impossible to 
undertake treatment. Many reported that depression and ongoing substance 
abuse issues, made them unable to deal with their health problems or engage 
with service providers for HCV treatment.  
Other similar studies have noted housing instability as one of the key reasons 
for IDUs not undertaking HCV treatment due to having no sense of normalcy 
and no secure place to deal with or recover from side effects and facilitate 
access to better care (Treloar, Newland, et al. 2010, Harris, Rhodes, and 
Martin 2013). Moreover, research shows that homeless IDUs are more at risk 
of experiencing mental illnesses that can make treatment more challenging 
(Neal 2008, Cooper 2008). This is an important consideration, as strict 
adherence to the prescribed medication is essential with DAA treatment. 
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Homeless participants have diminished ability to maintain appointment 
schedules, consistent medical records and treatment regimens, and to connect 
with networks of support and care to cope with adverse effects of HCV 
treatment. Several studies have reported that lack of a permanent address and 
telephone number can prevent homeless IDUs from registering with a GP and 
other services in order to access treatment services and general health care 
(Cooper 2008, Jack et al. 2009, Harris and Rhodes 2013). The care 
requirements of the potentially severe side effects of HCV treatment are 
inconsistent with the lifestyle of homeless individuals (Treloar, Newland, et 
al. 2010, WHO 2012 , Harris, Rhodes, and Martin 2013, Gundlapalli et al. 
2015 ).  
 
Homeless participants in the non-treatment group and focus groups reported 
that they focused on the day-to-day problems of living on the street, includ ing 
lack of regular sleep, physical exhaustion, daily anxiety and depression. Some 
homeless participants reported that they practised unsafe injecting, injected 
drugs very frequently and drank large amounts of alcohol. It was difficult for 
them to follow medical advice about coping with HCV treatment such as 
getting plenty of rest, eating nutritious food and following the strict schedule 
of daily medication and weekly injections. This is confirmed by the 
quantitative analysis, which found that stable accommodation was a 
significant predictor of high intention to undertake HCV treatment in the 
univariate analysis and multivariate analysis. 
 
This is in line with other studies that reported unstable housing as associated 
with non-adherence to HCV treatment (Harris and Rhodes 2013, Mehta et al. 
2008), and that high HCV treatment willingness and early treatment intent are 
associated with stable housing (Charlebois et al.2012, Gundlapalli et al 2015). 
As noted earlier, the new DAAs require strict adherence to be effective, hence 
unstable housing is likely to remain a significant factor deterring homeless 
IDUs from treatment uptake. Missing, forgetting or skipping doses are 
common issues among homeless IDUs, as are lack of a safe place to keep the 
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medications and constantly moving, all of which lead to failure to take 
medication as instructed (Weiss et al. 2009, Marcellin et al. 2011, Mishra et 
al. 2011). Additionally, physicians’ lack of willingness to prescribe to 
homeless IDUs, often labelling them as non-adherent with poor appointment 
attendance (Mravčík et al. 2013 , Mathes, Antoine, and Pieper 2014), could 
lead to poor adherence to new interferon-free HCV treatments. It is important 
to examine the influence of unstable housing on DAAs uptake among the 
homeless population, and to consider homeless IDU’s as a unique population 
with specific needs and issues that will need to be addressed for treatment 
availability and adherence.  
6.1.5 Treatment duration  
Study participants in the non-treatment group and focus groups reported 
difficulty in making a commitment to a lengthy antiviral therapy course, and 
treatment duration was one of the main reasons for treatment discontinuation 
and refusal. Extended treatment duration has been identified as a key factor 
for treatment withdrawal and treatment refusal in previous studies (Fusfeld et 
al. 2013, Berg et al. 2006). Prolonged treatment promotes higher rates of 
treatment interruption or default and patient non-adherence (Fusfeld et al. 
2013, Berg et al. 2006). In one study, the rates of dropout among patients who 
were on a 48-week standard combination HCV treatment plan ranged from 
24% to 41% within 12 and 24 weeks respectively (Berg et al. 2006).  
Qualitative detail gathered in the treatment group, non-treatment group and 
focus groups provides additional insights as to the impact of treatment 
duration on cessation and refusal. For example, several treatment group 
participants reported that they eventually felt frustrated, fatigued and burnt 
out, and unable to find motivation to remain on treatment. Most participants 
in the non-treatment group and focus groups reported that prolonged 
treatment regimens, in the light of adverse medication effects, continuing 
household obligations and other responsibilities, discouraged them from 
undertaking treatment. Several studies have reported that duration of HCV 
treatment can decrease patience, stability and control and disturb family life, 
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personal relationships and work obligations (Hopwood and Treloar 2005, 
Hopwood, Treloar, and Bryant 2006, Fusfeld et al. 2013). However, long 
treatment duration is necessary to maximise virological response (Marcellin 
et al. 2011). 
 
Several participants engaged in paid work reported that they had no interest 
in reducing their number of shifts, earning less or losing their income to 
undergo prolonged HCV treatment. The survey participants confirmed this 
finding, reporting that coping with treatment in shorter-duration was 
associated with higher intention to undertake treatment. However, the 
multivariate analysis was unable to demonstrate that treatment duration was 
a significant independent predictor of intention to uptake treatment among 
HCV-infected IDUs. The advent of interferon-free treatment HCV with a 
shorter duration of treatment could attract many people (Zoulim et al. 2015) 
to undertake treatment and deter early discontinuation. Further study is 
needed to determine the association between shortened treatment duration 
and increased treatment uptake. 
6.1.6Peer experience of treatment 
Treatment group participants reported that observing others going through 
HCV treatment or hearing positive stories from others who had been treated 
motivated them to undertake treatment. However, the non-treatment group 
and focus group participants reported that seeing or hearing peers who 
experienced harsh side effects and had unsuccessful treatment outcomes 
discouraged them from undertaking treatment. Peers’ experiences of HCV 
treatment has been identified as a key factor for motivating and discouraging 
treatment in previous studies (Grebely and Tyndall 2011, Swan et al. 2010, 
Grebely et al. 2010, Munoz-Plaza et al. 2008). 
Several treatment group participants reported that learning about peers’ 
successful treatment led to the impression that they too could accomplish the 
treatment. Other participants reported that peers’ experiences helped them to 
gain a full picture of HCV treatment and served as reference points. Studies 
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have shown that dissemination of positive HCV treatment stories can improve 
patients’ coping strategies, reduce fears, boost confidence and develop 
control during treatment (Bova, Ogawa, and Sullivan-Bolyai 2010, Petraglia 
2009). In contrast, having a friend or family member whose HCV treatment 
failed and/or who encountered harsh side effects was associated with negative 
attitudes towards the uptake of HCV treatment (Treloar et al. 2014, Swan et 
al. 2010). 
Qualitative phase participants reported that they wanted to obtain information 
from peers about their experiences of HCV treatment. They wanted a deeper 
understanding of what was involved in treatment and especially the chances 
of encountering treatment side effects and of clearing the virus. Treatment 
group members reported that positive stories offered encouragement and 
inspiration, which resulted in more confidence and better treatment 
performance. In contrast, non-treatment group and focus group members 
reported that hearing negative stories increased their concerns, making them 
pessimistic about HCV treatment. Peer experiences are likely to be useful in 
the context of DAA treatment, due to positive reports of shorter duration, 
tolerable side effects, high effectiveness and simple management, attracting 
more IDUs to undertake treatment.  
6.1.7 Protecting family, health and wellbeing and job goals 
Study participants in the treatment group reported a fear of HCV transmiss ion 
to their family and children, HCV symptoms, concerns about liver health and 
career worries as major influences on their treatment intention. These were 
strong motivators to undergo treatment. Previous studies have shown that 
concern about future liver damage and liver cancer (Swan et al. 2010, 
Strathdee et al. 2005, Grebely et al. 2008, Yap et al. 2014), and achieving 
career (Yap et al. 2014) and life goals (such as living a happy, healthy, and 
long life) are motivators for undertaking HCV treatment (Swan et al. 2010, 
Treloar et al. 2014). 
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This finding manifested two secondary reasons related to the primary impact 
of HCV and its symptoms leading to treatment uptake. These include the 
constant reminder that the participant was HCV carrier and the negative 
impact on functional ability. Treatment group participants reported that they 
were unable to restore themselves to normal levels of wellbeing and to fulfil 
both their family and occupational roles while experiencing HCV symptoms. 
Several other studies have also reported that the effects of HCV can 
significantly impair quality of life and subsequently create restrictions on 
lifestyle (Spiegel et al. 2005, Eriksson and Svedlund 2006, Fusfeld et al. 2013, 
Yap et al. 2014). Study participants who were the main breadwinners were 
often unable to maintain a balance between work and HCV symptoms, which 
led them to either lose their jobs or reduce working hours. These disruptions 
made them rethink their priorities about HCV treatment. They wanted HCV 
treatment to give them a better quality of life, a more productive working life, 
increase their life expectancy, reduce their concern over fibrosis, cirrhosis and 
liver cancer, and allow them to maintain their current job. 
6.1.8 Alcohol  
Quantitative analysis detected an association between not drinking alcohol in 
the past year and intention to undertake HCV treatment. Univariate and 
multivariate analyses showed that IDUs who intended to undergo HCV 
treatment were six times more likely not to drink alcohol in the previous year 
than IDUs with no such intention. More than half of participants reported not 
drinking alcohol in the past year. This could be related to their health-seek ing 
behaviour, meaning a discussion with a GP convincing them that they needed 
to quit drinking. The implication of this is that IDUs with a desire to take care 
of their liver, who are more concerned about their health and more likely to 
follow their doctor’s recommendations have higher intention to undertake 
HCV treatment. This finding was expected and is similar to that of Strathdee 
et al. (2005), who reported that intention to undertake treatment was higher 
in individuals who did not drink alcohol in the previous few years than in 
those who did (Strathdee et al. 2005). Studies also show that willingness to 
undergo HCV treatment decreases with increased alcohol use (Moirand et al. 
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2007, Gidding et al. 2011, Butt et al. 2007). However, this finding seems to 
be inconsistent with the recent figures from Western Australia which reported 
that 58% of IDUs who lived in Perth drank alcohol within the past year 
(Fetherston and Lenton 2015), along with alcohol which is perceived as the 
common way to facilitate communication among IDUs (NHMRC 2009). 
However, the current study did not explore the amount and type of alcohol 
consumed and the study samples may differ between the two studies. Further 
study about alcohol use among HCV-infected IDUs in Perth metropolitan is 
needed to provide accurate information and to confirm this result.  
6.1.9 Ethnicity 
In the univariate analysis, ethnicity was strongly associated with intention to 
undertake HCV treatment and it remained independently associated with 
HCV treatment intention in the multivariate analysis. These analyses found 
that IDUs who had intention to undergo HCV treatment were eight times 
more likely to be non-Aboriginal. This could be related to their health-seek ing 
behaviour, where more than half of IDUs who were non-Aboriginal IDUs had 
a discussion with their GP about their liver health status. Australian studies 
indicated the significance role of a GP in supporting links to HCV treatment 
(Treloar, Newland, et al. 2010, Grebely, Bryant, et al. 2011). The finding of 
the current study was expected and is in agreement with those of previous 
studies. A recent study reported that 96% of non-Aboriginal people accessed 
HCV treatment compared to 4% of Aboriginal people (McDonald 2010). 
Alavi et al. suggest that non-Aboriginal Australian are more likely to 
undertake HCV treatment (Alavi et al. 2015) due to higher levels of health 
education and better access to health care services (Paquette, McEwan, and 
Bryant 2013).  
Access to culturally appropriate health care services (AIHW 2011), coupled 
with higher socio-economic status (Grebely, Bryant, et al. 2011), is associated 
with higher willingness to undertake treatment among non-Indigenous than 
Indigenous people. This finding seem to be consistent with the view that non-
Aboriginal people are more likely to have effective communication with 
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health care providers, stable lifestyles, higher health literacy and good 
comprehension of HCV treatment and the long-term effect of HCV on liver 
health compared to Aboriginal IDUs (Alavi et al. 2015, Treloar et al. 2016 ). 
However, the current study did not compare the factors associated with 
intention of treatment uptake between Aboriginal and non- Aboriginal people. 
Further comparison study needs to be undertaken to obtain better 
understanding of factors that might contribute to treatment uptake.  
6.1.10 Intention to undertake HCV treatment 
The quantitative analysis found a high level of expressed intention to 
undertake treatment among HCV-infected IDUs. Sixty-three per cent of the 
participants indicated an intention to undertake treatment in the future. The 
current study used measures of intention to uptake treatment similar to those 
used in two previous Australian studies, and the high level of intention among 
IDUs in this study is approximately in line with their results. Two recent 
studies were conducted in an opioid substitution treatment clinic in inner 
Sydney. Alavi et al. reported that 67% of IDUs were willing to be treated 
(Alavi et al. 2015). Similarly, Treloar et al reported that more than 53% of 
IDUs were interested in HCV treatment (Treloar et al. 2012 ). Other studies 
have reported even higher levels of HCV treatment intention among IDUs; 
78% of IDUs recruited from a methadone clinic in inner Sydney (Doab, 
Treloar, and Dore 2005) and 77–86% in studies conducted in Canada and the 
United States (Fischer et al. 2005, Grebely et al. 2008, Strathdee et al. 2005, 
Zeremski et al. 2014). These higher rates could be explained by the use of 
different measures and less-stigmatising health care services that make HCV 
treatment easier and more convenient for clients. 
The high level of HCV treatment intention found in the current study is 
surprising given low efficacy, lengthy duration and harsh side effects of HCV 
treatments based on standard combination treatment and triple therapy. 
However, as reported by participants in the qualitative phases of this study, if 
HCV treatment provides a guaranteed cure with protection against relapse , 
take less than either 6 or 12 months, and does not involve harsh side effects, 
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it is likely that this could increase IDUs’ intention to undertake treatment. 
Additionally, the high rate of intention to be treated could be because 
participants were recruited from community settings, which provide 
opportunities for IDUs to engage with health care. Furthermore, the majority 
of participants were non-Indigenous (with all the disadvantage that status 
represents) and had stable housing, and this is consistent with a high rate of 
intention to undertake treatment. Further research using a cohort method with 
a large, nationally representative sample size would verify and enrich the 
results of the study. With the advent of new DAA HCV treatments, it is 
important to examine change in intention of IDUs towards HCV treatment 
and to precisely record and better understand the pattern of treatment uptake 
in Australia.  
6.2 Summary  
The qualitative research findings from treatment group, non-treatment group 
and focus groups revealed several common factors that influenced intention 
to undergo treatment, including: peer experience of treatment; the desire to 
protect family; health and wellbeing; and career. The quantitative findings 
largely confirmed the findings of the qualitative research which included 
significant associations between intention to undertake treatment, treatment 
side effects, treatment effectiveness, support, housing status and stigma. Not 
drinking alcohol in the past year and non-Aboriginal status were significantly 
associated with higher intention to undertake treatment in the quantitat ive 
findings.  
Despite the advent of the new HCV treatments with reduced side effects, 
shorter duration of treatment and higher efficacy, some adverse effects still 
occur. These adverse effects are specific to HCV treatment and genotype 4, 
which is still based on pegylated interferon. Other factors including unstable 
housing, forgetfulness, lack of priority, patients’ lack of control in their lives 
and pre-existing mental health issues could also lead to poor adherence to new 
HCV treatment, particularly among IDUs. Therefore, adherence to new HCV 
treatment brings challenges as it did for interferon-based HCV treatment. 
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Further research needs to be undertaken to enrich and verify the identified 
predictors in this study and to determine how to maximise adherence to the 
new treatment protocal.  
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Chapter 7: Limitations, Recommendations 
and Conclusions 
This chapter describes the limitations of the study, provides some 
recommendations for further research and better clinical practice and health 
policies related to HCV treatment, and concludes the thesis.  
7.1 Limitations of the study  
This study had some limitations to consider when drawing conclusions from 
its findings.  
Although this is the first mixed-methods study of HCV treatment intent ion 
that covered a sample of HCV-infected IDUs in the Perth metropolitan area, 
HCV status for all participants and HCV genotype 1 for participants in the 
focus group were self-reported. As a result, there may have been some recall 
bias. However, previous studies, particularly Australian studies indicated 
good levels of validity and reliability of self-reported data (Dowling-Guyer et 
al. 1994, Napper et al. 2010, Grebely, Matthews, et al. 2011b, Grebely et al. 
2008). In order to minimise this bias, the researcher specified receiving an 
HCV diagnosis by a health care professional as an inclusion criterion for this 
study, which likely improved the self-reporting accuracy.  
Self-reporting is also susceptible to social desirability bias. Sensitive issues 
such as housing status, education level and employment may involve social 
desirability bias, for example, an IDU with no job, a low level of education 
and unstable housing might feel embarrassed to disclose. They may also have 
indicated they had intention to undertake HCV treatment to avoid 
stigmatisation and remain socially acceptable, considering that most of them 
assumed HCV treatment provides a guaranteed cure with protection against 
relapse, takes less than either 6 or 12 months and does not involve side effects. 
However, giving a brief description of standard combination treatment and 
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triple therapy to the participants before commencing the survey may have 
reduced this form of bias.  
Selection bias may have occurred in the study sample, as the sample was 
based on purposive sampling not random sampling. Recruiting from Perth 
community settings may have led to a potential bias towards participants who 
had easier and better access to health care services. To minimise this and to 
increase the geographical diversity in the sample, data were collected from 
HCV-infected IDUs at three different NSP sites and an NSP mobile service 
visiting eight suburbs. The study sample was not diverse particularly in terms 
of age and duration of injection, for example, a small minority of study 
participants (13%) were aged below 30 years and all study participants had 
injected for more than eight years, which is not representative of the entire 
population HCV-infected IDUs in Perth. Therefore the findings of this study 
may not be generalisable to other region in Australia. However, some adverse 
side effects still occur and other factors including unstable housing, 
forgetfulness, lack of priority, patients’ lack of control in their lives and pre-
existing mental health issues could also lead to poor adherence to new HCV 
treatment, particularly among IDUs.  
Another limitation was the cross-sectional study design, which could only 
estimate intention to undertake treatment at one point in time, whereas 
participants’ intention to undertake treatment may change over time. Finally, 
this study was conducted when pegylated interferon and ribavirin was the 
standard HCV treatment. New DAA HCV treatments with higher efficacious, 
shorter duration and more tolerable side effects became available in Australia 
in March 2016. The availability of these new treatments could significantly 
increase the intention of IDUs to undertake HCV treatment. 
7.2 Recommendations for future research  
Based on the findings of this mixed-methods study, this section presents 
suggestions for future research studies to increase understanding of the factors 
associated with treatment intention. These recommendations are designed to 
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increase access to and uptake of the new HCV treatments, and reduce the 
burden of HCV-associated disease in Australia.  
 Further research on intention to undertake new treatments should 
adopt a prospective cohort design. Such a study could produce reliable 
information on treatment intention and data that could be used to 
develop appropriate interventions for populations that are both easier 
and harder to reach. 
 
 The measures used in this study, such as treatment effectiveness, 
treatment side effects, and treatment duration have undergone checks 
for validity and reliability. However, the measures could benefit from 
further reliability and validity assessment, for example, systematic 
validation through factor analysis.  
 
 Treatment effectiveness, treatment side effects, treatment duration 
support, stigma, housing status and peer experience of treatment need 
to be further examined in the context of new HCV treatments 
programs. This will provide understanding of any changes in the 
factors influencing IDUs’ intention to undertake treatment, and 
subsequent policy and practice.  
 
 Further qualitative study could explore IDUs’ life changes after new 
HCV treatment, such as changes in their personal, family, social and 
work lives and general health status. This will add to current 
knowledge about improved overall health, physical and mental 
health–related quality of life and social function, and subsequently 
will increase understanding of IDUs’ lives without HCV.  
 
 The number of Aboriginal IDUs in the study was unexpected. As there 
is limited information about Aboriginal IDUs’ intention to undertake 
HCV treatment, there is need for future research to measure their 
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treatment intention, as well as the factors associated with their either 
accepting or refusing treatment uptake within a cultural context.  
 
 The amount and type of alcohol consumption and its relation to new 
HCV treatment uptake should be further examined in relation to HCV-
infected IDUs and included in future studies.  
7.3 Recommendations for clinical practices and health 
policies   
The following recommendations are designed to increase access to and uptake 
of the new HCV treatments to reduce the burden of HCV-associated disease 
in Australia.  
 Provide training on the new HCV treatments for all relevant health 
care providers, including GPs, clinical and practitioner nurses. The 
training should aim to raise awareness of the new HCV treatments and 
highlight the benefits of DAAs, so as to potentially increase treatment 
uptake. In particular, such training should be also provided for 
Aboriginal medical services in a culturally appropriate way.  
 
 Provide grants or funds for clinical nurses who are interested in 
becoming nurse practitioners to increase delivery of the new HCV 
treatment in Western Australia.  
 
 Set up HCV community clinics in NSPs (or near NSPs) to provide 
support, encourage IDUs to assess their liver health status and to 
undertake treatment and change their lifestyles. This treatment service 
should provide treatment in a non-judgmental environment. The 
benefits of such clinics need to be emphasised in an HCV treatment 
program. Setting up such clinics could also be recommended in 
Aboriginal health care settings.  
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7.4 Conclusion  
This study was conducted when combination treatment with pegylated 
interferon and ribavirin and triple therapy were the only HCV treatment 
options available. The study used a mixed-methods approach that allowed for 
the collection of data rich in detail to gain better understanding of what factors 
can influence the intentions of HCV-infected IDUs to undertake HCV 
treatment. A qualitative study included semi-structured interviews and focus 
groups to explore the factors influencing the intention of HCV-infected IDUs 
in relation to the uptake of HCV treatment. A quantitative survey was used to 
measure the prevalence of intention to undertake treatment among HCV-
infected IDUs and quantitatively assess the associations between treatment 
effectiveness, treatment side effects, treatment duration, stigma, support, 
demographic factors, drug-history and health characteristics, and intention to 
undertake HCV treatment. A unique element of this study was the 
incorporation of factors identified by study participants in the qualitat ive 
phase, in statistical predictor models. 
Treatment effectiveness, treatment side effects, treatment duration, lack of 
support, and stigma were the most common factors identified in the 
qualitative study. Peers’ experience of treatment, both positive and negative, 
were reported as an important influence on intention to undertake HCV 
treatment by both the treatment group and the non-treatment group in the 
semi-structured interviews. The motivating factors for treatment uptake 
reported by the treatment group were to protect family, to increase personal 
quality of life and to maintain their careers. Unstable housing was reported 
by the non-treatment group as a potential factor which influenced their 
intention not to undertake HCV treatment. Treatment effectiveness, treatment 
side effects, treatment duration, stigma, lack of support, drinking alcohol in 
the past year, ethnicity and housing status were all independently associated 
with intention to undertake treatment. Although there were some 
discrepancies between the qualitative and survey findings, the findings were 
largely consistent.  
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This study provided comprehensive information on HCV treatment intent ion 
and insight in regards to the factors influencing HCV-infected IDUs in Perth. 
The finding contribute to the international literature on intention to undergo 
HCV treatment in several ways. Identification of the prevalence of intent ion 
to undertake HCV treatment and the factors influencing this intention among 
HCV-infected IDUs who have not engaged in HCV treatment allows the early 
recognition of groups with special characteristics. These group that should be 
carefully supported along the antiviral treatment pathway, particularly in the 
context of new HCV treatments. Therefore there is a need to focus efforts on 
both development of HCV treatment programs and potential factors 
influencing treatment adherence, combined with non-judgementa l 
environments and opportunities to enhance treatment uptake leading better 
health and well-being.  
It is hoped that the recommendations resulting from this study will be of value 
to Australian policy makers in the development of interventions and policies 
aimed at highlighting the significance of interferon-free treatment in ways 
that encourage infected IDUs to undertake HCV treatment. Such an outcome 
would help to reduce steep rises in health care costs associated with HCV. 
The researcher believes that the results of this study will help to make the 
world a better place by scaling up HCV treatment for IDUs in the community 
setting. 
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Appendices 
Appendix 1: Demographic and drug-history questions 
for semi-structured interviews and focus groups.  
1. Are you: 
1. Male 
2. Female  
3. Other (specify)…………………………………………… 
 
2. How old are you? yrs old…………….. 
 
3. What type accommodation do you have?  
1. Own house/flat 
2. Rented house/flat 
3. Sharing house  
4. Homeless  
 
4. Are you currently?  
1. Single / separated / divorced? 
2. Married/ living with sexual partner? 
 
5. Who do you live with? (Please tick all that apply)  
1. Partner 
2. Alone 
3. Parents  
4. Children 
5. Share with others  
  
6. Are you Aboriginal or Torres Strait Islander Origin? 
1. No  
2. Aboriginal  
3. Torres Strait Islander 
 
7. What is the highest level of education you have completed? 
1. Primary School 
2. Some high school education  
3. Year 10  
4. Year 12  
5. TAFE/University  
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8. How are you employed at the moment? 
1. Full time work  
2. Part time/Casual work  
3. Student full time  
4. Student part- time  
4. Unemployed  
 
9. What is your MAIN source of income? 
 1. Unemployment benefits  
 2. Sickness benefits  
 3. Pension  
 4. Job  
5. None  
 
10. What country were you born in? 
1. Australia 
2. Other (specify)…………………………………………… 
 
11. What is your current residential postcode? ………. 
 
12. What language was the main one spoken at the home you grew up in? 
1. English 
2. Other (specify) 
 
The following questions are about your drug use history. 
 
13. How long have you been injecting drugs? 
1. Six months -one year  
2. Two- four years  
3. Three-six years  
4. Six-eight years 
5. Eight-ten years 
6. More than ten years  
  
14. What is your preferred drug? 
1. Amphetamines  
2. Heroin 
3. XTC 
4. LSD  
5. Cannabis  
 
15. Which of the following drugs have you used in the past 6 months? 
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1. Amphetamines  
2. Heroin 
3. XTC 
4. LSD  
5. Cannabis  
6. Cocaine  
7. Other opioids (for example oxycodone)  
 
16. How many times have you injected any drugs in the last month? 
1. Hasn’t hit up  
2.Once a week  
3.More than once a week  
(but less than once a day) 
4. Once a day 
5. 2-3 times a day 
6. More than 3 times a day 
 
17. Did you drink alcohol over the last year?  
A. Yes  
B. No 
Appendix 2: Interview questions for treatment group 
1. In general, what would you say about hepatitis C treatment? 
  
2. What factors influenced your intention to have hepatitis C treatment? What 
was the main factor? 
 
3. What are the challenges you have noticed while you are on treatment? How 
do you cope with them?  
 
4. What is your opinion about hepatitis C treatment? What kind of problems 
do you see with the treatment as it is now? 
 
 
5. Do you wish to add any other comments that may assist us with the 
research? 
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Appendix 3: Interview questions for non-treatment 
group  
1. In general, what would you say about hepatitis C treatment? 
 
  
4. What factors influenced your intention not to have hepatitis C treatment 
until now?  
 
4. Do you have HCV symptoms? How do you cope with HCV symptoms? 
 
5. Do you think HCV treatment is challenging? In what way do you think 
HCV treatment is challenging?  
 
5. What is your opinion about hepatitis C treatment? What kind of problems 
do you see with the treatment as it is now? 
 
 
6. Do you wish to add any other comments that may assist us with the 
research? 
 
Appendix 4: Focus groups questions  
1.Have you thought about HCV treatment? If you haven’t can you tell what 
the main reasons are?  
 
2.What factors influenced your intention not to uptake new HCV treatment 
(triple therapy?  
 
3.How or in what way do you think new HCV treatment is challenging? 
 
4.What would encourage you to go for HCV treatment? 
 
5.For what other reasons do you think people who infected with HCV don’t 
take treatment? 
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Appendix 5: poster treatment group  
Hepatitis C Treatment Study 
I am looking for people who are injecting drug users and are in 
hepatitis C treatment or have recently been treated for chronic HCV 
(within the past 2 years) 
I am conducting an interview to find out your opinion about hepatitis C 
treatment. If you are happy to take part in an interview, you will be 
reimbursed $35 Coles or Kmart Voucher for any out of pocket expenses. It 
will take 45-60 minutes.  
 
 To take part in this study you need to be: 
 Currently injecting drug (actively injecting )  
 Over 18 years of age, and  
 Currently being treated or have recently been treated for 
chronic HCV (within the past 2 years   
 Have English as your first language 
 Living in Perth 
Your involvement in this study will improve access to treatment for hepatitis 
C. For more information or an appointment Phone Amineh: 0405805614 and 
leave your name and contact details. Study Approved by Curtin Univers ity 
and South Metropolitan Area Health Service Human Research Ethics 
Committees. All information is strictly confidential.  
  
Appendix 6: poster non-treatment group  
Hepatitis C Treatment Study 
 
Do you have hepatitis C?  
I am conducting an interview to find out your opinion about hepatitis C 
treatment. If you are happy to take part in an interview, you will be 
reimbursed $35 Coles or Kmart Voucher for any out of pocket expenses. It 
will take 45-60 minutes.  
 
To take part in this study you need to: 
 Currently injecting drugs (actively injecting ) 
 Received hepatitis C diagnosed by a health care professional 
more than 6 months earlier  
 Have No Experience with HCV treatment. 
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 Be over 18 years of age, and  
 Be comfortable to speak English  
 Living in Perth 
 
Your involvement in this study will improve access to treatment for hepatitis 
C. For more information or an appointment Phone Amineh: 0405805614 and 
leave your name and contact details. Study Approved by Curtin Univers ity 
and South Metropolitan Area Health Service Human Research Ethics 
Committees. All information is strictly confidential.  
 
Appendix 7: poster focus group  
Hepatitis C Treatment Study 
 
Do you have hepatitis C?  
I am conducting focus groups to find out your opinion about hepatitis C 
treatment. If you are happy to take part in a focus group, you will be 
reimbursed $30 Coles or Kmart Voucher for any out of pocket expenses. It 
will take 60-80 minutes.  
 
To take part in this study you need to: 
 Currently injecting drugs (actively injecting ) 
 Received hepatitis C diagnosed by a health care professional 
more than 6 months earlier with Genotype 1  
 Being aware of new hepatitis C treatment known as triple 
therapy (pegylated interferon and ribavirin in combination 
either boceprevir and telaprevir) 
 Have No Experience with HCV treatment. 
 Be over 18 years of age 
 Be comfortable to speak English  
 Living in Perth 
 
Your involvement in this study will improve access to treatment for hepatitis 
C. For more information or an appointment Phone Amineh: 0405805614 and 
leave your name and contact details. Study Approved by Curtin Univers ity 
and South Metropolitan Area Health Service Human Research Ethics 
Committees. All information is strictly confidential.  
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Appendix 8: Information Sheet semi-structured 
interview  
Name of Investigators: Amineh Rashidi 
    Dr Susan Carruthers (Supervisor) 
 
This study is about hepatitis C treatment. I would like to understand what the 
intentions of injecting drug users are in regards to hepatitis C treatment and 
the best way to do this is to find out their thoughts directly from them. This 
study is being performed for my doctor’s dissertation and has been approved 
by the Curtin University of Technology and the South Metropolitan Area 
Health Service Human Research Ethics Committees. 
If you decide to take part in this research study, it is important that you 
understand the purpose of the study and the procedures you will be asked to 
undergo. Please read the following pages, which will provide you with 
information about the procedures involved, and also the potential benefits, 
discomforts and precautions of the study. If you are currently involved in a 
research study you will be ineligible to participate in this one. 
 
Nature and Purpose of the Study 
 
You are being invited to take part in the study as you are an injecting drug 
user and are either currently receiving hepatitis C treatment or have sought 
information about treatment. This study aims to provide evidence for 
developing appropriate interventions that can assist in increase intention to 
uptake treatment. It is hoped that this study will provide specific outcomes, 
from which I will develop an appropriate model for delivery of hepatitis C 
treatment programs to hepatitis C positive populations, particularly injecting 
drug users. 
What the Study Will Involve 
You are invited to take part in this study.  
If you decide to participate, I will ask you questions about your background, 
and drug history. Then, I will ask you more detailed questions about factors 
which affect your intention to undertake  hepatitis C treatment. The interview 
will take 45-60 minutes. With your permission, the interview/s will be taped-
recorded. 
Benefit  
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Research studies from overseas and within Australia have identified a number 
of common barriers to accessing hepatitis C treatment, especially for those 
people who may be current illicit drug users. There may no direct benefit to 
you participating in the study, however, the information obtained in 
connection with this study may be used to modify existing national guidelines 
for the management of hepatitis C treatment. The information may also be 
used to provide information and advice to current illicit drug users who may 
wish to access hepatitis C treatment.  
Discomfort and Risks  
Talking about illicit drug use or hepatitis C treatment may cause mild 
psychological discomfort to participants. If you feel any discomfort please 
inform the interviewer who can provide referral to appropriate support.  
Referral will be made to Hepatitis WA, a non-government community 
organisation, which provides a support service for people with hepatitis C, 
their carers and family members. 
The risks associated with participating in this research are minimal. 
However, if you feel there are questions about your drug use which you do 
not wish to answer please tell the interviewer. If you have any concerns 
about any of the questions you may refuse to answer these questions without 
giving a reason. 
Confidentiality 
Any information that is obtained in connection with this study will remain 
confidential. The information you provide will not be communicated back to 
your treating clinician/counsellor, unless you specifically request that I do so. 
The information will not have any bearing on the care you receive at the 
service you are attending. The findings from this study will be published in 
my Master’s dissertation and in journal articles for publication. You are free 
to use pseudonyms.  
Tape recordings will be quickly transcribed, all identifying information will 
be removed, and the tape recordings immediately destroyed by means of bulk-
erasure (shredder eraser) equipment. All computer data will be kept in 
password protected accessible only by the Student Researcher for five years 
then will be shredded and disposed into confidential document disposal bins.  
Any information that is obtained in connection with this study will remain 
confidential. The consent forms will be stored separately to interview data 
obtained during the study; there will be no identifying link between the 
interview information and consent forms. The information from the research 
will still be published- just in an unidentifiable format, grouped with other 
responses.  
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You will be reimbursed up to $35 for out of pocket expenses involved in 
taking part in the including travel or any costs study.( you are required to 
provide a receipt of any expenses that you have incurred) 
 
Voluntary Participation and Withdrawal from Study 
You are free to decide whether or not you want to participate in this study. If 
you decide not to participate, this will have no consequences and you will be 
treated according to routine clinical guidelines, without any prejudice to 
present or future management of your condition. You don’t have to sign 
anything to notify your withdrawal, and you don’t have to say why you 
decided not to participate. You are also free to withdraw your participation at 
any time during the study for whatever reason. Such withdrawal will not in 
any way influence decisions regarding future standard or conventiona l 
medical treatment you may require. 
 
If you would like any more information about this study, please do not 
hesitate to contact my supervisor Dr Susan Carruthers of the National Drug 
Research Institute, Curtin University of Technology (Telephone Number  
9266 1604). She will be happy to answer your questions. 
If you have any concerns or complaints regarding this study, you may contact 
the Chairman of the South Metropolitan Area Health Service Human 
Research Ethics Committee on (08) 9431 2929. Alternatively you may 
contact the Human Research Ethics Officer at Curtin University of 
Technology (telephone number (08) 9266 2784) on a confidential basis. Your 
concerns will be drawn to the attention of the Human Research Ethics 
Committee that is monitoring the study. 
 
Appendix 9: Information Sheet focus groups 
 
Name of Investigators: Amineh Rashidi 
    Dr Susan Carruthers (Supervisor) 
This study is about hepatitis C treatment. I would like to understand what the 
intentions of injecting drug users are in regards to new hepatitis C treatment 
known as triple therapy (pegylated interferon and ribavirin in combination 
either boceprevir and telaprevir) and the best way to do this is to find out their 
thoughts directly from them. This study is being performed for my doctos’s 
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dissertation and has been approved by the Curtin University of Technology 
and the South Metropolitan Area Health Service Human Research Ethics 
Committees. 
If you decide to take part in this research study, it is important that you 
understand the purpose of the study and the procedures you will be asked to 
undergo. Please read the following pages, which will provide you with 
information about the procedures involved, and also the potential benefits, 
discomforts and precautions of the study. If you are currently involved in a 
research study you will be ineligible to participate in this one. 
 
Nature and Purpose of the Study 
 
You are being invited to take part in the study as you are an injecting drug 
user and have sought information about new HCV treatment (triple therapy). 
This study aims to provide evidence for developing appropriate interventions 
that can assist in increase intention to uptake treatment.It is hoped that this 
study will provide specific outcomes, from which I will develop an 
appropriate model for delivery of hepatitis C treatment programs to hepatitis 
C positive populations, particularly injecting drug users. 
What the Study Will Involve 
You are invited to take part in focus group.  
If you decide to participate, I will ask you questions about your opinion about 
hepatitis C treatment and it will take 60-90 minutes. With your permission, 
the conversation will be taped-recorded. 
Benefit  
Research studies from overseas and within Australia have identified a number 
of common barriers to accessing hepatitis C treatment, especially for those 
people who may be current illicit drug users. There may no direct benefit to 
you participating in the study; however, the information obtained in 
connection with this study may be used to modify existing national guidelines 
for the management of hepatitis C treatment. The information may also be 
used to provide information and advice to current illicit drug users who may 
wish to access hepatitis C treatment.  
Discomfort and Risks  
Talking about illicit drug use or hepatitis C treatment may cause mild 
psychological discomfort to participants. If you feel any discomfort please 
inform the interviewer who can provide referral to appropriate support.  
Referral will be made to Hepatitis WA, a non-government community 
organisation, which provides a support service for people with hepatitis C, 
their carers and family members. 
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The risks associated with participating in this research are minimal. However, 
if you feel there are questions about your drug use which you do not wish to 
answer please tell the interviewer. If you have any concerns about any of the 
questions you may refuse to answer these questions without giving a reason. 
Confidentiality 
Any information that is obtained in connection with this study will remain 
confidential. The information you provide will not be communicated back to 
your treating clinician/counsellor, unless you specifically request that I do so. 
The information will not have any bearing on the care you receive at the 
service you are attending. The findings from this study will be published in 
my Master’s dissertation and in journal articles for publication.  
All information from the study will be stored in a Curtin University approved 
secure location in locked storage for a period of 5 years and then destroyed. 
All computer and data analysis files will be password-protected. 
You will be reimbursed up to $30 Coles or Kmart Voucher for out of pocket 
expenses involved in taking part in the including travel or any costs study 
 
Voluntary Participation and Withdrawal from Study 
You are free to decide whether or not you want to participate in this study. If 
you decide not to participate, this will have no consequences and you will be 
treated according to routine clinical guidelines, without any prejudice to 
present or future management of your condition. You don’t have to sign 
anything to notify your withdrawal, and you don’t have to say why you 
decided not to participate. You are also free to withdraw your participation at 
any time during the study for whatever reason. Such withdrawal will not in 
any way influence decisions regarding future standard or conventiona l 
medical treatment you may require. 
 
If you would like any more information about this study, please do not 
hesitate to contact my supervisor Dr Susan Carruthers of the National Drug 
Research Institute, Curtin University of Technology (Telephone Number  
9266 1604). She will be happy to answer your questions. 
If you have any concerns or complaints regarding this study, you may contact 
the Chairman of the South Metropolitan Area Health Service Human 
Research Ethics Committee on (08) 9431 2929. Alternatively you may 
contact the Human Research Ethics Officer at Curtin University of 
Technology (telephone number (08) 9266 2784) on a confidential basis. Your 
concerns will be drawn to the attention of the Human Research Ethics 
Committee that is monitoring the study. 
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Appendix 10 Consent form qualitative and 
quantitative study 
 
Consent from  
TO BE USED IN CONJUNCTION WITH THE INFORMATION SHEET 
 
PROJECT TITLE: Treatment of Hepatitis C (HCV) in Injecting Drug 
Users (IDUs) in Perth Metropolitan area 
 
 
 
Participant’s Name…………………………………  
 
1. I agree entirely voluntarily to take part in the Treatment of Hepatitis  
C in Injecting Drug Users in Perth Metropolitan area. This study 
is being undertaken as part of the requirement for a Doctor’s of 
Philosophy post-graduate degree at Curtin University in Perth, 
Western Australia. I am over 18 years of age. 
 
2. I have been given a full explanation of the purpose of this study, of 
the procedures involved and of what will be expected of me. The 
researcher has explained the possible problems that might arise as a 
result of my participation in this study. 
 
3.  I understand that I am entirely free to withdraw from the study at any 
time and that this withdrawal will not in any way affect my future 
standard or conventional treatment or medical management. 
 
4. I understand that I will not be referred to by name in any report 
concerning this study. In turn, I cannot restrict in any way the use of 
the results that arise from this study. 
 
5. I have been given and read a copy of this Consent Form and 
Information Sheet. 
 
If you would like any more information about this study, please do not 
hesitate to contact my supervisor Dr Susan Carruthers of the National Drug 
Research Institute, Curtin University of Technology (Telephone Number  
9266 1604). She will be happy to answer your questions. 
If you have any concerns or complaints regarding this study, you may contact 
the Chairman of the South Metropolitan Area Health Service Human 
Research Ethics Committee on (08) 9431 2929. Alternatively you may 
contact the Human Research Ethics Officer at Curtin University of 
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Technology (telephone number (08) 9266 2784) on a confidential basis. Your 
concerns will be drawn to the attention of the Human Research Ethics 
Committee that is monitoring the study. 
 
Signature by participant Signature by Student Researcher  
 
Signed…………………………………… 
Signed……………………………... 
 
Date……………………………………….. 
Date………………………………... 
 
Appendix 11 Survey questionnaire 
 
 
HCV treatment for Genotype 2 and 3 
HCV treatment (combination therapy) specifically for hepatitis C genotype 2 
and 3 is a combination of two drugs interferon and ribavirin. Interferon is a 
drug taken by injection under the skin (subcutaneously) once a week and it 
can increase a person’s immune response and stop the growth of hepatitis C 
virus in the body. Ribavirin is a drug taken orally twice a day which changes 
the body’s immune response to hepatitis C virus. For HCV these drugs are 
given together to help the immune system and to stop or slowing down the 
diseases process.  
 
The treatment is given over a 6 month period with a success rate of up to 80% 
(8 out of ten people will be cured).  
Some people report no side effects while others may have flu-like 
symptoms, such as fever, chills, muscle aches and headaches. Other side 
effects may include becoming forgetful, short-tempered, tired or depressed. 
These are usually experienced in the first few months of treatment.  
HCV treatment for Genotype 1 
 
HCV treatment (triple therapy) specifically for hepatitis C genotype 1 is now 
available which still combines weekly interferon injections with daily 
ribavirin tablets, and a course of daily boceprevir or telaprevir tablets (they 
are oral medications which must be taken three times daily). The success rate 
for the treatment of hepatitis C genotype 1 has increased from 40 to 70%.  
The side-effects of pegylated interferon and ribavirin side-effects still could 
occur in addition to any side effects of boceprevir or telaprevir tablets but for 
a shorter duration.  
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Boceprevir triple-therapy regimen : it should be taken with a light meal or 
snack. For the first 4 weeks of treatment only interferon plus ribavirin must 
be taken then Boceprevir is added at week 5. Therefore interferon, ribavir in 
and boceprevir must be taken for 24-44 weeks.  
 
The most common side effects of boceprevir in combination with 
interferon/ribavirin include fatigue, anemia, nausea, headache, and a change 
in taste. In some patients, anemia may become severe. (Anaemia is a decrease 
in number of red blood cell or less than the normal quantity of haemoglob in 
in the blood). 
 
Telaprevir triple-therapy regimen: it should be taken with food containing 
approximately 20 grams of fat. At the beginning of day 1 telaprevir, interfe ron 
and ribavirin must be taken for the first 12 weeks and then interferon and 
ribavirin is continued for an additional 12 to 36 week. 
The most common side effects of telaprevir in combination with 
interferon/ribavirin include rash, with and without itchiness, and anemia. 
Although rash is usually mild, it can become severe.  
However, it is important to remember that everyone is different and side-
effects from treatments vary from person to person. If anemia and rashes 
become sever the treatment will be stopped. 
 
 
 
Thank you for being part of my research. Your answers will allow me 
to provide an overview of the people who complete this questionnaire.  
 
Part One  
I. The first part of this questionnaire is about your background and 
includes some short questions about your drug use. Please answer the 
following questions.  
 
1. Are you: 
1. Male 
2. Female  
3. Other (specify)…………………………………………… 
 
2. How old are you? yrs old…………….. 
 
3. What type accommodation do you have?  
1. Own house/flat 
2. Rented house/flat 
3. Sharing house  
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4. Homeless  
 
 
4. Are you currently?  
1. Single / separated / divorced? 
2. Married/ living with sexual partner? 
 
 
 
5. Who do you live with? (Please tick all that apply)  
1. Partner 
2. Alone 
3. Parents  
4. Children 
5. Share with others  
  
6. Are you Aboriginal or Torres Strait Islander Origin? 
1. No  
2. Aboriginal  
3. Torres Strait Islander 
 
 
7. What is the highest level of education you have completed? 
1. Primary School 
2. Some high school education  
3. Year 10  
4. Year 12  
5. TAFE/University  
8. How are you employed at the moment? 
1. Full time work  
2. Part time/Casual work  
3. Student full time  
4. Student part- time  
4. Unemployed  
 
9. What is your MAIN source of income? 
 1. Unemployment benefits  
 2. Sickness benefits  
 3. Pension  
 4. Job  
5. None  
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10. What country were you born in? 
1. Australia 
2. Other (specify)…………………………………………… 
 
11. What is your current residential postcode? ………. 
 
12. What language was the main one spoken at the home you grew up in? 
1. English 
2. Other (specify) 
 
The following questions are about your drug use history. 
 
13. How long have you been injecting drugs? 
1. Six months -one year  
2. Two- four years  
3. Three-six years  
4. Six-eight years 
5. Eight-ten years 
6. More than ten years  
  
14. What is your preferred drug? 
1. Amphetamines  
2. Heroin 
3. XTC 
4. LSD  
5. Cannabis  
 
 
15. Which of the following drugs have you used in the past 6 months? 
1. Amphetamines  
2. Heroin 
3. XTC 
4. LSD  
5. Cannabis  
6. Cocaine  
7. Other opioids (for example oxycodone)  
 
16. How many times have you injected any drugs in the last month? 
1. Hasn’t hit up  
2.Once a week  
3.More than once a week  
(but less than once a day) 
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4. Once a day 
5. 2-3 times a day 
6. More than 3 times a day 
 
17. Did you drink alcohol over the last year?  
A. Yes  
B. No 
 
 
Part Two  
The second part of this questionnaire health care seeking characteristics   
 
1. How long have you been diagnosed with hepatitis C?  
A. Less than five year  
B. More than five years  
C. More than ten years  
 
2. Do you know about your hepatitis C genotype? 
A. Yes please specify your genotype  
B. No 
 
3. Were you aware of hepatitis C treatment before commencing to fill the 
survey ?  
A. Yes  
B. No  
  
4. Have you discussed with your GP about your liver health status? 
A. Yes  
B. No 
 
Part three  
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For each of the following statements, please indicate how much you agree 
or disagree by circling the number that most closely corresponds to your 
opinion. The number ‘1’ indicates strong disagreement, whereas ‘5’ 
indicates strong agreement 
 
1. I assumed hepatitis C treatment has a guaranteed cure.  
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5  
 
2. I assumed once I clear hepatitis C virus, it does not come back.  
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
  
3. I assumed hepatitis C treatment takes less than 6 months. 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
4. I assumed hepatitis C treatment takes less than12 months. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
  
6. I assumed hepatitis C treatment does not involve harsh physical side 
effects. 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
 
7. I assumed hepatitis C treatment does not involve harsh psychological side 
effects. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
 
8. I assumed hepatitis C treatment does not involve sever kin problems.  
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Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
9. I assumed hepatitis C treatment does not involve post treatment side effects.  
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
10. I get the emotional help and support I need from either family or friends.  
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
11. I have a special person who is a real source of comfort and help to me.. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
12. There is a special person with whom I can share my joys and sorrows. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
13. There is a special person who is around when I am in need with my 
daily chore. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
 
Part Four  
This part of this questionnaire is about stigma .  
 
 1. I feel I need to hide the fact that I am a drug user and have hepatitis C. 
 
 
Strongly disagree disagree neutral agree strongly agree  
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 1----------------2-----------------3 -------------------4-------------------5 
 
2. I believe injecting drug users with hepatitis C are treated like outcasts. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
 
3. I felt I wouldn’t get as good health care if health care providers knew 
about my drug status. 
 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
4. I feared my family and my friend would reject me if they learned about 
my illness 
 
Strongly disagree disagree don’t know agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5 
 
Part five 
Please select the most appropriate response to each question below 
which is about the intention to go on hepatitis C treatment. 
 
1. I am planning to undertake hepatitis C treatment within the next 12 months. 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5  
 
2. I am planning to undertake hepatitis C treatment within the next 1-2 years. 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5  
 
3. I am planning to undertake hepatitis C treatment in the next 2-5 years. 
Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5  
 
4. I am planning to undertake hepatitis C treatment BUT not at least for 
another 5 years. 
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Strongly disagree disagree neutral agree strongly agree  
 1----------------2-----------------3 -------------------4-------------------5  
 
Appendix 12 poster for questionnaire survey  
Hepatitis C Treatment Study 
 
Do you have hepatitis C?  
I am conducting a survey questionnaire to find out your opinion about 
hepatitis C treatment. If you are happy to take part in a survey, you will be 
reimbursed $20 Coles or Kmart Voucher for any out of pocket expenses. It 
will take 10-15 mintues  
 
To take part in this study you need to: 
 Currently injecting drugs (actively injecting ) 
 Received hepatitis C diagnosed by a health care professional 
more than 6 months earlier  
 Have No Experience with HCV treatment. 
 Be over 18 years of age, and  
 Be comfortable to speak English  
 Living in Perth 
 
Your involvement in this study will improve access to treatment for hepatitis 
C. For more information or an appointment Phone Amineh: 0405805614 and 
leave your name and contact details. Study Approved by Curtin Univers ity 
and South Metropolitan Area Health Service Human Research Ethics 
Committees. All information is strictly confidential.  
 
Appendix 13 Information Sheet survey questionnaire  
 
Name of Investigators: Amineh Rashidi 
    Dr Susan Carruthers (Supervisor) 
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This study is about hepatitis C treatment. I would like to understand what the 
intentions of injecting drug users are in regards to hepatitis C treatment and 
the best way to do this is to find out their thoughts directly from them. This 
study is being performed for my doctor’s dissertation and has been approved 
by the Curtin University of Technology and the South Metropolitan Area 
Health Service Human Research Ethics Committees. 
If you decide to take part in this research study, it is important that you 
understand the purpose of the study and the procedures you will be asked to 
undergo. Please read the following pages, which will provide you with 
information about the procedures involved, and also the potential benefits, 
discomforts and precautions of the study. If you are currently involved in a 
research study you will be ineligible to participate in this one. 
 
Nature and Purpose of the Study 
 
You are being invited to take part in the study as you are an injecting drug 
user and have sought information about treatment. This study aims to provide 
evidence for developing appropriate interventions that can assist in increase 
intention to uptake treatment. It is hoped that this study will provide specific 
outcomes, from which I will develop an appropriate model for delivery of 
hepatitis C treatment programs to hepatitis C positive populations, 
particularly injecting drug users. 
 
What the Study Will Involve 
You are invited to take part in a survey questionnaire.  
If you decide to participate, I will ask you questions aboutbcakground, your 
drug use history, treatment intentions and beliefs about HCV treatment. It will 
take 15-20 minutes.  
Benefit  
Research studies from overseas and within Australia have identified a number 
of common barriers to accessing hepatitis C treatment, especially for those 
people who may be current illicit drug users. There may no direct benefit to 
you participating in the study; however, the information obtained in 
connection with this study may be used to modify existing national guidelines 
for the management of hepatitis C treatment. The information may also be 
used to provide information and advice to current illicit drug users who may 
wish to access hepatitis C treatment.  
Discomfort and Risks  
Talking about illicit drug use or hepatitis C treatment may cause mild 
psychological discomfort to participants. If you feel any discomfort please 
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inform the interviewer who can provide referral to appropriate support.  
Referral will be made to Hepatitis WA, a non-government community 
organisation, which provides a support service for people with hepatitis C, 
their carers and family members. 
The risks associated with participating in this research are minimal. However, 
if you feel there are questions about your drug use which you do not wish to 
answer please tell the interviewer. If you have any concerns about any of the 
questions you may refuse to answer these questions without giving a reason. 
Confidentiality 
Any information that is obtained in connection with this study will remain 
confidential. The information you provide will not be communicated back to 
your treating clinician/counsellor, unless you specifically request that I do so. 
The information will not have any bearing on the care you receive at the 
service you are attending. The findings from this study will be published in 
my Master’s dissertation and in journal articles for publication.  
All information from the study will be stored in a Curtin University approved 
secure location in locked storage for a period of 5 years and then destroyed.  
All computer and data analysis files will be password-protected. 
You will be reimbursed up to $20 Coles Voucher for out of pocket expenses 
involved in taking part in the including travel or any costs study 
 
Voluntary Participation and Withdrawal from Study 
You are free to decide whether or not you want to participate in this study. If 
you decide not to participate, this will have no consequences and you will be 
treated according to routine clinical guidelines, without any prejudice to 
present or future management of your condition. You don’t have to sign 
anything to notify your withdrawal, and you don’t have to say why you 
decided not to participate. You are also free to withdraw your participation at 
any time during the study for whatever reason. Such withdrawal will not in 
any way influence decisions regarding future standard or conventiona l 
medical treatment you may require. 
 
If you would like any more information about this study, please do not 
hesitate to contact my supervisor Dr Susan Carruthers of the National Drug 
Research Institute, Curtin University of Technology (Telephone Number  
9266 1604). She will be happy to answer your questions. 
If you have any concerns or complaints regarding this study, you may contact 
the Chairman of the South Metropolitan Area Health Service Human 
Research Ethics Committee on (08) 9431 2929. Alternatively you may 
contact the Human Research Ethics Officer at Curtin University of 
Technology. “This study has been approved by the Curtin University Human 
Research Ethics Committee (Approval Number HR77/2012). The Committee 
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is comprised of members of the public, academics, lawyers, doctors and 
pastoral carers. If needed, verification of approval can be obtained either by 
writing to the Curtin University Human Research Ethics Committee, c/- 
Office of Research and Development, Curtin University, GPO Box U1987, 
Perth, 6845 or by telephoning 9266 2784 or by emailing hrec@curtin.edu.au. ” 
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Appendix 14 Letter of ethics approval  
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